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ANGLIA RUSKIN UNIVERSITY 
ABSTRACT 
FACULTY OF SCIENCE AND TECHNOLOGY 
DOCTOR OF PHILOSOPHY 
THE DETECTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS  
IN KERATINOUS MATRICES 
ALIX GARTH-GREEVES 
JUNE 2016 
The problems of non-steroidal anti-inflammatory drugs (NSAIDs) as environmental 
contaminants is an area of concern. NSAIDs are heavily relied upon to treat pain and 
inflammation. With such prevalence, these compounds are now entering the 
environment via many routes, such as water discharge and contaminated food. This 
results in subsequent exposure and effects on various animal species. One such 
example is diclofenac, which was associated with the extinction of Gyps vultures in 
Asia. The detection of diclofenac was based on post-mortem samples i.e. after a large 
decline in populations. In this research non-invasive samples i.e hairs and feathers are 
analysed pre-mortality as a preventive measure for early detection. 
A simultaneous liquid chromatography-mass spectrometry (LC-MS) method for 
detection of eighteen compounds, either of known toxicological effects or future threat 
(NSAIDs - aceclofenac, carprofen, diclofenac, flunixin, ketoprofen, mefenamic acid, 
meloxicam, nimesulide, phenylbutazone, piroxicam and suxibuzone; metabolites - 
oxyphenylbutazone, 3-hydroxymethyl mefenamic acid, 4-hydroxydiclofenac, 4-
hydroxynimesulide, 5-carboxymeloxicam, 5-hydroxyflunixin and 5-hydroxypiroxicam) 
has been developed and validated. A newly optimised sample preparation method was 
applied to hairs/feathers.    
Precision of the analytical method was within 10% relative standard deviations for the 
majority of compounds. Recoveries averaged 83% and limits of detection (LOD) 
ranged 0.01 to 0.2µg/g. For diclofenac, flunixin, mefenamic acid, oxyphenylbutazone, 
piroxicam and 5-hydroxyflunixin, LODs were lower than previously reported. Various 
animal hairs/feathers were analysed (n=20) and in two samples piroxicam and 
phenylbutazone were individually detected, at 1.2µg/g ± 0.002 and 1.8µg/g ± 0.011 
respectively. 
The LC-MS method reported here has been validated for the first time using animal 
hair/feather samples. This range of NSAIDs and metabolites have never been reported 
before.  LODs and LOQs of metabolites are reported for the first time. The detection of 
piroxicam and phenylbutazone in feathers highlights the viability of testing keratinous 
matrices. 
Keywords: NSAIDs, diclofenac, liquid chromatography-mass spectrometry, feathers, 
non-invasive  
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CHAPTER 1: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND THEIR 
PRESENCE, DETECTION AND IMPACT IN THE ENVIRONMENT 
1.1 RESEARCH RATIONALE  
With newer pollutants, such as pharmaceuticals being detected in the environment and 
resulting in concerns of exposure to wildlife, conservation practices are now starting to 
utilise forensic analytical techniques. Wildlife forensics has a new challenge in dealing 
with the exposure of NSAIDs as endangered species are now at risk, namely the Gyps 
vulture species, birds of prey such as eagles, and water species such as the water 
vole, living in contaminated waterways. First demonstrated with the devastating 
population declines of three Gyps vulture species (discussed in section 1.2), these 
compounds are entering the environment via many routes including, treated water 
discharge or contaminated food sources. It is not surprising such compounds enter the 
environment owing to their prescription and availability over-the-counter. This is due to 
the situation that medical and veterinary professionals rely heavily on these 
pharmaceuticals to treat pain and inflammation of muscles, bones and joints. Further 
risks from exposure to such NSAIDs are now more apparent with growing research into 
the effects of NSAIDs in the environment (Arnold, et al., 2013; Cuthbert, et al., 2011; 
Hutchinson, et al., 2015; Mandal and Khadka, 2013; Zorilla, et al., 2014).  
These compounds are already resulting in mass mortality (section 1.2) and continue to 
be of threat, yet remarkably, no methods have been published using alternative 
samples such as hairs and feathers, allowing for sampling pre-mortality. These 
alternative samples can be collected ethically without stress to the animal. This is 
especially important in species with already faltering numbers when conservation is 
paramount. Testing keratinous matrices pre-mortality will aid in early detection of 
NSAIDs, which could address the early signs of poisoning of protected species to 
prevent mass mortality and aid in the provision of treatment to the species effected by 
such compounds. Furthermore, it would help conservation efforts to remove exposure. 
Therefore this current project centres on the simultaneous detection NSAIDs in non-
invasive samples (feathers and hairs). 
This research includes a thorough literature review, providing essential background 
information on the known threats of NSAIDs, such as diclofenac, in the environment 
and the threats they pose to specific species, most notably vultures in India. Some 
understanding of the toxicity by relating the chemistry and the chemical process of 
NSAIDs, has allowed for an informed selection of metabolites, enhanced by a thorough 
2 
 
literature review, as included in this research. This enabled the research to centre on 
the NSAIDs and metabolites currently of concern and/or of future threat. Alongside 
considering current and future implications of exposure to NSAIDs to endangered 
species (Cuthbert, et al., 2011; Richards, et al., 2014; Sharma, et al., 2014; Zorilla, et 
al., 2014). 
It has been documented, that other birds of prey and aquatic species, for example 
otters, are now at risk of NSAID exposure (Brodin, et al., 2013; Richards, et al., 2011; 
Sharma, et al., 2014; Zorilla, et al., 2014). As reported in the vulture crisis (section 
1.2.2) Oaks, et al. (2004) hypothesised that species are exposed to NSAIDs through 
the consumption of dead livestock that have been treated with these pharmaceuticals 
(section 1.2.2). In a recent publication by Sharma, et al. (2014), residues of diclofenac 
was detected in kidneys, liver, heart and spleen samples of two steppe eagles (Aquila 
nepalensis). From necropsy and histopathological studies, the authors concluded that 
the mortality was attributed to diclofenac toxicity. Furthermore, from these results the 
authors deduced that NSAIDs may be toxic to other birds of prey, such as eagles. 
Steppe eagles are closely related to the golden eagle (Aquila chrysaetos) in the UK 
and Europe and the vulnerable Spanish imperial eagle (Aquila adalberti). These birds 
are all at risk of renal failure (also known as kidney failure, in which kidneys fail to 
remove waste products from the blood) caused by diclofenac (Sharma, et al., 2014), 
(section 1.2.2) highlighting the need for diclofenac poisoning to be considered as a 
global problem and an early detection system to be made available.  
Moreover, pharmaceutical compounds and their metabolites are entering waterways in 
the UK via human waste through treated and untreated municipal wastewaters. 
Conventional treatment facilities are not designed for the removal of these compounds 
and consequently, do not remove them, during waste water processing (Jelic, et al., 
2012). Currently, there are more than 3000 pharmaceuticals licensed for use in the UK, 
of which NSAIDs make up twenty two (MHRA, 2010). Consequently it is not feasible to 
monitor such a large number of compounds (Jones, Voulvoulis and Lester, 2005). With 
the wide-ranging chemical and physical properties of these pharmaceuticals, water 
treatment facilities must have a selection process by which they identify those to test 
for (Jones, Voulvoulis and Lester, 2005). Hence, treatment facilities often only test for 
common compounds, such as acetaminophen and ibuprofen, due to their prevalence, 
and antibiotics, such as sulfamethoxazole (Jones, Voulvoulis and Lester, 2005; WHO, 
2011).  
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There have been a few published studies documenting the presence of other 
pharmaceutical compounds. A study by Brodin, et al. (2013) showed how the 
benzodiazepine anxiolytic drug oxazepam altered the behaviour and feeding rate of 
wild European perch (Perca fluviatilis) at concentrations (1.8µg/L-1) related to those 
detected in effluent surface waters. Authors suggested that the altered behaviour could 
be detrimental to the perch depending on whether they were at risk from predators. 
Therefore exposure risks to other aquatic species, beyond fish, are of concern. 
Waterways in the UK are home to otters and mink amongst others; the NSAIDs 
diclofenac and ibuprofen have already been detected in samples from otters (Richards, 
et al., 2011b). Richards (2011) reported the presence of diclofenac and ibuprofen in 
otter hair samples. Their findings showed external exposure within the aquatic 
environment, whilst suggesting that the presence of these two NSAIDs could have 
contributed to pathological lesions that were identified in the otter carcasses. These 
results highlight the potential exposure via digested material by the food chain or 
through drinking.  
 
The detection of NSAIDs in waterways are especially concerning considering the 
potential exposure to protected aquatic species, such as the water vole (Arvicola 
amphibious), whose population declines have been reported in Britain (IUCN, 2014), 
thus putting the re-introduction at potential risk. If this were to be the case, the 
implementation of non-invasive samples is even more important where ethical 
considerations can restrict or forbid invasive sampling of protected species (as 
discussed in section 1.1.1).  
This research has developed a new analytical method to analyse aceclofenac, 
acetylsalicylic acid, carprofen, diclofenac, flunixin, ibuprofen, ketoprofen, mefenamic 
acid, meloxicam, nimesulide, phenylbutazone, piroxicam and suxibuzone and seven 
major metabolites, oxyphenylbutazone, 3-hydroxymethyl mefenamic acid, 4-
hydroxydiclofenac, 4-hydroxynimesulide, 5-carboxymeloxicam, 5-hydroxyflunixin and 5-
hydroxypiroxicam. This research is novel in its approach to detecting not only this 
unique selection of NSAIDs, but also major metabolites of some of the parent 
compounds, which has never been addressed in this field before. In addition, the 
method also offers the detection of parent compounds (for example aceclofenac and 
piroxicam) that have not been previously analysed in one simultaneous method. 
Furthermore, it includes NSAIDs that have potential future threat and/or available on 
the market in areas of still large populations of vulture, such as in the Indian 
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subcontinent and have been neglected in current published methods (Taggart, et al., 
2009).  
1.1.1 Importance of developing new detection methods and alternative samples 
In the field of wildlife forensics, current methods report the use of post mortem tissue 
samples for the detection of NSAIDs in endangered species (Mishra, et al., 2001; 
Shultz, et al., 2004). However, environmental conditions, such as extreme heat causing 
decay could impact on the quality and stability of analytes in these samples (Ng, et al., 
2006; Mishra, et al., 2001; Richards, et al., 2014; Shultz, et al., 2004). The analysis of 
hair (section 1.4) in forensic and environmental investigations has gained increasing 
acceptance as a viable alternative to tissue and blood analysis. The analysis of 
alternative matrices, such as hair, is not only environmentally robust but durable too. 
Such analysis allows for a much wider window of detection, from months to even years, 
after administration or exposure (Baumgartner, et al., 1989; Jickells and Negrusz, 
2008). Therefore the focus of this research is an investigation on the use of animal hair 
and feathers for the simultaneous detection of the NSAIDs.  
The use of invasive samples can be restricted or even forbidden due to ethics. For 
example sampling blood from a live animal would cause undue stress. Richards, et al. 
(2014) states this is especially important in the case of protected populations with 
already faltering numbers. To avoid stress to animals during sample collection, non-
invasive samples should be the preferred choice.  
When analysing non-invasive samples, i.e. feathers, all of the sample can be utilised 
rather than the potential loss experienced in a degraded conventional tissue sample i.e. 
muscle, and enables analysis pre-mortality as well as post-mortality. Owing to low 
populations of endangered species and the continued threat from NSAIDs, there is an 
urgency to use non-invasive samples. It is therefore important that such methods are 
developed and validated, published and adopted for the protection of threatened 
species, such as eagles, vultures and water vole, this also aids in identifying other 
species at risk of exposure.  
As such, this research developed and validated a simultaneous detection method that 
detects multiple compounds utilising liquid chromatography coupled with mass 
spectrometry (LC-MS). Furthermore, alternative samples, such as hair and feathers 
were used, as opposed to traditional blood and tissue samples. This research allows 
the continued improvement in wildlife and environmental monitoring, and wildlife 
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forensic investigations. Thus the newly validated method will not only aid in a timely 
response to wildlife mortality incidences, but could offer a means to monitor exposure 
of NSAIDs in other species, whilst enabling monitoring, ethically, in live animals. It is 
useful in alerting conservationists of possible future poisoning before another species is 
at the brink of the extinction. Hence, additionally giving an alternative method to post-
mortem samples used currently. It also provides a new simultaneous method to identify 
such pollutants in the field of environmental and analytical sciences for other matrices. 
This project presents development in an emerging area of research which contributes 
to areas of environmental and wildlife monitoring. In turn it is essential in strengthening 
the worldwide wildlife and environmental monitoring effort further.  
1.2 THE VULTURE CRISIS AND THE ROLE OF NSAIDS 
The vulture crisis centred on the mass mortality of three Gyps vulture species, namely 
the Oriental white-backed vulture (Gyps bengalensis), long-billed and slender-billed 
vultures (Gyps indicus and Gyps tenuirostris, respectively), where populations rapidly 
declined to a loss of more than 95% (Prakash, 1999; Prakash, et al., 2003). Some 
researchers have even estimated a decline of 99.9% in some species and predict 
extinction in the wild in the near future (Markandya, et al., 2008; Oaks, et al., 2004; 
Prakash, 1999; Prakash, et al., 2003). 
This section details, the early proposed causes of vulture demise and the difficulty in 
identifying the root cause of such mass mortality. It describes the break-through and 
consequently the role of diclofenac in the vulture crisis and ultimately, reflects on the 
phasing out of diclofenac. The ongoing conservation efforts and continued monitoring 
of diclofenac is also included.  
1.2.1 Reported decline in vulture populations, early proposals 
Decreases in vulture populations were first reported in 1999 in a publication by Prakash 
researching the status of vultures in Keoladeo National Park in Rajasthan (Prakash, 
1999). The author recorded 95% decline in populations across three species of Gyps 
vultures; the oriental white-rumped vulture (G.bengalensis), the long-billed vulture (G. 
indicus) and Slender-billed Vulture (G.tenuirostris). At this early stage, most other 
populations were stable and therefore the study concluded that other declines were the 
result of a natural reduction in food availability and even persecution by humans and 
poisoning. At this stage Gyps vulture were not deemed to be at threat so no 
conservation effort was put in place.  
6 
 
In a follow up study by Prakash, et al. (2003), they explored different hypothesis for 
these declines in vultures. Spatial patterns were considered and evidence of regional 
decline was researched to see whether they differed between protected areas and 
outside. These hypothesis were assessed to see if food availability could have caused 
the decline. In this early major study, conclusions were drawn and in turn initial 
hypothesis were proven incorrect, as food source was readily available and no 
significant differences in regional declines were reported (Prakash, et al., 2003). The 
rapid decline was not seen in other birds of prey and unprecedented beyond previously 
reported cases. Declines proved independent of any spatial patterns, whether 
protected or nominal geographical area, and no pesticides or metals had been 
detected. Therefore, the authors concluded infectious disease was the most probable 
cause of the vulture decline due to the absence of chemical contamination causing the 
abnormal mass mortality.  
Declines in populations were not restricted to India but in fact were mirrored in Pakistan 
(Gilbert, et al., 2006) and Nepal (Baral, et al., 2005, Chaudhary, et al., 2011). Some 
publications have since showed populations of the oriental white-rumped vulture 
declining on average at a rate of 43.9% per year in India (between 2000 and 2007) 
(Prakash, et al., 2007). Whilst in the Punjab province of India and in Pakistan the 
decline ranged between 11 and 61% (Murn, et al., 2002). Decline in Nepal was 
reported to be 14% from 2002 and 2011 (Chaudhary, et al., 2011). Whilst the rate of 
decline, today, are slower than those initially reported in the late 1990s, further declines 
in this protected species, with already low numbers, are of growing concern (Cuthbert, 
et al., 2011). 
1.2.2 The breakthrough of the cause of vulture mass mortality 
A major study carried out by Oaks, et al. (2004) to identify a probable cause of this 
case of mass mortality in Gyps vultures centred on post mortem analysis of 259 adult 
Oriental white-backed vultures, where authors reported urate (the salt of uric acid) 
deposits on the surface of internal organs. This lead to conclusions that the death of 
these vultures was caused by visceral gout, resulting in renal failure (Oaks, et al., 
2004). To verify renal disease and to determine the cause, detailed diagnostic tests 
were carried out. In the post mortem studies by Mishra, et al. (2001), it was proposed 
that the presence of excess abdominal fat indicated that vultures were still consuming 
food at the time of death. These results again indicated a lack of food was not the 
primary cause of death (Shultz, et al., 2004) supporting Prakash, et al. (2003). 
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However, Shultz, et al. (2004) findings were in line with Oaks, et al. (2004), maintaining 
the same outcome of visceral gout in the dead vultures. 
Considering the vultures food source, Oaks commented that domestic animals are 
likely to receive different veterinary care than wild animals, in such cases 
pharmaceuticals are often prescribed to treat livestock for common ailments thus, in 
turn increasing the risk of exposure. The authors investigated the food source of the 
Oriental white-backed species, showing it to be mostly dead domestic livestock and 
hypothesised that ingested veterinary pharmaceuticals via the consumption of 
contaminated carcasses might be responsible for the renal failure in the scavenging 
birds. Surveys were conducted in the region, covering veterinarians and 
pharmaceutical retailers, in the hope to identify pharmaceuticals known to have 
nephrotoxic properties, administered orally and what is prescribed routinely. The only 
drug identified to meet both criteria was the NSAID, diclofenac.  
NSAIDs were first introduced in the 1970s, for human use as an anti-inflammatory and 
analgesic pharmaceutical (Smith, 2010). Diclofenac was initially registered for 
veterinary use in India in 1994 and in Pakistan in 1998 and was widely prescribed to 
treat lameness in domestic animals (Richards, 2010). However, it is well known to have 
a side effects causing hepatotoxicity and the increase in the concentration of uric acid 
in the kidneys resulting in renal failure (Mishra, et al., 2001; Shultz, et al., 2004). 
Research by Oaks, et al. (2004) revealed that the selling and use of diclofenac was 
prevalent on the Indian veterinary market at the time of the crisis; multiple companies 
were found to be selling it to treat livestock with an annual treatment estimate of 
approximately 10 million animals (Oaks, et al., 2004). Typically NSAIDs are used for 
the treatment of working animals to alleviate lameness and in turn increase their 
productive working life, this is especially important in a country where economy is relied 
on the working life of livestock (Richards, 2010). 
Oaks, et al. (2004) detected residues of diclofenac, in the kidneys of Oriental white-
backed vultures at concentrations of 0.051 to 0.643 µg/g after analysis using LC-MS 
(single compound analysis only). It was deduced that diclofenac was the most probable 
cause of mortality, and more specifically it was the exposure through consumption of 
contaminated carcasses with diclofenac, that ultimately led to renal failure and the 
demise of these vultures. Since initial research by Oaks, et al., (2004) proposing the 
actual cause of the mass mortality of Gyps vultures, many more papers have been 
published with similar findings (Green, et al., 2004; Shultz, et al., 2004). Shultz, et al. 
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(2004) concluded that vulture’s corpses, without symptoms of visceral gout, contained 
no detectable residues of diclofenac. Therefore it was concluded that the occurrence of 
gout was related with the presence of diclofenac residues. How diclofenac causes 
visceral gout in vultures is still not fully understood (Cuthbert, et al., 2007b; Meteyer, et 
al., 2005) and is discussed in more detail in section 1.3.7. Studies have suggested the 
occurrence of diclofenac may initiate blood deficiency in the renal portal whereby 
valves open and close at random intervals redirecting the blood supply. This results in 
visceral gout after a build-up of uric acid in the bloodstream (Meteyer, et al., 2005).   
1.2.3 Phasing out the use of diclofenac  
With vultures at the brink of extinction it was necessary to set out conservation efforts 
and protection. Following the confirmation that diclofenac was the root cause of the 
mass mortality, the International Union for Conservation of Nature (IUCN) (IUCN, 2004) 
listed many species, including the Gyps, as critically endangered. However with such 
wide use and readily available sources of diclofenac on the Indian subcontinent, 
researchers called for conservation intervention and urgent action to be taken (Green, 
et al., 2004). This was to be of upper most importance in the main animal reserves that 
house endangered species for protection to prevent the continued exposure to 
contaminated carcasses (Oaks, et al., 2004; Green, et al., 2004; Shultz, et al., 2004). 
Green, et al. (2004) highlighted that the only probable way to achieve this urgent action 
was by setting out a ban on the diclofenac. Thus, the Indian government led a ban on 
diclofenac use, prohibiting both its manufacture and importation which came into force 
in May 2006. This was also followed with legislation being introduced in Nepal and 
Pakistan in the same year (Cuthbert, et al., 2011). Researchers, did however, note that 
the legislation banning the use of diclofenac would cause a likely increase in use of 
other NSAIDs, therefore further research to identify safer alternatives would be needed 
(Cuthbert, et al., 2007; Green, et al., 2004; Oaks, et al., 2004).  
Until this point, only flunixin and ketoprofen had been reported to cause renal disease 
in chickens, cranes, quail and the African white-backed vultures (Gyps africanus) 
(Oaks, et al., 2004). Hence, it was vital to find alternative NSAIDs that would be 
relatively non-toxic and could offer a replacement for diclofenac use in the veterinary 
treatment of livestock. Prior to the ban in 2006, tests on the safety of the NSAID 
meloxicam were carried out on vultures after oral administration and feeding with 
tissues from meloxicam dosed cattle (Swan, 2006; Swarup, et al., 2007). It was found 
to be a suitable alternative to diclofenac owing to its low toxicity to vultures (Cuthbert, 
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et al., 2011, Naidoo, et al., 2007; Swan, et al., 2006; Swarup, et al., 2007). The 
mechanisms of how this pharmaceutical works is discussed further in section 1.3.7. 
Despite the ban of diclofenac, there have since been discoveries of the pharmaceutical 
still being used; to conservationists this is of great concern (Cuthbert, et al., 2011). 
Therefore conservationists are frequently monitoring the use of diclofenac and steps 
are continually put into place to eradicate its use from agricultural farming systems in 
the Indian subcontinent. Cuthbert, et al. (2011) reported that diclofenac from human 
medication is being illegally used for veterinary purposes and summarises data 
collected from pharmacy visits from one and half to four years after the ban on 
diclofenac came into force. Across eleven Indian states it was apparent that diclofenac 
was still being sold on the market at considerably low cost compared to the safer 
alternative meloxicam. Mandal and Khadka (2013) reported that meloxicam was double 
the cost of diclofenac for the same size. For example, a 30ml vial costs 72 Indian 
Rupee respectively (£0.77) compared to 35 Rupee (£0.37) for diclofenac. With the high 
cost of the safer alternative it is no doubt that this explains, a slower use of meloxicam 
and the illegal use of diclofenac (Mandal and Khadka, 2013). 
Another concern is, the majority of Nepalese and Indian pharmacists are not linking 
diclofenac with the vulture mortality, despite government awareness programs and 
training (Cuthbert, et al., 2011).  It is also of interest to note that there are also calls for 
incentives to encourage the use of meloxicam, in order to attempt to break the heavy 
reliance on diclofenac (Cuthbert, et al., 2011; Mukherjee, et al., 2014).  
In Cambodia, the use of diclofenac is entirely absent and studies have shown an 
increase in populations of Gyps vultures species since 2004 (Clements, et al., 2012). 
The noticeable outcome of recent studies into the availability of meloxicam is 
encouraging however, it is the sale of diclofenac and its illegal use that continue to be 
of concern. Conservationists are continually working on potential actions to eliminate 
the misuse and miss-selling of diclofenac. Measures to alter or restrict vial sizes and 
increase the price of diclofenac have been set out to make them less practical for 
veterinary use (Cuthbert, et al., 2011). The average cost of injectable diclofenac in 3ml 
vials is 2.1 - 4.1 Indian Rupee (£0.02 – 0.04) according to Cuthbert, et al. (2011). 
Veterinarians typically inject a 30ml vial of diclofenac when treating cattle thus by 
restricting vial sizes to 3ml, the cost of treatment with will raise to 62 -123 Indian Rupee 
(£0.62 – 1.24) acting as a deterrent to the misuse of diclofenac. Work to achieve the 
removal of diclofenac in excess of 3ml capacity is ongoing (Mukherjee, et al., 2014). 
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Recently, concerns of the use of diclofenac have spread to Europe after conservation 
foundations reported an Italian veterinary medicine company, FATRO, using loopholes 
in risk assessment protocols to have diclofenac approved for veterinary use in Italy and 
Spain (Richards, et al., 2014). Spain has the largest population of European vultures 
and if the presence of NSAIDs in livestock carcasses were in the food source of the 
vultures in the EU, the repercussions could be detrimental for the already faltering 
Gyps species (Richards, et al., 2014).  
1.2.4 Ecological implications of vulture crisis  
Ongoing threats extend beyond the use and ingestion of such pharmaceuticals; not 
only has the vulture demise led to considerable population decline, but as a result the 
ecological balance has quickly shifted. Vultures are remarkable scavengers and are 
key species in many ecosystems; they can safely digest a rotting carcass that may be 
lethal to other species and in the process they act as the cleaners of the environment 
removing potential toxic bacteria and infections (Prakash, et al., 2003; Stoyanova, 
Stefanov, and Schmutz, 2010). Concerns of the potential cultural and economic 
repercussion from the loss of these ‘cleaners’ extends to other ecosystems and their 
integrity (Markandya, et al., 2008). Therefore additional exposure of diclofenac could 
not only result in further mortality but could be damaging to the many other ecosystems 
which were never considered at risk before. With the loss of the vulture populations, 
there is a potential for increased occurrence of feral dogs and rats. Not only are these 
far less effective scavengers, than vultures, it could result in an increase of diseases 
attributed to dog and rat populations. Consequentially this could further kill other 
livestock and threaten human population (Markandya, et al., 2008). 
There are ecological implications beyond the Indian subcontinent population of vultures 
too. Following the EU outbreak of Bovine Spongiform Encephalitis (BSE) or mad cow 
disease in livestock in the year 2000, carcasses and vulture feeding sites were 
controlled. The EU stipulated that carcasses must immediately be disposed of and 
authorities were to manage the food source given to vultures. There is a concern that 
this may change the feeding and foraging behaviour of vultures (Richards, et al., 2014). 
The safety of these sites has not yet been confirmed and carcasses that are given to 
the vultures may be intensively reared and hence could be from heavily medicated 
stock (Richards, et al., 2014). Thus, it is more important than ever to utilise screening 
methods, such as the employment of unconventional samples, before another mass 
mortality instance can occur in species at risk of exposure. Carcasses should be 
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continually monitored; conventional tissue samples can be utilised in the detection of 
NSAID residues however, the condition of these samples must be considered. Where 
conventional samples are decomposed, the use of unconventional samples are much 
more reliant and are not affected by environmental conditions. This research uses non-
invasive samples which would aid current screening methods but also provides a viable 
alternative to traditional samples that may have degraded. The utilisation of a 
simultaneous detection method, as developed in this research, enables the detection of 
a variety of NSAIDs, including metabolites, in non-invasive samples.  
1.3 AN OVERVIEW OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
(NSAIDS) 
Owing to the threat of NSAIDs on various species and the preceding literature, this 
section discusses the choice and selection of NSAIDs used in this research. It 
examines the chemical properties and structures of these NSAIDs and aims to relate 
the compounds to their potential toxicity. This section describes the use of NSAIDs 
(section 1.3.1), particularly in both human and veterinary medicine and pays attention 
to the mechanism of action in the body (section 1.3.6); how such compounds are 
released at the injury site are inhibited through specialist enzyme. It includes the 
modes of administration (section 1.3.5), mechanism of action and ultimately the 
adsorption, distribution and metabolism in the body (section 1.3.7). Particular interest is 
paid to human administration of NSAIDs due to the lack of literature on animal 
administration and mechanism of action, thus by understanding this, suggestions could 
be made on the little known information of NSAIDs action on animals.  
1.3.1 The definition and uses of NSAIDs in human and veterinary medicine 
There are more than fifty compounds that fall under the category of NSAIDs on the 
global market. These are pharmaceutical compounds that are used as everyday 
medicine for both human and veterinary treatment. NSAIDs include a range of 
compounds that are commonly used for pain relief and in the treatment of joint 
inflammation (Saraf, 2008) and are classed as non-steroidal to distinguish them from 
corticosteroid compounds which have similar actions, as discussed in section 1.3.7.  
NSAIDs are not restricted to human use, as demonstrated by diclofenac as a veterinary 
pharmaceutical and its role in the vulture crisis (section 1.2). In veterinary treatment, 
NSAIDs are administered to livestock for pain relief and to manage conditions such as 
arthritis, joint lameness and laminitis, musculoskeletal discomfort, visceral pain and 
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post-operative pain (Mandal and Khadka, 2013). The use of NSAIDs in veterinary 
treatment is widespread due to their reliability, quick acting effects and low costs (Lees, 
et al., 2004; Suojala, Kaartinen and Pyorala., 2013) these are especially important in 
areas where conditions such as lameness can slow farming production. Animals are 
often used as working machines, vital to the livelihood of the farmer, thus the relied use 
of NSAIDs in working animals can increase their productive working life.  
In human medicine NSAIDs are routinely implemented in the treatment of pain and 
stiffness resulting from inflammation and are most commonly prescribed for the 
treatment of rheumatic conditions such as arthritis (BNF, 2012). Whilst these 
compounds are prescribed, millions are continually bought over the counter making 
them among the most widely used drugs in the world (CNT, et al., 2013). These 
compounds have three main long lasting properties; anti-inflammatory, antipyretic and 
analgesic effects (Modi, et al., 2012) making them particularly useful for the treatment 
of continuous or regular pain as in rheumatic conditions. Differences in anti-
inflammatory activity between NSAIDs are small; often there are considerable 
variations between users in both the response and tolerance (BNF, 2012). The British 
National Formulary, BNF (2012), states that up to 60% of patients respond to most 
common NSAIDs, such as, Ibuprofen or diclofenac. If patients do not respond to one of 
the main NSAIDS, they often respond well to an alternative. Therefore, alternatives to 
NSAIDs are not developed and reliance on NSAIDs is perpetuated. Consequently, this 
heavy reliance on these pharmaceuticals makes their prevalence in the environment a 
common occurrence.  
1.3.2 Current NSAIDs known to be of threat  
The research into NSAIDs and their exposure to endangered species, such as Gyps 
vulture, is limited, with safety testing carried out on only six NSAIDs, whereby five of 
which have proven toxic (Cuthbert, et al., 2015; Naidoo, et al., 2010; Oaks, et al., 2004; 
Swan, et al., 2006; Swarup, et al., 2007; Sharma, 2012; Zorilla, et al., 2014). Currently 
there is only one published analytical method representing the detection of NSAIDs in 
livestock tissue (Taggart, et al., 2009). Furthermore, there are only a handful of 
publications on the detection of NSAIDs in non-invasive samples such as animal hair 
(Richards, et al., 2011 and Richards, et al., 2011b). Conservationists and researchers 
have reported on the availability of a number of NSAIDs in areas of threat (Cuthbert, et 
al., 2011; Mandal and Kadka, 2013). This, in turn has provided an updated list of such 
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compounds that may pose a threat to endangered species as considered in this 
project.    
Previous studies have also highlighted that other NSAIDs; carprofen, flunixin, 
ibuprofen, phenylbutazone and ketoprofen have been associated with mortality in 
chickens, cranes, quail and the African white-backed vultures (Cuthbert, et al., 2007b; 
Oaks, et al., 2004). Most recently, concerns have been expressed over the NSAID 
nimesulide (Figure 1.11) after its consumption by vultures has been associated with 
visceral gout and has similar toxic effects to diclofenac (Cuthbert, et al., 2015).  
Additionally, hepatotoxicity has been reported when used in human and veterinary 
medicine by Modi, et al. (2012). These studies have led to much debate on the safety 
of nimesulide, with the toxicity of still not understood despite its sale in pharmacies 
(Modi, et al., 2012), therefore, nimesulide has been included in this research (section 
1.3.3, Table 1.1) 
Another NSAID identified as a threat is ketoprofen; studies have found ketoprofen is 
toxic to vultures and has been found to be present in livestock carcasses in India 
(Naidoo, et al., 2010; Taggart, et al., 2009). Safety testing has been carried out to 
deduce symptoms of toxicity and clinical signs of necropsy or visceral gout and kidney 
damage related to ketoprofen mortality (Naidoo, et al., 2010). Research into the 
availability of ketoprofen on the market showed that 33% of Indian pharmacies stock 
six brands of ketoprofen, suggesting it has become widely used (Cuthbert, et al., 2011; 
Taggart, et al., 2009). Furthermore, ketoprofen and phenylbutazone have also been 
reported to be toxic to other avian species after studies in broiler chicken (Awan, et al., 
2003). Post mortem studies on chickens showed necrosis at the injury site and liver 
(Awan, et al., 2003; Awan, et al., 2011). In addition, Mefenamic acid has been indicated 
in several cases of nephrotoxicity in rats including renal failure (Huq, 2007).  
There are also reported concerns on the use of aceclofenac (Sharma, 2012). In 
humans diclofenac is a metabolite of aceclofenac (Bort, et al., 1996). As such, 
aceclofenac is likely to be toxic either independently or as a result of its metabolism in 
the body into diclofenac. More concerning are their major metabolites 4-
hydroxyaceclofenac and 4-hydroxydiclofenac, will metabolise into each other. This 
metabolic pathway has also been documented in monkey, rat and human subjects 
(Bort, et al., 1996). As discussed in section 1.2.2, livestock are the primary food source 
of many birds of prey, especially carrion. Thus, given the documented metabolism of 
aceclofenac into diclofenac, in all mammal subjects tested to date (Sharma, 2012), 
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there is a real concern that this metabolism would occur in livestock and hence render 
this NSAID, especially in areas of endangered species, as toxic (Sharma, 2012). 
Therefore, the threat of these NSAIDs may extend beyond the parent compound itself 
and hence was included in this research (section 1.3.3, Table 1.1).  
Alongside the concerns of the metabolic products of aceclofenac, likewise the NSAID 
suxibuzone metabolises to the known toxic phenylbutazone, with its links to 
gastrointestinal effects (Cuthbert, et al., 2007b). There is a noticeable lack of studies of 
metabolic pathways and possible subsequent toxicity in species that are at risk, such 
as vultures. Currently, and more importantly, there is a notable absence of the inclusion 
of metabolites in reported analysis methods and the analysis when their parent 
compounds have been implicated in toxicity. It is important to consider these 
metabolites as these compounds could also be toxic. Therefore a method that detects 
parent compounds alongside their metabolites, like the one developed and validated in 
this research, will offer a means of detecting these NSAIDs simultaneously. This is the 
first reporting of its kind in this field of research.  
Despite findings from toxicity and safety studies, Cuthbert, et al. (2011) reported the 
NSAIDs; aceclofenac, diclofenac, flunixin meglumine, ibuprofen, ketoprofen, 
mefenamic acid, meloxicam, nimeuslide, phenylbutazone and piroxicam to be offered 
for sale on the Indian subcontinent by various pharmaceutical companies and 
veterinarians. Often these are sold in formulations with other NSAIDs as a secondary 
ingredient and in bolus and injectable forms. Surprisingly, with the exception of 
diclofenac, meloxicam and ketoprofen, little is known about the toxicity or safety of the 
other NSAIDs. Therefore the continued sale of these compounds is of serious concern 
and hence the development, and application thereafter, of this method is very 
important. This novel method offers a means to monitor these compounds and more 
conclusively identify them as potential threats in the event of recurring mass mortality. 
1.3.3 NSAIDs used the in this study 
Through a review of the literature, continued threat and exposure from a range of 
NSAIDs to protected species have been identified. This included species of an already 
declining population and those at potential risk. Furthermore, a review on NSAIDs 
availability, their toxicity or potentially toxic nature owing to similar chemistry, has 
informed a selection of NSAIDs to be included in this research (section 1.3.3 and 
1.3.4). The NSAIDs investigated in this research were selected as they were either of 
known threat and toxicity or continued exposure, i.e. aceclofenac, carprofen, 
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diclofenac, flunixin, ibuprofen, ketoprofen, nimesulide and phenylbutazone (Cuthbert, et 
al., 2015; Naidoo, et al., 2010; Oaks, et al., 2004; Swan, et al., 2006; Swarup, et al., 
2007; Sharma, 2012; Zorilla, et al., 2014) or available for sale in areas of protected 
species and/or may pose risk i.e. mefenamic acid, meloxicam and piroxicam (Cuthbert, 
et al., 2011).  
In addition, it was identified that there was a lack of the inclusion of metabolites in 
analytical methods in this field. Specifically, there was only one published study looking 
at metabolites of aceclofenac (diclofenac and 4-hydroxydiclofenac) in cattle available to 
vultures (Galligan, et al., 2016). This current research ensures the inclusion of these 
metabolites alongside major metabolites of the known toxic parent compounds flunixin 
(5-hydroxyflunixin), nimesulide (4-hydroxynimesulide) and phenylbutazone 
(oxyphenylbutazone). It also includes the metabolite of meloxicam (5-
carboxymeloxicam), currently the only safe alternative to diclofenac, and 5-
hydroxypiroxicam, the major metabolite of piroxicam (Figure 1.12), considered to be 
related to meloxicam structurally (Figure 1.7). Lastly the metabolite 3-hydroxymethyl 
mefenamic acid is included as its parent compound mefenamic acid is found on sale in 
areas of protected species (Cuthbert, et al., 2011). The selection of these are 
discussed in more detail in section 1.3.7.1.  
This research aims to provide a new analytical detection method. Thus, with a limited 
number of methods published in this research area, thirteen NSAIDs (Table 1.1) and 
seven metabolites (section 1.3.7.1, Table 1.2) have been included in initial 
investigations and preliminary method development and validated for eleven NSAIDs 
and seven metabolites, resulting in the first analytical method to analyse metabolites 
alongside parent compounds. This is also the first time that the NSAIDs selected to be 
investigated, in this field, have been analysed for their detection in feathers.  
1.3.4 The chemical properties and structures of NSAIDs  
NSAIDs are broadly structurally classified as enolic or carboxylic acids, which each 
have specific chemical grouping, such as oxicams and prazolones, and differing 
biological effects (Van Hoof, et al., 2004). These compounds have many functional 
groups in common. The structures of the NSAIDs investigated in this research are 
presented in the Figures 1.1 to 1.13 and their individual classification are presented in 
Table 1.1 Alongside the structures, relative molecular mass (RMM) and corresponding 
pKa acid dissociation constants, are provided, which were later used in the 
development of an efficient sample extraction method and aid in the separation using 
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liquid chromatography. Table 1.1 shows each NSAID listed alongside their generic 
name and their corresponding International Union of Pure and Applied Chemistry 
(IUPAC) chemical name. It is necessary to consider that each NSAID will vary in their 
pharmacokinetics, pharmacodynamics and possible side effects, their modes of 
administration is discussed in detail in section 1.3.5.   
The hepatotoxicity and nephrotoxicity side effects of NSAIDs are suggested to be 
linked to their chemical structure (Cuthbert, et al., 2007). The functional group 
considered to be toxic is the carboxylic acid group with a proximal amine group, as 
highlighted in the structure of diclofenac below by the red and blue rings respectively.  
 
Figure 1.1 Structure of diclofenac  
These functional groups are present in NSAIDs diclofenac, carprofen and flunixin that 
are known to be toxic (Figures 1.1, 1.2 and 1.3 respectively) and aceclofenac (Figure 
1.4), that has been recently highlighted as a concern (Sharma, et al., 2012). However, 
this does not offer an explanation for ibuprofen and phenylbutazone (Figures 1.5 and 
1.6) as both of these are found to cause nephrotoxicity in birds and lack a proximal 
amine group (Sharma, et al., 2012). Ibuprofen, however, does have a carboxylic acid 
group supporting conclusions drawn by Naidoo, et al. (2007). The proposed argument 
(Naidoo, et al., 2007) that meloxicam (Figure 1.7) is considered a safe alternative is on 
the premise that the structure does not contain a carboxylic acid, but does have an 
amine group.  
Additionally, toxicity has also been linked with the metabolism these compounds 
(discussed further in section 1.3.7). During research on the pharmacokinetics of 
meloxicam, Naidoo, et al. (2007) found deficiencies in vulture metabolism, particularly 
in enzymes involved in the conversion of metabolites through a carboxy pathway 
(section 1.3.7). It is proposed meloxicam is a safe alternative (section 1.2.3) due to 
different enzymes used during its metabolism (section 1.3.7), however, in compounds 
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like diclofenac and ketoprofen, they suggested that these deficiencies can result in an 
accumulation of the parent compound and metabolite rendering these compounds toxic 
(Naidoo, et al., 2010b). However, no research has been published on this, thus it 
remains to be fully described and is beyond the scope of this research.  
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Figure 1.2 Structure of carprofen Figure 1.3 Structure of flunixin Figure 1.4 Structure of aceclofenac 
 
 
 
 
Figure 1.5 Structure of ibuprofen Figure 1.6 Structure of  phenylbutazone Figure 1.7 Structure of meloxicam 
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Figure 1.8 Structure of acetylsalicylic acid Figure 1.9 Structure of ketoprofen Figure 1.10 Structure of mefenamic acid 
 
 
 
Figure 1.11 Structure of  nimesulide Figure 1.12 Structure of piroxicam Figure 1.13 Structure of suxibuzone 
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Table 1.1 Classification of NSAIDs 
NSAID RMM pKa Classification Chemical Group IUPAC chemical name 
aceclofenac 354.2 4.7 
carboxylic acids 
acetic acids 
2-[2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxyacetic 
acid 
diclofenac 296.2 4.2 2-(2-(2,6-dichlorophenylamino)phenyl)acetic acid 
flunixin 491.5 5.8 aminonicotinic acid 
2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-
carboxylic acid 
nimesulide 308.1 6.5 anthralic acid N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide 
mefenamic acid 241.3 4.2 fenamic acid 2-(2,3-dimethylphenyl)aminobenzoic acid 
carprofen 273.7 4.4 
propanoic acids 
2-(6-Chloro-9H-carbazol-2-yl)propanoic acid 
ketoprofen 254.3 4.5 2-(3-benzoylphenyl)propanoic acid 
ibuprofen 206.3 4.4 2-(4-(2-methylpropyl)phenyl)propanoic acid 
acetylsalicylic acid 180.2 3.5 salicylic acid 2-acetoxybenzoic acid 
meloxicam 351.4 4.2 
enolic acids 
oxicams 
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-
benzothiazine-3-carboxamide-1,1-dioxide. 
piroxicam 331.1 6.3 
4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-
carboxamide 1,1-dioxide 
phenylbutazone 308.4 4.4 
prazolones 
4-butyl-1,2-diphenyl-3,5-pyrazolidinedione 
suxibuzone 438 4.3 
4-[ [4-butyl-3,5-dioxo-1,2-di(phenyl)pyrazolidin-4-
yl]methoxy]-4-oxobutanoic acid 
Adapted from Richards, 2010; Van Hoof, et al., 2004 
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1.3.5 Modes of administration  
The route of administration is an important factor in determining the onset, duration and 
intensity of the effects of the compound administered. The administration route will 
determine the length of time taken to reach the site of action (BNF, 2012; Jickells and 
Negrusz, 2008). This is also dependent on the individual, but ultimately it is the mode 
of administration that determines the time of action. All compounds in the body undergo 
four main stages; absorption, distribution, metabolism and excretion (Jickells and 
Negrusz, 2008).  
In humans, absorption relates to the mode of administration and the resulting entry of 
the compound. NSAIDs are typically administered to humans orally in tablet form; 
however, they may be administered intravenously and intramuscularly, the latter 
referred to as parenteral, (which has the added benefit of reducing gastric irritation, 
rectally or topically. NSAIDs are short acting and have to be taken a number of times in 
one day (O’Shaughnessy, 2011). In oral administration, absorption is expected to be 
relatively slow compared to intravenous. None the less, taken orally, NSAIDs start to 
relieve pain within an hour after administration (BNF, 2012). The bioavailability of a 
compound is dependent on their solubility in the gastrointestinal tract (GI) and 
absorption within the body (Jickells and Negrusz, 2008).  
Whilst parenteral modes of administration are preferred in veterinary medicine, oral 
administration is used as well (Merck, 2014). Cuthbert, et al. (2011) reported 83 oral 
and 80 injectable formulations of NSAIDs, which are available for sale on the Indian 
subcontinent as the primary formulations in veterinary treatment. European Medicines 
Agency (EMA) state a typical treatment via intramuscular injection at a dose of 2.5 µg/g 
per day for between one to three days treatment in cattle (EMA, 2003; EMA, 2009).   
1.3.6 Mechanism of action in the body  
NSAIDs, as defined in section 1.3.1, exhibit analgesic, antipyretic and anti-
inflammatory properties. These compounds have a shared mechanism of action, 
namely the inhibition of the cyclooxygenase enzyme (COX) function responsible for the 
synthesis of the enzyme prostaglandin (Modi, et al., 2012). Prostaglandins are 
chemicals that maintain the inflammatory process; at the injury site prostaglandins are 
produced to express pain and fever in the body. This mechanism of action was 
discovered in ground-breaking research by Vane (1971) who first proposed inhibition of 
prostaglandin synthesis in acetylsalicylic acid. Vane’s research subsequently helped 
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reveal that the therapeutic benefits and toxicity of NSAIDs are related to their affinity of 
COX inhibition mechanism (Lees, et al., 2004).  
NSAIDs work by blocking arachidonic acid, a short chain fatty acid, from its binding site 
on the COX enzyme. Arachidonic acid serves as a substrate for inflammatory 
mediators which, through a series of cascade reactions, will produce eicosanoid 
mediators; prostaglandins and thromboxanes (Lees, et al., 2004; Modi, et al., 2012). In 
the presence of these mediators, an increased prostaglandin production occurs. Thus 
by means of NSAID administration, inhibition of these chemicals inhibits inflammation 
at the injury site.   
Predominantly there are two main isoforms of the COX enzymes, namely COX-1 and 
COX-2. COX-1 generates prostaglandins that maintain organ function and are 
expressed in all tissues. COX-1 regulates many physiological processes including the 
protection of the GI tract and its mucosa. COX-2 is induced during the body's response 
to inflammation, prostaglandins in this case mediate pain and inflammation at the injury 
site (Lees, et al., 2004). As with most pharmaceuticals, NSAIDs are not without side 
effects and often cases of gastrointestinal and renal conditions are documented (BNF, 
2012). NSAIDs are divided into two major groups; COX inhibitors and selective COX-2 
inhibitors. NSAIDs that inhibit COX-1, such as first generation acetylsalicylic acid and 
ibuprofen, are associated with abdominal conditions like ulcers and bleeding of the gut 
due to the lowered prostaglandin levels (Lees et al. 2004; Vane & Botting 1995). 
Inhibition of these enzymes is often reversible, unlike in acetylsalicylic acid which is 
irreversible. For example, COX-1 is required for maintaining a thick stomach lining, by 
the irreversible blocking of such enzyme, long term use of acetylsalicylic acid could 
lead to thinning of the mucus that protects the stomach. In response new compounds 
have been developed to selectively inhibit COX-2 and as a result decrease the adverse 
GI side effects (Modi, et al., 2012).  
The NSAID meloxicam is one of these newer NSAIDs, selectively inhibiting COX-2 and 
thus reducing risk of adverse effect on GI tract and renal function whilst offering the 
analgesic, anti-inflammatory and antipyretic properties. Whilst the main function of 
prostaglandins have been discussed, these enzymes have an important role in the 
regulation of blood circulation, and vascular permeability and kidney function (Lees, et 
al., 2004; Vane & Botting 1995). In animals, prostaglandins have a minor role in renal 
function, therefore, a possible consequence of continued treatment with NSAIDs can 
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ultimately lead to renal failure. Renal failure results in an accumulation of uric acid in 
the bloodstream and as a result causes visceral gout (Modi, et al., 2012). 
1.3.7 NSAIDs metabolism   
After the adsorption of an NSAID, metabolism occurs. Metabolism is a process by 
which the structure of the compound is changed to aid the removal of compounds from 
the body (Gibson and Skett, 2001). In principle, drug metabolism converts lipophilic 
(“fat-loving”) compounds that cannot be efficiently eliminated by the kidneys into polar 
hydrophilic (“water loving”) products that are easily excreted in urine. Metabolism is 
divided into two phases. Phase 1 reactions include 3 main types; oxidation, reduction, 
hydrolysis alongside N- and O-dealkylation and sulfoxide formation. Phase 1 reactions 
primarily involve introducing a chemically reactive group, for example a hydroxyl, a 
result of a hydrolysis reaction. These groups then serve as an attack site for the 
conjugating system of phase 2 reactions which involves the attachment of an ionised 
group to the drug. These include glucuronic acid, methyl or acetyl groups (Rang, et al., 
2012). Phase 1 metabolism essentially prepares the compound to undergo phase 2 
reactions. The attachment of an ionised group in phase 2 reactions increases the 
polarity of the compound and hence water solubility to enable its excretion and 
elimination from the body (Jickells and Negrusz, 2008).  
Phase 1 reactions take place mainly in the liver although NSAIDs can undergo this 
metabolism phase in the lungs, kidneys and GI tract (Rang, et al., 2012). Metabolites 
produced in phase 1 reactions are often more chemically reactive, interfering with 
cellular function and reacting with certain types of cellular macromolecules. These 
reactions can result in hypersensitivity and necrosis as examples. Therefore, 
sometimes these products are more toxic than the parent compound itself. This is 
especially of concern when the parent compound are known to be toxic (section 1.3.2). 
Products from phase 2 reactions however, are, as mentioned, more polar and therefore 
cannot diffuse across membranes hence, their excretion as generally inactive 
metabolites (Lees, et al., 2004; Rang, et al., 2012).  
Administered orally, NSAIDs may undergo first-pass metabolism where they travel 
through the liver so substantial metabolism of the parent compound can occur prior to 
entry into the circulation system. As a result the amount reaching the circulatory system 
is considerably less than the amount absorbed and hence their bioavailability is greatly 
reduced (O’Shaughnessy, 2011). Whilst first-pass metabolism will reduce the amount 
available for site of action of the parent compound, drugs that are metabolised into 
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active products will have a different profile of activity than a parent compound 
administered parenterally. As such, much larger dosages of drugs are needed when 
taken orally. However, often first-pass metabolism is important for many therapeutic 
compounds whereby a drug may only become pharmacologically active upon 
metabolism. As an example, acetylsalicylic acid has anti-inflammatory properties 
alongside inhibiting platelet function, it becomes hydrolysed to salicylic acid in phase 1 
metabolism whereby it exhibits the desired anti-inflammatory properties (Moffat, 
Osselton and Widdop 2004; Rang, et al., 2012). 
Metabolites are often more persistent in the body than their parent compounds, giving 
rise to longer clinical effects (Willis, et al., 1979). This is due to longer biological half-life 
(t½). The t½ is defined as the time required for drug concentrations in plasma to fall 
below 50% or one half (Jickells and Negrusz, 2008). An example is the main active 
metabolite of phenylbutazone; oxyphenylbutazone is excreted slowly in urine over 
twenty one days compared to two to five days of its parent compound (Dieterle, Faigle, 
Fruh and Mory, 1976). The disposition of compounds, including metabolites, in the 
body includes incorporation into hair, thus they are likely to be present in non-invasive 
keratinous samples, as discussed in more detail in section 1.4.1. These compounds 
diffuse from the blood supply at the base of the follicle into the hair itself. This 
incorporation is dependent on the chemistry of metabolites, such as their hydrophilic 
nature, owing to increased polarity, a result of metabolism. This exhibits lower plasma 
protein binding, and therefore this can result in metabolites being present in lower 
concentrations in blood, than their parent compound (Lees, et al., 2004; Modi, et al., 
2012). This protein binding and the degree to which a compound will bind can affect its 
efficacy; with only the unbound components exhibiting the pharmacological effects. 
Protein binding describes the ability of proteins to form bonds with other compounds, 
hence only the unbound drug is free to interact with receptors, active in the body and 
able to be metabolised and excreted (Lees, et al., 2004; Modi, et al., 2012). For 
example, the major metabolite of meloxicam, 5-carboxymeloxicam, is 95% bound to 
protein meaning 5% is active in the system. This protein binding is presented in Table 
1.2 for each metabolite.   
The metabolism of each NSAID, in humans is well documented. However, in birds of 
prey, specifically vultures, and protected species such as water vole, there is a lack of 
knowledge in metabolic pathways and possible subsequent toxicity information. 
Currently the enzymes that control metabolism of NSAIDs are not described in Gyps 
Vulture. Moreover, the environmental fate and effects of these metabolites in veterinary 
25 
 
medicine is extremely limited (Crane, Boxall and Barrett, 2008). Despite this, research 
into the pharmacokinetics of meloxicam in humans enabled Naidoo, et al. (2008) to 
make some assumptions regarding NSAID metabolism in said species.  
In mammals, tested to date i.e. monkey and rat, NSAIDs are metabolised by 
cytochrome P450 enzymes (CYP450), specifically meloxicam is metabolised by 
enzyme CYP2C9 during phase 1, and as a result the major metabolites 5-
carboxymeloxicam and 5-hydroxymethyl meloxicam are produced. Naidoo, et al. 
(2008), using LC tandem mass spectrometry (LC-MS/MS), tentatively identified 5-
hydroxymethyl meloxicam and one glucuronide conjugate metabolites and concluded 
that vultures are likely to use the same cytochrome P450 enzymes (CY450) and 
standard metabolic pathways as described in other animals. However, highlighted that 
the carboxy- metabolite was absent thus, as hydroxy- metabolites are converted into 
carboxy- metabolites, during phase 1 metabolism, by noncytochrome dependant 
pathway this would suggest the absence of the CYP450 pathways. Deficiencies in 
CYP450 may therefore explain the toxicity of NSAIDs, such as diclofenac and 
ketoprofen, as these deficiencies would allow the accumulation of parent compounds 
and their potentially toxic metabolites, which may interfere with intercellular function 
(section 1.3.2). As stated by Sharma (2012), whether the toxicity of parent compounds, 
such as diclofenac, is caused by themselves or by the metabolites remains unknown. 
Therefore, knowing phase 1 metabolites are often more chemically reactive than parent 
compounds and together with deficiencies in CYP450 enzymatic pathways, metabolites 
may pose a real threat to declining populations.  
1.3.7.1 Metabolites to be detected in this research  
There are two parts when considering metabolism of NSAIDs I) the metabolite in the 
food source i.e. ungulate and II) the metabolism within the species investigated i.e. bird 
of prey or the protected water vole. Currently there is a gap in the literature on the 
metabolism of NSAIDs in protected species, such as birds of prey. Hence, where this 
thesis discusses metabolism it has been primarily inferred through human metabolism, 
and covers metabolism in animals where possible and available. Whilst current 
literature is limited, research has suggested that mammals and birds of prey may use 
standard metabolism (cytochrome P450 enzyme system, as in man). Thus, with the 
uncertainty of the involvement of metabolites in toxicity and the lack of published 
analytical methods offering metabolite detection in this area, this research includes 
seven major metabolites alongside their parent compounds. This data has not been 
available previously.  
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The NSAIDs investigated in this research, as described in section 1.3.2 and 1.3.3, have 
been identified as either of known or potential threat through potential toxicity to 
endangered species. Further to this, a thorough literature review has identified the 
major metabolites (section 1.3.3) of some of these NSAIDs and their relation to 
hepatotoxicity and/or nephrotoxicity. As first introduced in section 1.3.3, the major 
metabolites included as an analyte of interest in the simultaneous detection method 
are; 4-hydroxydiclofenac, 3-hydroxymethyl mefenamic acid, oxyphenylbutazone, 5-
hydroxyflunixin, 5-hydroxypiroxicam, 5-carboxymeloxicam and 4-hydroxynimesulide. 
These have been selected not only due to reported adverse effects (in humans and 
animals), but the threat they may pose. Their threats and metabolism are discussed in 
detail below. The structures of the metabolites discussed are presented in Table 1.2, 
alongside plasma protein binding percentages (section 1.3.7), and functional groups 
considered to be toxic, namely a carboxylic acid with a proximal amine, highlighted in 
red and blue rings respectively (section 1.3.4).  
As discussed in previous section 1.3.6, parent compounds undergo metabolism and 
may produce active major metabolites, these in turn are often more chemically 
reactive. This is especially the case in the major metabolites (Table 1.2) of 
aceclofenac, diclofenac, mefenamic acid, phenylbutazone and suxibuzone, as 
discussed throughout this section.   
As first introduced in section 1.3.2, the metabolic pathways of aceclofenac (Table 1.1) 
were reported by Bort, et al. (1996) in humans. The major metabolites of aceclofenac, 
4-hydroxyaceclofenac (Table 1.2), is known to metabolise into diclofenac and its major 
metabolite 4-hydroxydiclofenac (Table 1.2), in several mammalian subjects. Thus, 
where the sale of aceclofenac is still legal on the sub-Indian continent in areas of 
endangered species, this could highlight another exposure route to diclofenac, even 
before the toxicity of aceclofenac itself has been confirmed. Sharma, et al. (2012) 
suggests that while metabolism has not been reported in livestock, given that 
aceclofenac metabolises into diclofenac in all mammalian species tested to date, and 
that livestock make up principal food source of scavengers, this highlights there may be 
a real threat from aceclofenac metabolising into diclofenac in the food source of 
protected species. For this reason the major metabolites of aceclofenac and diclofenac 
(diclofenac and 4-hydroxydiclofenac, respectively) (Table 1.2) have been included in 
this investigation.  
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In the case of 3-hyroxymethyl mefenamic acid (Table 1.2), the major metabolite of 
mefenamic acid, toxicological consequences remain unclear however, the metabolic 
pathway of this compound and its major metabolite employs the same noncytochrome 
dependant pathway that has been reported to be absent in birds of prey (section 1.3.6) 
(Naidoo, et al. 2008). Whether this would accumulate and render these compounds as 
toxic needs to be investigated. The fact remains that these compounds are closely 
related to diclofenac with very similar chemical structures (Figures 1.1, 1.11 and Table 
1.2).  
Whilst some NSAIDs produce toxic metabolites other NSAIDs may not, such as 
meloxicam, nimesulide. However, these are still of concern as there is a lack of 
knowledge surrounding the toxicity of the parent compounds and metabolic pathways, 
as is the case in meloxicam. Whilst currently the only safe alternative to diclofenac 
(section 1.2.3), meloxicam is reported to metabolise into 5-carboxymeloxicam (Table 
1.2) in humans and mammals (Turck, Roth and Busch, 1996), the same group 
identified as potentially toxic by Cuthbert, et al. (2006) (section 1.3.4) and metabolised 
by the absent pathway in birds of prey, namely vultures (Naidoo, et al. 2008). 
Furthermore, with a relatively long half-life of twenty hours (Aberg, et al., 2009), if 
proven to be toxic it is highly likely that it would accumulate in the body and interfere 
with cellular function. For these reasons, 5-carboxymexloicam (Table 1.2) has been 
selected in this research as it is a carboxy metabolite 
To date, there are only a few research papers on the detection of nimesulide and 
metabolites in human plasma and urine (Singla, Chawla and Singh, 2000). However, 
as recent publications are now suggesting nimesulide is toxic (Cuthbert, et al., 2015), 
the major metabolite 4-hydroxynimesulide is also included in this research. The 
pharmacokinetics and metabolism of nimesuide was studied in humans, whereby the 
main metabolite (4-hydroxynimesulide) (Table 1.2) provides anti-inflammatory and 
analgesic properties after phase 1 metabolism. It has been suggested that its toxicity is 
lower than that of the parent compound (Bernareggi, 2001). However, Bernareggi 
(2001) did note that nimesulide is almost exclusively eliminated by hepatic metabolism 
(metabolism in the liver) and thus, hepatic impairment can reduce the rate of 
elimination. If an accumulation was to occur this could cause adverse effects in 
protected species, but more research would need to be carried out to investigate this.  
Other metabolites included in this research are oxyphenylbutazone (metabolite of 
phenylbutazone), 5-hydroxyflunixin (metabolite of flunixin) and 5-hydroxypiroxicam 
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(metabolite of piroxicam) (Table 1.2). These metabolites have been selected as their 
parent compounds have been implemented in toxicity and have been reported on sale 
in areas of protected species (section 1.3.2 and 1.3.3). This is especially the case with 
oxyphenylbutazone, the major metabolite of phenylbutazone, and phenylbutazone itself 
(the major metabolite of suxibuzone, section 1.3.2, Table 1.2) are reported to have high 
incidences of GI adverse effects and blood deficiencies in humans and mammals 
(Woodhouse and Wynne, 1987).  Thus as it seems most NSAID metabolites are, or 
have the potential of being toxic, this research has included not only those highlighted 
as a concern, like aceclofenac and diclofenac, but includes others that may be studied 
later showing them to be the same.  
Some major metabolites of parent compounds (carprofen ester glucuronide - carprofen, 
salicylic acid - acetylsalicylic acid, 2-hydroxyibuprofen – ibuprofen and ketoprofen ester 
glucuronide – ketoprofen) (Table 1.2) have not been included in this research as, unlike 
those to be investigated, there has been no reporting’s of toxicity or adverse effects in 
this field of research, often a result of efficient elimination from the body. As an 
example, carprofen metabolism has been reported to vary greatly between some 
animal species and humans but has shown not to accumulate and eliminate rapidly, its 
mechanism of action is still relatively unclear (Ray and Wade, 1982). Carprofen 
undergoes phase II metabolism to produce an ester glucuronide metabolite. As 
discussed in section 1.3.6, this would suggest this metabolite is polar and thus 
excreted with little activity in the body, this metabolite has not been implemented or 
documented in any toxicity.  
This research intends to simultaneously detect seven major metabolites of NSAIDs 
(Table 1.2) as identified that may be toxic to endangered species. It includes those 
where toxicity needs to be investigated further, due to the limited understanding of 
metabolic pathways and mechanism of action in birds of prey and mammals. This 
makes the analytical method presented in this current research novel, as this is the first 
reporting of its kind in this area.  
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Table 1.2  Major metabolites and chemicals structures  
Parent 
compound/NSAID 
Major metabolite (% 
protein binding) 
Chemical Structures 
Metabolic 
phase and 
reaction 
Reference 
aceclofenac 
4-hydroxyaceclofenac 
(74-79%) 
 
Phase 1 
hydroxylation  
Bort, et al., 1996 
diclofenac 
4-hydroxydiclofenac 
(40%) 
 
Phase 1 
hydroxylation  
Menasse, et al., 1978 
mefenamic acid 
3-hydroxymethyl 
mefenamic acid (52%) 
 
Phase 1 
hydroxylation 
Huq, 2007 
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meloxicam 
5-carboxymeloxicam 
(95%) 
 
Phase 1 
oxidation 
Naidoo, et al., 2007 
nimesulide 
4-hydroxynimesulide 
(40%) 
 
Phase 1 
hydroxylation 
Singla, Chawla, and 
Singh., 2000 
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phenylbutazone 
oxyphenylbutazone 
(60%) 
 
Phase 1 
oxidation 
Bakke, Draffan and 
Davies., 1974 
flunixin 
5-hydroxyflunixin 
(NA)* 
 
Phase 1 
hydroxylation 
Wasfi, et al., 1998 
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piroxicam 
5-hydroxypiroxicam 
(60%) 
 
Phase 1 
hydroxylation 
Woodhouse and 
Wynne, 1987 
suxibuzone Phenylbutazone (NA)* 
 
Phase 1 
hydroxylation 
Yasuda, et al., 1981 
carprofen 
carprofen ester 
glucuronide (50-60%) 
 
Phase 2 
conjugation 
Rubio, et al., 1980 
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acetylsalicylic acid salicylic acid (50-80%) 
 
Phase 1 
hydrolysis 
Rang, et al., 2012 
ibuprofen 
2-hydroxyibuprofen 
(28%) 
 
Phase 1 
hydroxylation 
Woodhouse and 
Wynne, 1987 
ketoprofen 
ketoprofen ester 
glucuronide (65%) 
 
Phase 2 
conjugation 
Advenier, et al., 1983 
*(NA) protein binding percentage not available 
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1.4 NON-INVASIVE SAMPLES 
Previously in section 1.1.1, the emphasis on the importance of unconventional sample 
analysis was discussed in relation to non-invasive sampling from protected species. 
With continued threats to many species by the continued exposure to veterinary 
pharmaceuticals, particularly NSAIDs, there is an urgency for a method to enable the 
detection of such compounds using non-invasive samples such as hairs and feathers. 
As previously discussed, the use of primarily conventional samples, such as blood and 
tissue, could pose ethical issues, decomposition problems and conservation concerns 
when working with fragile populations. In this section; the concept of hair and feather 
analysis is considered, the incorporation of NSAIDs in hair is discussed including the 
use in the context of forensic and environmental sciences and advantages of promising 
environmentally robust samples selected to be analysed in this study. 
1.4.1 The incorporation of NSAIDs and their metabolites in hair 
Hair analysis works on the premise that as the hair grows, compounds are incorporated 
into the hair structure (Gaillard and Pépin, 1999). Essentially, hair, whether human or 
animal, is composed of keratin and is an outgrowth from a follicle (Harkey, 1993). 
Situated at the base of the follicle, the bulb generates the various layers of the hair 
shaft which includes the medulla (core layer), cortex and cuticle. There are three 
stages of hair growth, anagen, catagen and telogen respectively; during the anagen 
stage, compounds are incorporated into the hair from the bloodstream (Richards, 
2010).  
The main factors that influence the incorporation of compounds into the hair are 
melanin affinity, lipophilicity and basicity (pKb) of the compound (Wenning, 2000). It is 
proposed that the incorporation of compounds in hair is through diffusion from the 
blood supply at the base of the hair follicle and thus, affected by the same parameters 
influencing the transport of the drug in the body i.e. adsorption, distribution and 
elimination (section 1.3.5 and 1.3.6) (Gaillard and Pépin, 1999). The compound must 
first cross the plasma membrane to permeate a cell, thus the chemistry of a compound 
plays an important role in its affinity to bind. As such, most veterinary pharmaceuticals 
are weak acids or bases and are present in the blood bonded to plasma protein or in 
the ionised form. It is only the fraction which is non-bonded i.e. non-ionised (section 
1.3.7) and of suitable liposolubility that can undergo passive diffusion (Gratacos-
Cubarsi, et al., 2006). Furthermore, plasma membrane exhibits low permeability to 
polar compounds thus basic and hydrophobic compounds have a stronger binding 
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capacity to hair (Moffat, Osselton and Widdop 2004). NSAIDs used in this project are 
generally weak acids and since they are often administered for long periods of time this 
will ensure a constant presence of parent compounds and metabolites, through their 
accumulation, in the body tissues and hair samples. As was the case in the dead 
carcasses of livestock on the Indian subcontinent.  
It is proposed that after elimination of the parent compound from the body, metabolites 
are likely to be present and are often more persistent in the body due to longer t½ 
(section 1.3.7) (Willis, et al., 1979). However, the parent compounds tend to be 
incorporated into the hair follicle more readily due to their lipophillic properties. For 
example, it was reported by Huq (2007) that the major metabolites of mefenamic acid 
(Table 1.2) are more soluble in water than parent compound thus incorporation into 
keratinous matrices may be lower than the parent compound. It is important to 
remember that in the food source parent compounds and metabolites are likely to be 
present therefore both compounds may pose a threat. As such, recent studies have 
suggested that the toxicity of diclofenac, to vultures specifically, is still unclear and 
whether it’s the toxicity of diclofenac itself or in fact by its metabolites or a combination 
of both is unknown (Sharma, 2012). Therefore, metabolites have been included in this 
research. 
The major advantage of hair analysis is the sampling of hair which is relatively non-
invasive, as mentioned in section 1.1 and 1.1.1. The incorporation of compounds 
through the bloodstream and into a matrix such as hair can be applied to animals 
(section 1.4.2). Thus sampling, non-invasively, wildlife species that may be exposed to 
NSAIDs in the environment, may offer the detection of these compounds both pre or 
post mortality but could essentially offer an early detection method to identify exposure 
prior to mass mortality or loss of population. 
1.4.2 History and advantages of hair analysis 
The analysis of hair was first introduced in the 1960s and 1970s after the pioneering 
analysis to assess human exposure to heavy metals, such as lead or mercury, using 
atomic absorption spectroscopy (Baumgartner, et al., 1979). At this point examination 
of hair for organic chemicals was not possible as analytical methods were not sensitive 
enough (Kintz, 2004). However, ten years after the first investigations, Baumgartner, et 
al. (1979) reported differences in the concentrations of morphine along the hair shaft 
correlating to the time of heroin use. Reservations were still apparent in the scientific 
community and it wasn’t until well after the 1990s, when numerous studies illustrated 
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hair to be a highly suitable matrix in the detection of drugs of abuse in forensic 
toxicology (Kintz, 2004). The detection of drugs of abuse in human hair and nails has 
since become a commonly used practice in forensic science, particularly the detection 
of illicit drugs (Englehart, et al., 1998; Henderson, 1993; Kintz, 2004; Ng, et al., 2006).  
Hair analysis has gained increased acceptance as a viable alternative to the 
conventional analysis of blood and urine for drug testing in forensic toxicology 
(Nakahara, 1999). So far in forensic investigations, the analysis of feathers has 
primarily consisted of physical examinations in the identification of birds and external 
contaminates. However, in safety testing of food animals, poultry feathers are gaining 
recognition as matrices in which to monitor for residues of compounds that could be 
harmful to human health (Love, et al., 2012). In environmental investigations, the 
analysis of feathers, like hair, has been used since the 1960s as a viable matrix for 
monitoring heavy metals in birds (Burger, 1995; Haskins, Kelly and Weir, 2013; 
Pilastro, et al., 1993). Researchers have suggested birds will reduce their body burden 
by excreting metals into their feathers and it is thought this may be the case with other 
compounds too. Analysing keratinous matrices allows for a wide window of detection 
(months to years) of many compounds depending on the length and rate of hair growth 
(Baumgartner, et al., 1989). This is in contrast to the analysis of tissue samples where 
the detection window would have ceased, via excretion as discussed below and shown 
in Table 1.3.  
In forensic toxicology, the screening test for drugs of abuse traditionally includes 
conventional matrices such as plasma, tissue, serum and blood. The analysis of these 
matrices is limited and such samples timeframe of detection falls far short in 
comparison to hair samples (Table 1.3). Furthermore, the exposure to environmental 
conditions and length of time contribute to the degradation of conventional matrices. As 
mentioned previously, it is clear that the longest window of detection is in hair (120 
days, Table 1.3), with drugs of abuse detectable well after they would cease to be 
detected in the conventional samples, such as blood and urine.  
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Table 1.3 The timeframe of detection for drugs of abuse in corresponding 
matrices 
Matrix Detection timeframe / days 
Saliva 1-36 (hours) 
Blood / plasma 1-2 
Urine 1-7 
Sweat 1-14 
Hair 120 
Adapted from Richards, et al. (2014) 
1.4.3 Feathers and the incorporation of analytes  
In response to the limited knowledge of NSAID detection in alternative matrices, this 
research investigates the analysis of feather samples on the premise that, like hair, 
compounds will be incorporated and thus detectable via analytical instrumentation. 
Feathers are primarily made up of keratin and are formed in the same way as hair from 
follicles (Lucas and Stettenheim, 1972). The feather filament epidermis has three 
layers; the outermost layer is the feather sheath, the middle intermediate layer and the 
inner basal layer, the later forms the feather rachis and barb (Lucas and Stettenheim, 
1972; Richards, 2010). Feathers grow rapidly until they reach their final size and 
remain attached to an inert follicle. The feather cycle, like in hair, is divided in a growth 
phase (anagen) which spans over several days to months or years, and a resting 
phase (telogen) which can span a few days to around fourteen months. All avian 
species undergo moulting to shed or replace feathers; most moults occur gradually but 
this varies for each species depending on breeding cycle habitat and migrations. Molts 
can also be either complete or partial; complete in which the bird replaces all feathers 
or partial where only some feather types are replaced (Lucas and Stettenheim, 1972; 
Richards, et al., 2014). 
Once the feather is fully formed the blood vessels degenerate and thus the 
incorporation of any compound is stopped. A newly formed feather will have a direct 
blood supply hence NSAIDs are incorporated during the growth phase. If the 
concentrations in feathers accurately mirror the body burden during formation, feathers 
that are replaced should reflect the highest levels whilst feathers that are moulted last 
should accumulate the lowest concentrations (Haskins, Kelly and Weir, 2013; Richards, 
et al., 2014). 
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1.4.3.1 The selection of optimal feathers for analysis 
There are five main types of feathers; contour or veined, the down, filoplume, 
semiplumes and bristles. Each of these types have a particular function, namely, the 
contours are the major flight feathers whilst the semiplumes act as insulation (Yu, et al., 
2004). The contour feathers are laid in complex patterns of tracts over the body of the 
bird covering most of the surface and act as protection from the elements i.e. the sun 
and rain. The contour feathers are divided into those that cover the body and the flight 
feathers. The flight feathers of the wing are separated into three groups, the primaries, 
secondaries and tertiaries, collectively known as the remiges. The primaries are 
responsible for the forward thrust of the bird and are at the end of the wing, while the 
secondaries are located in the middle of the wing providing the lift. The tertiaries are 
the flight feather closest to the body, however, are not as important as primary and 
secondary feathers. The tail and coverts are the last flight feathers, of which the tail 
(retrices) act as the brakes and rudder controlling the flight while the coverts are at the 
very base of the flight feathers acting as a cover. The down, filoplumes, semiplumes 
and bristles, are thought to have sensory and offer insulation and protection. As there 
are many different types of feathers, the difficulty surrounds which are optimal for 
analysis (Proctor, 1993; Richards, et al., 2014), this is discussed below.  
With the growth phase of some feathers taking months, this far exceeds the predicted 
36 to 58 hour period between exposure to diclofenac and resulting mortality as 
presented by Oaks, et al. (2004). In a growing feather this lengthy timeframe should 
allow for the incorporation of the compounds of interest into the blood vessels in the 
feathers prior to death and allow for its detection thereafter. The difficulty is being able 
to identify the subsequent feathers whose growth coincides with the exposure. Given 
their length, primary and secondary flight feathers should be the optimal samples for 
analysis, however on ethical grounds and from an animal welfare prospective, the 
removal of these feathers in living birds is unacceptable, flight can be disrupted and 
can cause discomfort. Thus in living birds alone, body feathers, such as down, 
filoplume, semiplumes and the bristles, should be sampled, unless primaries or 
secondaries can be collected when moulted or lost naturally. These continuously grow 
and are relatively non-invasive, do not disrupt flight and can be collected from several 
locations of the body even external sites like identified nests may be advantageous. In 
this research, previously donated moulted feathers have been analysed (Chapter Five).  
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1.5 THE ANALYTICAL TECHNIQUES EMPLOYED IN THIS RESEARCH 
This section includes the use of analytical techniques currently being used in the 
investigation of NSAIDs. There is specific emphasis on LC-MS as this is the technique 
used in this research. However, a comparison of LC-MS and LC coupled with tandem 
mass spectrometry (MS/MS) and gas chromatography coupled with mass spectrometry 
(GC-MS) is presented. GC-MS techniques are readily used and relied on in this field of 
research with LC-MS/MS being applied too, however, these involve expensive set up 
and running costs compared to LC-MS used in this research. This research has also 
highlighted the comparable, and in some cases, better sensitivity of LC-MS when 
compared to LC-MS/MS, as discussed in Chapter Four.  
1.5.1 Review of use of analytical techniques  
Current publications present analytical techniques for the detection of NSAIDs in 
tissue, serum, urine and wastewater, whether through singular or simultaneous 
analysis (Gallo, et al., 2006; Haj, et al., 1999; Ibanez, et al., 2009; Loffler and Ternes, 
2003; Redderson and Heberer, 2003). In these publications the analytical methods 
employed varies between the traditional GC-MS and LC-MS, however, some have 
implemented tandem mass spectrometry (MS/MS), ultraviolet (UV) with diode array 
detection (DAD) (Hu, et al., 2012; Van Hoof, et al., 2004; Vinci, et al., 2006). Research 
conducted by Taggart, et al. (2009) is the first and only paper to describe the analysis 
of nine NSAIDs in ungulate liver tissues, collected from carcass dumps across seven 
Indian states, available to endangered vultures using LC-MS. This current project, 
implements the use of LC-MS to detect NSAIDs that previous methods do not include, 
such as aceclofenac and piroxicam (section 1.3.3), and also includes seven major 
metabolites. Results from Chapter Four shows the LC-MS technique employed to be 
more sensitive than published LC-MS and in some cases LC-MS/MS methods (section 
4.4.5). 
The importance of analytical detection methods was first discussed in the earlier 
section 1.1 with the limitations of the published method discussed throughout the 
chapter. It is apparent that overall, analytical techniques in this field are limited and so 
need to be developed. This research will provide this through the development of a 
new analytical method capable of detecting, simultaneously, NSAIDs and metabolites 
currently known to be of threat.  
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With the continued advances in chromatography and the applications of LC-MS gaining 
more and more interest, alongside the potential of analysing unconventional samples 
being both promising and growing, there is a gap in knowledge (SAVE, 2012) for a new 
method that will in turn fulfil the calls for an LC-MS method capable of the detection of 
more than ten NSAIDs (SAVE, 2012). Simultaneously employing LC-MS, this study 
aims to detect thirteen NSAIDs and seven major metabolites, including two internal 
standards flufenamic acid and piroxicam-d3. The selection of internal standards is 
discussed in section 1.6.1 investigating their suitability within the method for 
development (section 3.1), and in Chapter Four for its validation.  
1.5.2 LC-MS in comparison to other available techniques  
LC-MS (also often referred to as high performance or ultra-performance liquid 
chromatography coupled with mass spectrometry; HPLC-MS or UPLC –MS 
respectively) is a fundamental separation technique in analytical laboratories 
(Shimadzu, 2012). It has been used for separating, analysing and purifying mixtures 
since the 1970s (McMaster, 2005). However it has not always been the preferred 
choice of technique; until the millennium, the favoured analytical technique was GC-MS 
(McMaster, 2005; Petrovic, et al., 2005). Unlike GC-MS, LC-MS has the capabilities of 
separating a variety of compounds varying from small molecular compounds and 
biological molecules and compounds, including those that are thermally liable and 
volatile (McMaster, 2005; Petrovic, et al., 2005). Furthermore, owing to the elevated 
polarity and weakly acidic nature of NSAIDs, employing LC avoids derivatisation steps 
that are required in GC-MS, especially in the analysis of acidic compounds (Barcelo 
and Hansen, et al., 2009). These factors are particularly important when analysing a 
wide range of environmental samples, from water to keratinous matrices, and where 
the analytical method is to be employed in countries with basic instruments where 
funding may be limited. This is especially important as LC-MS is often more cost 
effective than typically used LC-MS/MS (section 1.5.1).  
In recent years it has been reported that LC-MS sales have nearly equalled to those of 
GC-MS and it is the advances in the technology, such as new interfacing techniques 
and more user friendly systems that have made LC-MS easier to implement 
(McMaster, 2005). Previously, interfaces that restricted or reduced gas flow into the 
mass spectrometer made combinations of GC-MS a widely used technique for years 
(Petrovic, et al., 2005; Shimadzu, 2012). In liquid chromatography, when vaporised, the 
solvent represents of volume 1000 times greater than that of carrier gas used in GC. 
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Developments have improved gas flow by using combinations of pumping and heating 
with an additional drying gas stream and ionisation at atmospheric pressure, this is 
discussed further 1.5.3.1. This is not without disadvantages, soft ionisation techniques 
can supress ion formation and in doing so will provide less structural information. 
However, it is important to remember LC-MS analysis will almost always yield a 
molecular ion (M+) unlike GC-MS and therefore making it possible to limit the possible 
target analyte identity.  
While both analytical methods require mobile and stationary phases the main 
difference between the two techniques are the mobile phases employed. GC-MS uses 
a gas phase typically an inert gas like helium, compared to solvents used in LC-MS. 
The latter is particularly disadvantageous due the large volumes used. LC-MS requires 
only ultra-pure solvents, meaning that the technique can become costly and less 
environmentally friendly than its GC-MS counterpart. Despite these disadvantages LC-
MS still remains the most suited technique for this field of research and the matrix 
under analysis. 
With these factors in mind, liquid chromatography has been selected as the technique 
of choice in this research as it provides a lower cost and simpler alternative to tandem 
mass spectrometry, whilst having many advantages over the use of GC-MS (Huber, 
2007). 
1.5.3 Liquid Chromatography with Mass Spectrometry  
LC-MS uses HPLC as a means of sample separation, consisting of a solvent pump, a 
sample injector, column, detector and data collection component. A computer connects 
these components of the system together providing control to the LC, the flow of 
solvent and injection. Furthermore the computer is used for the data acquisition and 
processing post analysis; thus acquiring peak area, determine molecular weights of the 
components and fragmentation pattern (McMaster, 2005, Petrovic, et al., 2005).  
The introduction of the analyte into the instrument begins with injection of the analyte 
into the mobile phase which carries the sample onto the column via a sample loop. 
When the liquid mobile phase reaches the injector the sample flows through the 
column by the flow of the liquid mobile phase where separation of analytes occurs. The 
analyte ultimately reaches the detector where it must pass through an interface when it 
enters the MS.   
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(McMaster, 2005) 
Figure 1.14 HPLC configuration 
The MS generates mass spectra to be interpreted in the identification of the compound. 
A more in-depth discussion on fragmentation, ions generated and choice of ions for 
detection is presented in Chapter Three. The MS consists of three main components; 
an ion source, which ionises analytes in a solution into a gas phase, a mass analyser 
which measures the mass of ions and the detector which measures the abundance. 
Critically, the analyte is introduced from the HPLC into the MS by being sprayed and 
ionised under atmospheric pressure by the atmospheric pressure ionization probe 
(e.g., Electrospray Ionisation (ESI) or Atmospheric Pressure Chemical Ionisation APCI 
probe). The ionised sample is introduced through the sample introduction unit, the 
desolvation line (DL). The charged droplets are heated by the DL thus, removing the 
solvent to introduce ions into the vacuum. The ions generated are focused and 
thereafter introduced into the quadrupole rods by the lens system comprising of the 
Qarray, skimmer, lens components and octapole (Figure 1.15). The Qarray and 
skimmer are responsible for focusing the scattering of the ions emitted from the DL. 
The Qarray main function is as an ion guide; where multi-stage high frequency ions are 
arranged. While the skimmer is the partition that separates the primary and secondary 
vacuum chambers. In the Octapole (a high-frequency ion guide located behind the 
skimmer), like the Qarray, high-frequency voltage is applied to eight plate electrodes to 
confine the ions and cause them to converge. Thereafter the resulting ions are 
separated in accordance to their mass-to-charge ratio (m/z) by the quadrupole mass 
analyser (section 1.5.3.2) (McMaster, 2005; Shimadzu, 2012). Figure 1.15 shows the 
configuration of the MS. 
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The final stage is the detector is made up of conversion dynode and electron multiplier 
whereby it detects positive and negative ions that have passed from the quadrupole 
rods. Ions are accelerated by the conversion dynode and collide. The collision of these 
rods releases ions and secondary electrons which travel to the electron multiplier. 
These secondary electrons are detected, amplified and sent to the data system. 
 
(Shimadzu, 2011) 
Figure 1.15 Configuration of Mass spectrometer  
1.5.3.1 Electrospray ionisation interface 
Electrospray ionisation (ESI) belongs to the wider atmospheric pressure ionisation 
(API) techniques. In this ionisation technique, ions in the HPLC solution are transferred 
to the gas phase prior to sampling into the mass analyser. The interface between a 
liquid phase and a gas phase whilst maintaining a vacuum has posed difficulty for 
some time (McMaster, 2005), as introduced in section 1.6.1. With the advances in ESI 
this has changed (McMaster, 2005). ESI is a very soft ionisation technique therefore 
results in little fragmentation (section 3.2.5).  
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The process, as shown in Figure 1.16, involves the application of an electric field 
across the interface, a heated metal capillary pipe surrounded by nitrogen flow 
(nebulising gas), by which the eluent is passed. An electrospray is dispersed into fine 
aerosol of charged droplets where an electrostatic field causes further dissociation of 
analyte droplets (seen in Figure 1.17). The electrospray droplets possess positive or 
negative charges, dependant on the charge applied to the sampling cone. The drying 
gas then causes the droplets to vaporise as the charge concentration increases. 
Repulsive forces between ions with like charges exceed the cohesive forces to allow 
the resulting ions to be desorbed (ejected) into the gas phase. These ions are attracted 
to and pass through a capillary sampling orifice into the mass analyser thus allowing 
separation of ions produced on the basis of mass to charge ratio (Watson and 
Sparkman, 2007).   
 
(Shimadzu, 2011) 
Figure 1.16 Electrospray Ionisation  
1.5.3.2 The quadrupole mass analyser 
At the heart of the mass spectrometer is the analyser that measures the mass of an 
ion. The quadrupole mass analyser is the most widely used analyser due to its ease of 
use, mass range covered, good linear and dynamic range for quantitative work, 
resolution and quality of mass spectra (Watson and Sparkman, 2007). The analyser 
consists of four parallel rods arranged in a square with a void down the middle where 
the analytes are directed down, see Figure 1.17. The four rods are electrically 
connected to each other in opposite pairs, two with constant direct current (DC) voltage 
and two with alternating current (AC) voltage. The latter makes ions spiral as they pass 
down the quadrupole whilst the constant charge pulls the ions in a constant direction 
towards one pair of electrodes (Watson and Sparkman, 2007; McMaster, 2005; 
Shimadzu, 2012). 
46 
 
 
(Shimadzu, 2011) 
Figure 1.17 Quadrupole mass analyser  
The stability of an ion in the quadrupole is dependent on the size of the alternating and 
direct current. The stability refers to the analyte making it through the quadrupole rods 
rather than hitting the electrode where it is lost, depicted in Figure 1.17 in blue red and 
green. The conventional quadrupole works by scanning the voltages applied to the four 
parallel rods. During the majority of the scan the ion is unstable, however for a brief 
moment, scan lines past through the stable region and will result in the ion passing 
through to the detector at the other end and thus producing an emerging peak 
(Shimadzu, 2012).  
The quadrupole can operate in two modes; scanning mode (scan) or selected ion 
monitoring mode (SIM). The latter is significantly more sensitive than scan mode, as it 
monitors only selected ions. Typically SIM mode is instigated for quantitation and 
monitoring of target compounds whilst scan mode is generally used for screening used 
for qualitative analysis and quantification when all analyte masses are unknown in 
advance. Sensitivity of scan mode is dependent on the number of ions scanned, scan 
speed and resolution. In LC-MS it is possible to run both positive and negative mode in 
order to analyse molecules that will ionize in positive and negative modes specifically. 
The NSAIDs in this research favour the latter (section 3.2.4) (McMaster, 2005; Watson 
and Sparkman, 2007).   
1.6 DEVELOPMENT AND VALIDATION OF AN ANALYTICAL METHOD 
This section introduces the preliminary investigations needed to be carried out to 
develop and validate an analytical method. Analytical methods employed in quantitative 
analysis are required to obtain reliable, repeatable and accurate data and as such, 
method development, and validation thereafter, is carried out to demonstrate that the 
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method of choice is suitable for its intended use (Ellison, Barwick and Farrant, 2009; 
Peters, Drummer and Mussholf, 2007).  
A number of guidance documents regarding the development and validation of 
analytical methods have been published by various organisations (FDA, 2014; EMA, 
1995; Huber, 2007). For example, IUPAC published “harmonized guidelines for single 
laboratory validation of method of analysis” whilst the United States Food and Drug 
Administration (FDA) have developed two guides; one for the validation of analytical 
methods and another for bioanalytical analysis (ICH, 2005; Huber, 2007). 
Investigations and guidelines set out by Commission Decision (2002), Centre for Drugs 
Evaluation and Research, International Conference on Harmonisation, and in Huber 
(2007) were followed throughout the analytical parts of this project.  
1.6.1 Selection of NSAIDs and internal standards 
In analytical chemistry the use of internal standards is often employed to aid in 
reproducible quantitative results. Internal standards are compounds that are known to 
the analysts and will produce a relative signal between the analyte and internal 
standard so that any changes in instrumental response or noise is counteracted 
(Nakahara, 1999). By calculating a ratio between the analytical response of an internal 
standard and that of the analyte, a calibration plot can be constructed. Therefore, on 
the addition of an internal standard to samples of unknown concentration this ratio can 
be calculated for quantification (Dolan, 2012). The first step of the method development 
was to choose a suitable internal standard for the simultaneous analysis of NSAIDs 
(section 3.1). It was also paramount to consider that the selected internal standards 
should not be present in samples, should form well-resolved peaks, elute around the 
analyte of interest and be stable. Additionally it is necessary for the internal standard to 
have a close chemical relationship to the analyte, i.e. of a similar structure, so that it 
has comparable chromatographic response namely; extraction characteristics, 
retention times, stability and detector response (Dolan, 2012).  
Two internal standards were selected in this research, namely flufenamic acid and 
piroxicam-d3, the former was selected owing to its common use by previous 
researchers on similar analysis (Kang and Kim, 2008, Niopas and Daftsios, 2002, Ou 
and Frawley, 1984). Piroxicam-d3 was selected as a deuterated analogue having a 
similar structure and analytical response to target analyte (piroxicam under 
investigation in this case) and are unlikely to be found in environmental samples, such 
as feathers (Davison, Milan and Dutton, 2013, Owen and Keevil, 2012).  
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The suitability of the internal standards were verified during initial method development, 
recording retention time (RT) and relative retention factor (RRF) (section 3.1). The 
stability of these compounds (section 3.3) were tested prior to method validation 
thereafter. RT is the time taken for the compound to elute at maximum peak height 
from injection (Nakahara, 1999). RTs of compounds are dependent on many 
operational parameters of the instrument. Therefore the RRF (the ratio of retention time 
of analyte to retention time of internal standard) is calculated to correct the difference in 
analytical response i.e. peak area and noise, essentially providing a ratio that can be 
used for identification due to its independence from fluctuations in response.  
1.6.2 Method optimisation 
Method optimisation involves the development and modification of instrumental 
parameters such as the stationary phase, mobile phase, gradient elution programs 
(where mobile phase composition is changed during the analytical run), optimal solvent 
selection (section 1.6.2.8) and injection volume (section 1.6.2.9). As a result of these 
modifications, any that affect chromatographic profiles in a negative way are 
minimised, and those that improve performance are selected.  
A good chromatographic profile is a peak, originating from Gaussian distribution, i.e.  
tall, sharp, narrow and symmetrical. The distinction between good chromatography and 
poor chromatography is influenced by several factors, for example, column efficiency 
(N) (section 1.6.2.1 and 1.6.2.2), capacity factor (𝑘) (section 1.6.2.4), selectivity (∝) 
(section 1.6.2.5), resolution (𝑅𝑠) (section 1.6.2.6) and peak asymmetry (𝐴𝑠) (section 
1.6.2.7). Hence, these were studied to achieve an optimised method suitable for 
method validation (Chapter Four). During the development and modification of the 
gradient elution program, the chromatographic profiles of each compound were 
assessed until the most optimal method had been developed (section 3.2) (Huber, 
2007; CDER, 1994). As part of this optimisation, the selection of a suitable column 
(section 1.6.2.3) was an important consideration alongside changes to the gradient 
elution program.  
1.6.2.1 The Plate Theory of chromatography – column efficiency  
Column efficiency is measured as theoretical plate number, an indirect measure of 
peak width and the ability of a column to produce narrow sharp peaks. The plate theory 
proposes that a chromatographic column is made up of a large number of separate 
layers, called theoretical plates and it is these plates that govern the shape of the 
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resulting peaks in the chromatogram (Braithwaite and Smith, 1996; Neue, 1997). In 
these plates, equilibration of the sample between the stationary and mobile phase 
occur. As the mobile phase moves through the column, this results in the transfer of 
mobile phase and analyte from one plate to the next (also known as mass transfer). In 
these plates, compounds with a greater affinity for the stationary phase will bond more 
strongly and thus, be retained in the column for longer. This results in the separation of 
compounds into bands and with the movement of the mobile phase the bands move 
down the column separating as they travel.   
In terms of the resolving power to separate analytes in the column, it is said, the higher 
the plate numbers the more efficient the column, (Neue, 1997) and by reducing the 
particle size of the UHPLC column, efficiency (plate number) is increased (Neue, 
1997). Hence, a column with a high plate number will produce a sharper (narrower) 
and more intense peak, showing normal distribution, i.e. Gaussian shape and overall 
results in better separation from adjacent peaks. Plate number or column efficiency can 
be calculated from the half-height method in the following equation 1.1, where 𝑡𝑟 is the 
retention time of the peak of interest and 𝑊0.5 is the peak width (units of time) at half-
height (Dolan, 2016).  
𝐍 = 𝟓. 𝟓𝟒 (
𝒕𝒓
𝑾𝟎.𝟓
)
𝟐
                (Equation 1.1) 
This half-height method is commonly used as it enables calculation of N if the peak is 
not fully separated from the neighbouring peak. This method assumes that the valley 
between the peaks is lower than half-height of the peak under investigation (Dolan, 
2016).   
Figure 1.18 systematic of half height method for plate number 
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As an alternative to plate number (N) for column efficiency, plate height (H) is a 
measure of the length of column needed for the equilibrium process to proceed (the 
resolving power of the column). H is defined as the height equivalent of the theoretical 
plate (HETP) determined by plate number (as discuss above) and is given by the 
equation 1.2 (IUPAC, 2014). Where L is the length of column and N is the plate number 
(calculated in Equation 1.1). 
𝐇𝐄𝐓𝐏 = 𝐋/𝐍                  (Equation 1.2) 
1.6.2.2 The Rate Theory of chromatography 
Whilst the plate theory helps to understand the processes inside the column, the rate 
theory of chromatography considers the time taken for the compound under analysis to 
equilibrate between the two phases. Thus, it considers the resulting band shape (band 
broadening) which is affected by kinetic variables such as, the rate of elution, diffusion 
(the net movement of molecules) and mass transfer of the analyte between the 
stationary and mobile phase (section 1.6.2.2) (Braithwaite and Smith, 1996; Neue, 
1997).  
Band broadening is a phenomenon that reduces the efficiency of separation in the 
analytical column, leading to poor chromatographic response, i.e. resolution (section 
1.6.2.6), and peak asymmetry (section 1.6.2.7). For this reason the Van Deemter 
equation for height equivalent of the theoretical plate (HETP) (Equation 1.3) arises from 
rate theory to relate the resolving power of the column to the experimental variables 
that affect band broadening namely, Eddy diffusion (A), longitudinal diffusion (B) and 
resistance to mass transfer (C) (Neue, 1997). A graphical presentation on Equation 1.3 
is presented in Figure 1.19.  
𝐇𝐄𝐓𝐏 = 𝐀 +
𝐁
𝐮
+ 𝐂𝐮              (Equation 1.3) 
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Figure 1.19 Graphical presentation of contributing factors to the Van Deemter 
equation 
Eddy diffusion (A) (Figure 1.19) describes the movement of the analyte through the 
column, whereby the analyte will take different paths, at random, through the stationary 
phase. These paths occur due to small variations in particle size and lack of 
homogeneity of the stationary phase. This causes band broadening, a result of 
differences in path length, consequently resulting in a board peak shape (Braithwaite 
and Smith, 1996; Neue, 1997). As such, the effects of Eddy diffusion can be minimised 
by selecting a well packed column with smaller particle size, as was the case in this 
research by changing from a HPLC column with 5µm particle size to a UHPLC column 
of 1.7µm (section 1.6.2.3 and 3.2.1). 
Meanwhile, an analyte will diffuse from the centre of a peak meaning the concentration 
of the analyte is at its highest in the centre and lowest at the edges of the peak as it 
diffuses, this process is called longitudinal diffusion (B) (Figure 1.19) (Neue, 1997). 
Longitudinal diffusion arises from the effects of linear velocity i.e. the flow rate. Band 
broadening will be worsened at low flow rates as the compounds under investigation 
will spend more time on the column resulting in a broader peak when compared to high 
linear velocity. To overcome this effect, a narrower column (decreasing the internal 
diameter) with a higher flow rate will ensure less time spent on the column resulting in 
tall, sharp and narrow peaks (section 1.6.2.3 and 3.2.1) (Neue, 1997).  
Lastly, mass transfer (C) (introduced in section 1.6.2.1, Figure 1.19) refers to the time 
taken for the compound of interest to equilibrate between the stationary and mobile 
phase. The time spent in equilibration is thus dependent on the velocity of the mobile 
phase and the compounds affinity for the stationary phase. As such, if the analyte has 
a strong affinity to the stationary phase and the velocity of the mobile phase is high, 
then band broadening will occur as the mobile phase moves ahead of the analyte of 
interest. Unlike longitudinal diffusion, mass transfer is therefore worsened with higher 
linear velocity, however, effects can still be minimised in the same way i.e. the smaller 
the column diameter the less band boarding will result from mass transfer (Braithwaite 
and Smith, 1996). Mass transfer was an important consideration during the solvent 
selection (sections 1.6.2.8 and 3.3.2) and injection volumes (section 1.6.2.9 and 3.2.3).  
It is important to understand these factors and their role in chromatographic response. 
It is apparent that these factors are therefore related to the column and the compounds 
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under investigation and therefore can be manipulated to optimise performance. As 
such, these factors were considered during method optimisation (section 3.2).   
1.6.2.3 Column selection 
The analytical method in this research was intially adapted from Baranowska and 
Kowalski’s (2010) simultaneous detection HPLC method (section 2.2.1, Table 1.2). 
This was selected based on the inclusion of four NSAIDs covered in this research and 
its applicability to environmental samples, specifically waste and surface waters. The 
first stage in method development, was the selection of a column. A commonly used 
column for the type of analytes investigated in this research is the UHPLC kinetex 
column C18 with trimethylsilyl (TMS) with a particle size of 1.7 µm, internal diameter 
2.1mm, 100mm in length. 
The kinetex column is a reverse phase, meaning generally the stationary phase is 
relatively non-polar and the mobile phase is polar. Analytes dissolve in like for like, 
hence the most polar analytes are eluted from the column first followed by the other 
analytes in order of decreasing polarity (Synder and Dolan, 2007). This type of 
chromatography is commonly used in the analysis of NSAIDs and is particularly 
advantageous in the analysis of hydrophilic and hydrophobic compounds (Miao, Koenig 
and Metcalfe, 2002; Baranowska and Kowalski, 2010). 
Additionally, improved peak symmetry (section 1.6.2.7) can be achieved at increased 
flow rates resulting in a shorter run time accompanied by the possible increase in 
resolution (section 1.6.2.6) (Guillarme and Veuthey, 2008; Neue, 1996). In a HPLC 
column, a larger internal diameter (ID), typically 4.6mm, requires higher volumes of 
mobile phase through high flow rates. Changing from a HPLC 4.6mm to a UHPLC 
2.1mm ID column, as used in this research, can lower the flow rate, in turn lowering the 
solvent volume, thus achieving optimal linear velocity (the speed at which the solvent 
front travels the length of the column) without an increase in analysis time (section 
1.6.2.2) (LGGC, 2015). Similarly a decrease in ID can increase sensitivity when 
injecting the same analyte mass. By changing the column diameter, the amount of 
stationary phase will reduce, in turn affecting the loading capacity, leading to an 
increased analyte concentration in the mobile phase (Neue, 1996). Therefore, the 
column selected in this research ensured a reduction in the solvent volume used 
without compromising the efficiency or selectivity of the analytical method (section 
1.6.2.2). The analysis time was shortened, typically this is determined by the length in 
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column. In general the length is directly proportional to retention time amongst column 
efficiency and backpressure (Guillarme and Veuthey, 2008). 
Whilst a reduction in analysis time and column length is acceptable, efficiency of 
chromatographic separation is paramount. Therefore, after the selection the UHPLC 
column, optimisation of the gradient method parameters were investigated (section 
3.2.1), making changes to improve overall chromatographic separation and peak 
resolution (Huber, 2007; CDER, 1994).  
1.6.2.4 Capacity factor 
The first parameter to be evaluated was the capacity factor (𝑘). 𝑘 is equal to the ratio of 
retention time (𝑡𝑟) of the peak under investigation to the retention time of the unretained 
peak  or the dead time of the column (𝑡𝑚), equivalent to the time where there is no 
affinity for the stationary phase, also referred to as dead time. This can be calculated in 
the following equation (CDER, 1994): 
𝒌 =
𝒕𝒓−𝒕𝟎
𝒕𝟎
                  (Equation  
1.4) 
 
Figure 1.20 Systematic of peak separation use in the calculation of capacity 
factor, selectivity, resolution and peak asymmetry   
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An ideal 𝑘 is between one and five, whereby if less than one it implies the analyte is not 
highly retained in the column and therefore, elution is quick compared to higher values 
(>5) signifying slow elution of anaytes from the column (IUPAC, 2014).  
1.6.2.5 Selectivity 
Selectivity (∝), is defined as the ability to assess explicitly the analyte in the presence 
of other components expected to be present (Huber, 2007). It is a measure of the 
separating power of the column. It considers two peaks at any one time and measures 
the separation between the 2 compounds (the ratio capacity factors for both analytes). 
Selectivity of <1 suggests that compounds cannot be separated as they are more or 
less retained in one peak. When selectivity is >1 this shows the two analytes are 
separated from each other. Selectivity is calculated through the following equation: 
∝=
𝒌𝟏
𝒌𝟐
=  
𝒕𝒓𝟐− 𝒕𝟎
𝒕𝒓𝟏−𝒕𝟎
                          (Equation 1.5) 
Where: 𝑘1 is the capacity factor of the less retained peak (eluting first) and 𝑘2 is the 
capacity factor of the more retained peak (eluting second). Calculated in values of time, 
as depicted in Figure 1.20. 
1.6.2.6 Resolution 
Where compounds are not fully separated, resolution (Rs), is the measure of peak 
overlap. To calculate Rs plate number (N), selectivity (∝) and capacity factor (𝑘) are 
incorporated into the equation. Selectivity and capacity factor are measures of retention 
in the column and therefore influence the retention of compounds. Consequently, 
increases in plate number and selectivity increase resolution, while an increase in 
capacity factor will decrease the resolution power (Dolan, 2016). It is paramount that all 
three factors are optimised to achieve optimal resolution overall. When peaks are fully 
resolved, Rs is said to be >2, however, mutual overlap is accepted for values between 
1.0 and 1.5 (Huber, 2007; CDER, 1994). Resolution is calculated using the following 
equation, as depicted in (Figure 1.20):  
𝑹𝒔 =
𝟏
𝟒
(
∝ −𝟏
∝
) (
𝒌
𝒌+𝟏
) √𝑵                        (Equation 1.6) 
55 
 
1.6.2.7 Peak asymmetry  
The last parameter is peak asymmetry factor, a measure of peak tailing and fronting, 
describing peak shape. The ideal chromatographic profile was surmised earlier in the 
section (1.6.2.1), however, undesirable effects, in the form of peak tailing and fronting, 
can occur during method development. Tailing and fronting occur when the peak 
becomes distorted, typically fronting occurs when too much sample has been 
introduced and tailing can arise from effects of mass transfer, between equilibrium of 
the phases and the analyte in the plates (section 1.6.2.2). The following equation is 
employed to calculate overall peak asymmetry (CDER, 1994): 
𝑨𝒔 =
𝒃
𝒂
                                     (Equation 1.7) 
Where: 𝐴𝑠 is the peak asymmetry factor, 𝑏 is the distance from the point at peak 
midpoint to the trailing edge (measured at 10% of peak height) and 𝑎 is the distance 
from the leading edge of peak to the midpoint (measured at 10% of peak height) 
(Figure 1.20). A peak asymmetry factor of <1 indicates fronting while >1 indicates 
tailing. 
Peak asymmetry is important to consider in method development, as problems with 
asymmetrical peaks often present problems with resolution and quantification. They 
become more difficult to resolve and thus, integrate to provide a peak area resulting in 
quantification that is much less reproducible (Braithwaite and Smith, 1996).  
After the investigation of these parameters, and optimisation of gradient elution 
program (section 3.2.1), retention times of all NSAIDs, and major metabolites were 
recorded, as shown in Table 3.3 and 3.4, alongside the RRF for identification purposes. 
These retention times were used throughout preliminary investigations, method 
validation (Chapter Four) and ultimately the identification process in the analysis of 
matrices (Chapter Five).  
1.6.2.8 Solvent and mobile phase selection 
Selecting solvents in liquid chromatography is an important step in achieving high 
sensitivity and selectivity, peak shape and chromatographic resolution (Ahuja and 
Rasmussen, 2007). Solvent selection can be just as important in method development 
as the instrumental parameters themselves, yet it is often overlooked (Ahuja and 
Rasmussen, 2007). The selection process must involve the selection of solvents that 
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analytical standards are prepared in, mobile phase constitution and use of additives. In 
LC-MS the use of additives is common practice. It involves the addition of chemicals to 
the mobile phase to supress unwanted ionisation in order to improve analyte response 
and enhance selectivity, this is especially advantageous in the analysis of complex 
matrices.  
Formic acid, as used in this research, is a commonly used in a wide range of 
applications with LC-MS. The use of formic acid is to facilitate ionization by ensuring 
the analyte of interest is more basic than that of the solvent (Waters, 2015). For 
example, in the compounds investigated in this research, some are carboxylic acids 
having pKa values ranging from 3.5 to 6.5 (Table 1.1) When the pH of the mobile phase 
is above this range, the acidic compounds are ionised. This results in poor 
chromatographic profiles due to shorter retention on the column. However, by lowering 
the pH below the pKa, the compounds will become unionised and thus the ionisation of 
the carboxylic acids supressed, this increases the retention and results in better 
chromatography (Dolan, 2001; Wrezel and Pakula, 2005). Furthermore, the addition of 
formic acid suppresses the silanol activity of the stationary phase, essentially 
decreasing the unwanted interactions between basic molecules and the acidic silanol 
groups, thus, improving chromatographic separations resulting in better retention and 
peak shape of the analytes of interest (Dolan, 2001). These developments in solvent 
selection are discussed in detail in section 3.2.2. 
The most obvious consideration for sample solvent and mobile phase selection is the 
solubility of the analyte. However, factors such as the ability to dissolve the analyte of 
interest, produce good chromatographic profiles (section 1.6.2.1), avoid degradation of 
the sample and increase selectivity should also be considered (Wrezel and Pakula, 
2005). In the case of the latter, the solvent is an important consideration as upon 
injection and entry into the column thereafter, this is the place where the solvent and 
mobile phase are mixed for the first time. If incorrectly chosen, the disparity in solvent 
strength, between the solvent and mobile phase, can result in peak distortion, and thus 
analytical response (such as fronting and tailing). This distortion arises during the mass 
transfer of sample and mobile phase between the theoretical plates and equilibrium 
between the two phases (section 1.6.2.2). To negate the disparity in solvent strength, it 
is suggested, that an ideal sample solvent is the starting composition of the mobile 
phase (MP at T0) (Wrezel and Pakula, 2005). MP at T0, acetonitrile and methanol were 
investigated during method development, assessing the chromatographic profiles of 
compounds to find the optimal solvent (section 3.2.2). 
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1.6.2.9 Injection volumes 
Chromatographic behaviour of a compound can be affected by many operational 
variables within the analytical method (section 1.6.2.2). This is especially relevant to 
injection volumes, whereby small changes can be made to obtain the best 
chromatographic results, giving rise to its investigation during method development 
(section 3.2.3). It is crucial that during development any changes or variables that can 
improve analytical response and chromatography are optimised (sections 1.6.2.1 to 
1.6.2.8). Ideal chromatography involves achieving a peak profile of normal Gaussian 
distribution, one that is symmetrical, narrow and sharp. Whilst tailing, fronting (section 
1.6.2.7) and band broadening (1.6.2.2) kept to a minimum. The latter, band 
broadening, is especially problematic as it can result in a loss of efficiency, poor 
resolution and poor chromatographic profiles of compounds investigated i.e. distorted 
peak shape and broad peak resolution. In this study, in addition to avoiding mass 
overloading, chromatographic profiles i.e. peak asymmetry (section 1.6.2.7) was 
investigated in the selection of the optimal injection volume, alongside RSD (section 
3.2.3).  
Overload in chromatography refers to the column condition where the sample size is so 
large and/or too concentrated, that performance is compromised (Synder and Dolan, 
2007). This is described at two levels, either mass transfer or volume overload. The 
first considers the mass or concentration of the sample that is injected, whilst volume 
overload considers the injection volume, whether too large or too small. Band 
broadening effects arising with mass transfer (introduced in the rate theory, section 
1.6.2.2, in the Van Deemter Equation (Equation 1.3)), will occur when too higher 
concentration saturates the column. As a result, the analyte will not equilibrate with the 
phases in the bands and will travel further down the column giving rise to broad peaks 
with drastically reduced resolution. Similarly in volume overload, effects of longitudinal 
diffusion will become apparent when high volumes of analyte are injected. Here peak 
broadening will be evident during the diffusion of the peak, if too much volume is 
injected then peaks will start to tail and retention times will increase (Hostettmann, 
Marston and Hostettmann, 1998).  
To avoid any possible overload, the sample volume injected should be less than 10µl 
injection volume when using 100% strong solvent (Synder and Dolan, 2007). Following 
these guidelines injection volumes of 0.2µl, 2µl and 10µl were investigated (section 
3.2.3) at corresponding concentrations of mixed NSAID standards prepared in 100% 
acetonitrile (section 2.3.3), with the starting composition of mobile phase and methanol.   
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1.6.3 Identification of NSAIDs and diagnostic ions                                                                                   
Compounds of interest can be identified through a series of parameters, whether 
qualitative i.e. comparison to standards, or quantitative i.e. determining the 
concentration of an unknown. In this research, compounds under investigation were 
initially identified by their RT and RRF. Solvent blanks were assessed by monitoring for 
any interference at RT of interest and mass spectra for each of the NSAIDs, in both the 
scan and selected ion monitoring (SIM) mode, were investigated (section 3.2.4). SIM 
(section 1.5.3.2) ensures a selective and sensitive method by distinguishing between 
detected compounds (Huber, 2007). 
In the identification of NSAIDs, some researchers monitor only 2 diagnostic ions, 
however, the World Anti-Doping Agency or WADA (2003), recommend the analysis of 
at least three diagnostic ions, including one quantification ion and two confirmations 
ions, to ensure the correct identification of compounds of interest (WADA, 2003). In this 
thesis, the guidelines provided by the World Anti-Doping Agency are followed, ensuring 
the use of 3 ions for each of the NSAIDs, thus enabling a minimum of one ion ratio for 
the identification according to the Commission Decision (2002). The identification of 
NSAIDs and diagnostic ions is discussed in section 3.2.4 with the implementation of 
SIM in section 3.2.5. 
1.6.4 Stability 
Stability is one of the parameters investigated during method development and 
validation (section 3.3 and 4.2) as analytes can decompose prior to investigation 
whether during preparation, storage or analysis. To determine the stability of the 
chosen analytes during analysis time, method development should include an 
investigation into their short term stability (autosampler stability). Typical sample 
analysis time in this research ranged between 24 to 54 hours, with the majority of that 
time spent in vials in situ on the temperature controlled autosampler at 150C (section 
3.3). These results offer a way of calculating, within certain degree of fluctuation, the 
allowed time span between sample preparation and analysis. In any analysis, products 
of degradation may exist and the presence of these can be monitored during stability 
testing (Huber, 2007). Furthermore, it is paramount to consider longer term stability 
(section 4.2), i.e. the maximum time from preparation to completion of all investigations 
and to account for standard storage in case of any unforeseen instrumental 
breakdown. With this in mind, a 6 day stability study was carried out in triplicate. 
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Stability considers samples to be stable if instrument response is within relative 
standard deviation (RSD) of 15% (Huber, 2007; Peters, 2007). 
1.6.5 Precision and Accuracy 
Precision is the close agreement between measurements, whilst accuracy is defined as 
the agreement between the true value and the experimental value. Precision is 
considered in intra-day repeatability and inter-day reproducibility studies (Huber, 2007). 
Repeatability refers to the precision of the analytical method achieved through replicate 
measurements made in a short time (section 3.4). Repeatability is often referred to as 
inter-assay precision. Intermediate precision expresses variations over days (section 
4.2). Accuracy was considered in terms of % Recovery during the application of the 
method (section 5.2.2) (Miller and Miller, 2010). 
Precision is determined and assessed by the relative standard deviation in percentage, 
often referred to as RSD. In terms of analytical methods acceptance criteria for 
precision is 15% RSD and if concentrations are nearer the limits of quantification (LOQ) 
then RSD of 20% are accepted (ICH, 2005; Peters, Drummer and Musshoff, 2007).  
1.6.6 Linear range 
The International Conference for Harmonisation (ICH) defines linearity as the capability 
of a method, within a range, to obtain results that are directly proportional to the 
concentration of the compound of interest in the sample. Linearity is investigated over a 
wide range of concentrations including at the very low and very high ends of 
concentrations. Ascertaining the linear range also provides information about the 
sensitivity of the method and the instrument, for example how low the method can 
detect at (Ellison, Barwick and Farrant, 2009). Results are presented as linear plots of 
instrumental response against concentration. A linear regression line is then fit and a 
linear regression equation calculated. Through the interpretation of linear regression 
plots, the linear range can be determined. The range of an analytical method is the 
region of upper to lower concentration levels that follow a linear trend within a degree 
of precision. Any data points that tail off and deviate at the low and high concentrations 
signify a change in non-linear behaviour in analytical response. When analysing 
linearity in this research the individual peak area ratios (peak area of the most 
abundant ion/most abundant ion of internal standard), were used for instrumental 
response. The resulting regression line of best fit is obtained from least squares which 
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minimises the sum of squared differences between the observed value and fitted 
values from the line (CDER, 1994; Ellison, Barwick and Farrant, 2009).   
Analytical methods should be free from bias and thus random and of normal 
distribution (Peters, Drummer and Musshoff, 2007). Although standard deviation gives 
a measure of the spread about the mean, it does not indicate the shape of the 
distribution or the randomness of errors. Normality or rather normal distribution refers 
to the distribution of random errors; a random variable will result in normal distribution 
(Peters, Drummer and Musshoff, 2007). To test normality of these errors, within the 
investigation of linearity, the non-parametric Shapiro Wilk or goodness of fit test and 
Wald-Wolfowitz runs test have been applied (section 4.4.4) (Mehta and Patel, 2012).  
The assessed linear range has been discussed in section 4.4. 
1.6.7 Limits of Detection (LOD) and Limits of Quantification (LOQ) 
The LOD and LOQ are determined at the lower end of linear range, the LOD is defined 
as the lowest concentration that the analyte can be detected at but not necessarily 
quantified and similarly the LOQ is the lowest concentration that the analyte can be 
quantified with suitable precision and accuracy (Ellison, Barwick and Farrant, 2009; 
Peters, Drummer and Mussholf, 2007). Furthermore, LOD and LOQ assesses if 
instrumental response is distinguishable from a response of the blank. LOD and LOQ 
arecalculated as shown in equations 1.8 and 1.9 (IUPAC, 2014): 
Limit of detection = 𝑦𝐵 + 3𝑠𝐵                (Equation 1.8) 
Limit of quantification = 𝑦𝐵 + 10𝑠𝐵               (Equation 1.9) 
Where 𝑦𝐵represents the response of the blank and 3𝑠𝐵 represents 3 times the standard 
deviation of the blank (10 times in LOQ 10𝑠𝐵).  
1.7 RESEARCH AIMS 
There is a considerable lack of research into NSAIDs detection and analysis in a 
wildlife context. A thorough literature review identified only one paper on the analysis of 
NSAIDs in such context, specifically the detection of nine NSAIDs in ungulate tissue 
available to endangered species using LC-MS (Taggart, et al., 2009). Furthermore, the 
method did not include NSAIDs since identified of concern nor any metabolites. This is 
especially important to consider, as some are more potent and persistent with slow 
excretion. From the initial literature reviews of this research it was identified there is a 
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need to address the lack of research surrounding the use of non-invasive samples in 
the detection of these compounds as currently in this field analysis is carried out on 
post-mortem traditionally used samples such as blood and tissue. Taggart, et al. (2009) 
analysed liver and kidney samples from livestock post-mortem. Other papers have only 
analysed for one NSAID, diclofenac and again only in post-mortem vulture samples 
(Oaks, et al, 2004). This research is novel in its approach to different samples 
(keratinous feathers and hairs) that could be sourced pre-mortality to quickly identify 
possible early exposure and some could be collected non-invasively through shedding. 
Additionally, feather samples are covered by this research but the method could be 
rolled out to samples (such as animal hair and furs) from other species that could be 
exposed to such pharmaceuticals. 
Typically NSAIDs are analysed using LC-MS/MS in environmental samples such as 
wastewater, however, this project uses LC-MS which is a lower cost and simple 
alternative. This method could be used in countries with basic analytical instruments. 
This is the first reported research/detection to include the combination of these eleven 
NSAIDs, importantly it also includes seven metabolites never analysed before in a 
wildlife sample. Therefore the aims of this research are: 
1) A critical review of literature to identify NSAIDs currently of environmental and 
toxic concern and to include other NSAIDs that pose a future environmental 
impact. To also include, metabolites that have been reported to be more potent 
and persistent in the body than their parent analyte. 
2) To develop and validate a new method for these NSAIDs and metabolites using 
LC-MS. 
3) To use the validated method on extracted keratinous samples and this 
extraction method will also become part of the validation. 
4) Publish and collaborate findings to organisations to aid in wildlife conservation. 
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CHAPTER 2: METHODOLOGY  
This chapter describes the LC-MS instrumental settings, methods and materials 
(section 2.1 and 2.2) used in this research. It is divided into three sections thereafter; (I) 
initial method development: preliminary development (section 2.3), (II) validation 
studies (section 2.4) and (III) sample preparation and application of the validated 
method (section 2.5). These sections highlight the various studies conducted in the 
development and validation of the analytical method and the application in feather 
samples. The LC-MS instrumental parameters have been discussed in the relevant 
section alongside the standards preparation and materials used.  
2.1 CHEMICALS AND REAGENTS 
Technical grade aceclofenac, acetylsalicylic acid, carprofen, diclofenac sodium, 
flufenamic acid, flunixin meglumine, ibuprofen, ketoprofen, mefenamic acid, meloxicam 
sodium, nimesulide, phenylbutazone, piroxicam, deuterated piroxicam (piroxicam-d3) 
and suxibuzone (all in powder form) were purchased from Sigma-Aldrich, UK. 
Technical grade metabolites 4-hydroxydiclofenac, 5-hydroxyflunixin, 5-
hydroxypiroxicam and oxyphenylbutazone (all in powder form) were purchased from 
Sigma-Aldrich, UK. Whilst 3-hydroxymethyl mefenamic acid, 4-hydroxynimesulide and 
5-carboxymeloxicam (all in powder form) were obtained from Santa Cruz 
Biotechnology, Germany. 
HPLC and LC-MS grade solvents acetonitrile, methanol and water alongside additives; 
formic acid, acetic acid and ammonium acetate were purchased through Fisher 
Scientific and Sigma-Aldrich, UK. Ultra-pure water suitable for HPLC use was purified 
using an Elga PURELAB Option, available at Anglia Ruskin University, Cambridge.  
2.2 STANDARDS PREPARATION  
2.2.1 Standards preparation: stock solution 
Single and mixed NSAIDs stock solution (aceclofenac, acetylsalicylic acid, carprofen, 
diclofenac, flunixin, ibuprofen, ketoprofen, mefenamic acid, meloxicam, nimesulide, 
phenylbutazone, piroxicam and suxibuzone) of 1mg/ml were prepared in acetonitrile 
and methanol.  
Stock solutions of 3-hydroxymethyl mefenamic acid, 4-hydroxydiclofenac, 4-
hydroxylnimesulide, 5-carboxymeloxicam were prepared at 0.5mg/ml in acetonitrile and 
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prepared at 1mg/ml for 5-hydroxyflunixin, 5-hydroxypiroxicam and oxyphenylbutazone 
in acetonitrile. Internal standards (flufenamic acid and piroxicam-d3) of 100µg/ml were 
prepared in acetonitrile.  
2.2.2 Standards preparation: working solutions 
Working solutions of single and mixed NSAIDs of 100µg/ml were prepared from the 
stock solution (1mg/ml) in acetonitrile and methanol (section 2.2.1). Working solutions 
of the metabolites were prepared at 50µg/ml and 100µg/ml from the single stock 
solutions (1mg/ml and 0.5mg/ml) in the presence of internal standard at 0.1µg/ml, in 
acetonitrile. 
2.3 INITIAL METHOD DEVELOPMENT: PRELIMINARY INVESTIGATIONS  
2.3.1 Optimisation of gradient elution program 
The analytical method in this research was adapted from Baranowska and Kowalski’s 
(2010) simultaneous detection HPLC method (Table 2.1). Optimisation was carried out 
using mixed NSAIDs standards as prepared in section 2.2.1. 
Table 2.1 original HPLC method (Baranowska and Kowalski, 2010) 
Original 
HPLC 
method 
Time 
(minutes) 
Solvent A % 
water/0.05% 
trifluoroacetic acid 
Solvent B % 
methanol  
Solvent C % 
acetonitrile 
Gradient 
elution 
program 
0 89 10 1 
10 50 30 20 
15 50 30 20 
17 30 20 50 
25 5 5 90 
30 89 10 1 
A Shimadzu LCMS-2020 was employed during method development and validation 
(section 2.3.1) fitted with a kinetex C18 with trimethylsilyl (TMS) endcapping stationary 
phase column with a particle size of 1.7µm, internal diameter 2.1mm, 100mm in length. 
With a matching SecurityGuard 2.1mm guard column and cartridge. The column was 
purchased from Phenomenex. LABSolutions software was used for system control, 
data acquisition and data retrieval. 
As Baranowska and Kowalski’s (2010) method employed HPLC, initial changes in the 
method parameters were made to the gradient elution program time from 30 to 16 
minutes to account for the change in column (from a HPLC Develosil RPAQUE-OUS-
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AR-5 C30, 250mm in length, 4.6mm internal diameter and 5.8µm particle size), 
particularly its length, and technique being employed (LC-MS) (Table 2.2, section 3.2.1, 
Figure 3.3). 
Table 2.2 Adapted gradient elution program analysis time, to account for change 
in column (method A) 
Method A 
Time 
(minutes) 
Solvent A % 
water/0.1% 
formic acid 
Solvent B % 
methanol/0.1% 
formic acid  
Solvent C % 
acetonitrile/0.1% 
formic acid 
Gradient 
elution 
program  
5 50 30 20 
7.5 50 30 20 
8.5 30 20 50 
13 5 5 90 
16 89 10 1 
Thereafter adaptions were made to the gradient elution program until the best 
separation was achieved (Table 2.3, section 3.2.1, Figure 3.4). 
Table 2.3 Adapted gradient elution program (method B) 
Method B 
Time 
(minutes) 
Solvent A % 
water/0.1% 
formic acid 
Solvent B % 
methanol/0.1% 
formic acid  
Solvent C % 
acetonitrile/0.1% 
formic acid 
Gradient 
elution 
program  
0.5 89 10 1 
1 60 25 15 
1.1   5 
5  30  
8  20  
10 5 5 90 
11 - 16 89 10 1 
Further method development was carried out changing the mobile phase. Method C, 
involved the removal of methanol, leaving water/0.1% formic acid (A) and 
acetonitrile/0.1% formic acid (B) as two mobile phases (Table 2.4, section 3.2.1, Figure 
3.5).  
  
65 
 
Table 2.4 Adapted gradient elution program, with two mobile phases (method C) 
Method C 
Time 
(minutes) 
Solvent A % 
water/0.1% formic acid 
Solvent B% 
acetonitrile/0.1% formic acid 
Gradient 
elution 
program 
0.5 98 2 
1 75 25 
5 65 35 
12.5 40 60 
15.5 0 100 
16.5 0 100 
17-18 99 1 
Thereafter, adaptions were made at one minute, decreasing mobile phase B 
percentage to 12.5% B, and adjusting the percentage at five minutes to 25% B instead 
of 35% B. This method formed the final optimised gradient elution used in validation 
studies (section 2.3.1) (Table 2.5, section 3.2.1, Figure 3.6).  
Table 2.5 Optimised LC gradient elution parameters (method D) 
Optimised 
Method 
Time 
(minutes) 
Solvent A % 
water/0.1% formic acid 
Solvent B% 
acetonitrile/0.1% formic acid 
Final 
gradient 
elution 
program 
0.5 98 2 
1.0 87.5 12.5 
5.0 75 25 
12.5 40 60 
15.5 0 100 
16.5 0 100 
17 - 20 99 1 
2.3.2 Optimal solvent selection for standards  
Mixed NSAID standards of 20µg/ml (section 2.2.1) were prepared in three solvents to 
test for analyte solubility and optimal solvent selection (section 3.2.2); 100% 
acetonitrile, 98:2 mix of water 0.1% formic acid and 2% acetonitrile 0.1% formic acid (to 
mimic the starting mobile phase constitution) and 100% methanol. Standards were 
analysed using parameters in Table 2.5 and 2.6. 
2.3.3 Injection volumes 
To investigate optimal injection volumes for ideal method performance (section 3.2.3), 
three injection volumes of 0.2µl, 2µl and 10µl were analysed at concentrations of 
20µg/ml in acetonitrile, respectively using ibuprofen and mefenamic acid as examples. 
Based on initial results (section 3.2.3), mixed NSAID standards at 20µg/ml were 
prepared in 100% acetonitrile were injected in volumes of 0.2µl and 2µl.  
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2.3.4 Initial autosampler stability in an intra-day study over 54 hours 
Mixed standards were analysed for 54 hour autosampler stability (15ºC). Stability 
(section 3.3) was investigated at three concentrations, 0.05, 0.5 and 5µg/ml 
respectively. These were prepared from the 100µg/ml mixed NSAID working solution in 
the presence of internal standard at 0.1µg/ml (section 2.2.2). 
2.3.5 Intra-day repeatability precision studies 
Intra-day repeatability precision (section 3.4) was tested at three concentrations, 0.05, 
0.5 and 5µg/ml respectively. These standards were prepared from the 100µg/ml mixed 
NSAID working solution in the presence of internal standard at 0.01µg/ml (section 
2.2.2).  
2.4 VALIDATION STUDIES 
2.4.1 LC-MS instrumental parameters  
Validation was conducted on a Shimadzu LCMS-2020 was fitted with a kinetex C18 
with trimethylsilyl (TMS) endcapping stationary phase column with a particle size of 1.7 
µm, internal diameter 2.1mm, 100mm in length. With a matching SecurityGuard 2.1mm 
guard column and cartridge. The column was purchased from Phenomenex. 
LABSolutions software was used for system control, data acquisition and data retrieval. 
Adapted from Baranowska and Kowalski’s (2010) HPLC method (section 2.3.1, Table 
2.2), the LC-MS parameters were developed (section 3.2.1, Figure 3.3 to 3.7) until a 
fully optimised method suitable for validation (Chapter Four) was achieved (Table 2.5 
and 2.6).  
The LC-MS analytical method employed gradient elution implementing two mobile 
phases; water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The 
gradient elution was operated as described in section 2.2.1 and Table 2.5, at a flow 
rate of 0.5 ml/min. At the start and very end of the elution re-equilibration steps (0.5 
minutes at the start and 3 minutes at the end) were included. At the end, the gradient 
was held at 99% A and 1% B.  
The initial and optimised LC-MS parameters are shown in Table 2.6. Specifically, 
electrospray ionisation (ESI) was used in negative mode, and the MS was operated in 
SIM using ions from Table 3.6 between 4 and 14 minutes (section 3.2.4). The wash 
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solution used for the autosampler was 2-propanol and the optimal injection volume of 
each sample was 2µl (section 3.2.3).  
Table 2.6 Optimised mass spectrometer settings 
mass spectrometer parameters 
Initial method 
development settings 
Method validation 
settings 
ionisation mode 
Negative and positive 
ESI-+ 
negative ESI- 
interface temperature 350ᵒC 
desolvation line (DL) temperature held at 2500C 
nitrogen nebulising gas flow rate 1.5L/min 
nitrogen drying gas 15L/min 10L/min 
heating block 3000C 
DL voltage 0 
Qarray voltage 0.0 
mass analyser mode 
Scan m/z 50-400 
between 0-20 minutes 
SIM between 4-14 minutes 
wash solution 2-propanol 
injection volume 0.2 µl 2µl 
autosampler temperature 150C 
oven 500C 
photo diode array detector (PDA) 
Scan between 190nm 
and 800nm 
scan between 190nm and 
400nm 
2.4.2 Longer term stability in an inter-day study over six consecutive days 
Longer term stability was considered for method validation over 6 days whereby 
samples were prepared and stored in a freezer in -20ºC conditions and thawed on the 
day of analysis.  
Stability in method validation was investigated at three concentrations, as per section 
2.3.4, in the presence of internal standard at 0.1µg/ml, in line with concentrations 
studied in the linearity (section 2.4.4). 
2.4.3 Inter-day reproducibility precision studies 
Inter-day reproducibility precision (section 4.3) was tested at three concentrations, as 
per section 2.3.5, in the presence of internal standard at 0.1µg/ml. The concentration of 
the internal standards was in line with that used throughout the validation.  
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2.4.4 Linearity and method detection limits  
Linearity (section 4.4) was determined by investigating eleven different concentrations 
of the mixed NSAIDs standard in triplicate injections. Calibration standards (0.01, 
0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 25µg/ml) were prepared in acetonitrile from 
the 100µg/ml working solution in the presence of internal standards at 0.1µg/ml 
(section 2.2.2). LABSolutions software was used for data procurement while Microsoft 
and IBM SPSS Statistics was used for data interpretation (regression, residual analysis 
and statistical tests (Shapiro-Wilk normality test and Wald-Wolfowitz run test). Microsoft 
Excel was used to calculate the LOD and LOQ values.  
2.5 SAMPLE PREPARATION AND APPLICATION OF VALIDATED METHOD 
2.5.1 Feather sample pre-treatment 
Feather samples were cut into 2-3 cm pieces (section 5.1.1, Figure 5.1). The samples 
were washed with warm water and sonicated for five minutes. This step was repeated 
until water was clear, the second and last washes were stored in vials and placed into 
the fridge for storage. Methanol was added and sonicated for a further five minutes, 
this wash was kept and refrigerated. Samples were left to dry in-between double layers 
of Whatman 542 ashless filter paper and once dry, transferred into sealable clear 
plastic sample bags (Figure 5.2). Which were frozen for two minutes in liquid nitrogen 
thereafter stored in a freezer until ready to be ground.  
After being frozen, samples were cut into 2-3mm pieces (Figure 5.3) ground in an 
Agate jar and ground at 300 revolutions per minutes (rpm) for fifteen minutes in a 
Retsch PM100 (Figure 5.4). After grinding any remaining large pieces were cut with 
nail scissors until a powder like consistency was achieved (Figure 5.5). 
2.5.2 Sample digestion and extraction 
Aliquots of 50mg pulverised feathers were weighed in triplicate into 2ml Eppendorf 
tubes. Into each tube 100µl of each internal standard at a concentration of 1µg/ml was 
added followed by 1ml of methanol. In spiked samples, 100µl of a 0.1µg/ml mixed 
NSAIDs and metabolite standard was also added. These tubes were then placed into a 
Microtherm 56 shaker (CamLab Ltd) overnight, the temperature set at 40⁰C for 17 
hours.  
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After digestion, samples were filtered using dampened (with methanol) cotton wool. 
After the initial filtration, 1ml of methanol was added to the sample, and filtered once 
again followed by a further 1ml of methanol for rinsing.  
To the filtrate, 1ml of hexane was added and mixed, the hexane layer was removed 
and kept for evaporation. Samples were evaporated to dryness using a miVac DNA 
sample condenser (Genevac Ltd) set at 40⁰C and 1000 rpm. Dried samples were 
reconstituted in 100µl of acetonitrile. Where samples were not reconstituted 
immediately dried samples were stored in a freezer in -20ºC conditions and thawed on 
the day of analysis. 
2.5.3 Analysis of spiked and unspiked feathers 
Spiked and unspiked feather samples were prepared as per section 2.2 and analysed 
using the LC-MS settings in section 2.3.1. Results are presented in Chapter Five.   
In recovery studies, samples were spiked (digested and filtered as per section 2.5.2) 
with 100µl of a 0.1µg/ml mixed NSAIDs and metabolites, alongside 100µl of each 
internal standard at a concentration of 1µg/ml. Standards were prepared in the same 
way (section 2.5.1 and 2.5.2) to mimic sample preparation for comparison in recovery 
studies.  
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CHAPTER 3: METHOD DEVELOPMENT RESULTS AND DISCUSSION 
Method development encompasses the improvement of an analytical method through 
several sequential preliminary investigations. Preliminary investigations involve the 
modification of initial parameters and preparation techniques whereby, experimental 
improvements are incorporated to produce a method that is developed under optimal 
conditions (Huber, 2007). Whilst Chapter One explains the selection of HPLC and LC-
MS techniques, and Chapter Two describing the preliminary investigations involved in 
the method development process, the results and discussion of those investigations 
are included in this chapter. It presents the results of LC-MS method optimisation prior 
to method validation (Chapter Four), including the assessment of chromatographic 
response, solvent selection and injection volume studies alongside initial stability and 
precision studies.   
3.1 SELECTION OF INTERNAL STANDARDS 
During initial method development the selected internal standards (IS) (piroxicam-d3 
and flufenamic acid) were studied in terms of chromatographic response. The 
characteristic ions used for their identification were taken from the literature specifically 
m/z 280, 341 and 250 for flufenamic acid and m/z 333, 341 and 250 for piroxicam-d3 
(Moffat, Osselton and Widdop, 2004). Retention times (RT) were recorded and used 
with diagnostic ions to establish correct identification. The RT and analysis of 
chromatographic profile for each IS are presented in Table 3.1. Figures 3.1 and 3.2 
shows examples of the peak profile (total ion chromatogram, TIC) of each internal 
standard.  
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Intensity 
 
minutes 
Figure 3.1 TIC peak profile of internal standard piroxicam-d3 
Intensity 
 
minutes 
Figure 3.2 TIC peak profile of internal standard flufenamic acid 
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Table 3.1 Qualitative data for the chromatographic profile of internal standards 
piroxicam-d3 and flufenamic acid 
Internal Standard RTa 𝑘b 𝛼c 𝑅𝑠d 𝐴𝑠e 
Piroxicam-d3 8.31 1.08 1.00 0.05 1.80 
Flufenamic acid 13.11 2.27 1.56 0.60 2.00 
aMean retention time (minutes), bcapacity factor, cselectivity  
dresolution, easymmetry 
The peaks for both internal standards were well defined and sharp, selectivity was high 
for both compounds (>1) indicating they were both separated from neighbouring 
analytes. Both exhibited an ideal capacity factor of >1 (section 1.6.2.4) showing elution 
was neither too quick nor too slow. The resolution of both compounds was lower than 
the accepted >2, indicating mutual overlap with adjacent compounds, however, during 
SIM flufenamic acid was resolved from its neighbouring peak (mefenamic acid). In the 
case of Piroxcam-d3, resolution was <1 due to its co-elution with its counterpart 
piroxicam. In LC-MS applications, deuterated standards are expected to exhibit this co-
elution and therefore, do not required chromatographic resolution if, the MS is able to 
distinguish between the two compounds within a degree of certainty (Synder, Kirkland 
and Dolan, 2010). Both compounds had different mass spectral characteristics, hence, 
on the application of SIM (section 3.2.4 and 3.2.5), the method was proven to be 
selective enough to distinguish between the two.  
The asymmetry (section 1.6.2.7) of each peak was also investigated. Both internal 
standards presented tailing with tailing factors calculated at 1.4 and 1.5 for piroxicam-d3 
and flufenamic acid respectively. This had an effect on the asymmetry factor which 
were both calculated over >1. Despite this the peaks still showed a good 
chromatographic profile (Gaussian distribution) and were repeatable throughout the 
method development (Figure 3.1 and 3.2, section 3.2.1). Furthermore, on initial 
investigations of mixed standards, in the presence of both NSAIDs and Internal 
standards, peak area ratios (PAR) were reasonable (0.75 to 3.3) (Table 3.2), this is 
especially important in terms of symmetry as any distortion in peak shape can make 
integration of peaks for quantification problematic (Synder, Kirkland and Dolan, 2010). 
The tailing factors did not cause any problems during the qualitative or quantitative 
stages of this research.  
As mentioned, as part of the investigation of internal standards, single standards were 
analysed in the presence of these two compounds. Resolution between the internal 
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standards and NSAIDs was above accepted guidelines (>2) in all cases (with the 
exception of prioxicam-d3 with piroxicam and flufenamic acid and mefenamic acid). 
From these early investigations RT and relative retention factor (RRF) were obtained 
(Table 3.2). Using RRF it was possible to determine which internal standard was used 
for which NSAID when calculating PAR for the entirety of the study.  
A RRF closer to one indicates the closeness of analyte and internal standard, 
essentially providing a ratio between retention times. Using the RRF based on 
closeness in retention, and higher analytical response, the internal standard piroxicam-
d3 (Table 3.2, in blue) was used for NSAIDs acetylsalicylic acid, piroxicam, flunixin, 
ketoprofen, meloxicam, nimesulide, carprofen, diclofenac, suxibuzone and ibuprofen, 
and flufenamic acid (Table 3.2, in black) for NSAIDs aceclofenac, phenylbutazone and 
mefenamic acid. In this early developmental stage the metabolites (section 1.3.7.1) had 
not been procured, however, RRF value and RT are reported later in section 3.2.1.   
Table 3.2 Retention times and RRF obtained through analysis of single NSAIDs 
standards  
NSAIDa RTb RRFc PARd 
acectysalicylic acid 5.14 ± 0.009 1.62 0.75 
piroxicam-d3 8.31 ± 0.005 1.00 1.00 
piroxicam 8.32 ± 0.004 1.00 1.75 
flunixin 9.54 ± 0.007 0.87 1.31 
ketoprofen 9.99 ± 0.00 0.83 1.09 
meloxicam 10.18 ± 0.006 0.82 2.53 
nimesulide 10.76 ± 0.007 0.77 3.33 
carprofen 11.57 ± 0.002 0.72 1.40 
diclofenac 11.99 ± 0.004 0.69 1.58 
suxibuzone 12.04 ± 0.026 0.69 1.08 
ibuprofen 12.13 ± 0.00 0.68 0.07 
aceclofenac 12.13 ± 0.010 1.08 0.37 
phenylbutazone 12.65 ± 0.009 1.04 0.65 
mefenamic Acid 12.97 ± 0.00 1.01 0.29 
flufenamic Acid 13.11 ± 0.005 1.00 1.00 
.a100µg/ml, bretention time (n=3), crelative retention factor 
 dmean peak area ratio (n=3), NSAIDs in blue= ratio with  
piroxicam-d3, NSAIDs in black= ratio with flufenamic acid 
74 
 
As a result of these studies, the selection and suitability of both internal standards was 
proven. They were shown to have a good chromatographic profile, albeit a low tailing 
factor and good resolution, taking into account capacity factor and selectivity.  
3.2 INITIAL METHOD DEVELOPMENT: PRELIMINARY INVESTIGATIONS 
3.2.1 Optimised gradient elution program  
In order to establish an optimised method for preliminary investigations and validation 
thereafter, changes in gradient elution program were investigated in terms of effects on 
chromatographic separation. The analytical method in this research was adapted from 
Baranowska and Kowalski (2010) (Table 2.1). Gradient elution programs were adapted 
as described in the methodology (section 2.3.1, method A (Table 2.2), method B (Table 
2.3), method C (Table 2.4) and the optimised method D (Table 2.5)). TIC generated for 
each gradient elution program are presented in Figures 3.3 to 3.7 respectively. Figure 
3.7 shows detection of more analytes than the other TIC as the metabolites 
(oxyphenylbutazone, 3-hydroxymethylmefenamic acid, 4-hydroxydiclofenac, 4-
hydroxynimsulide, 5-carboxymeloxicam, 5-hydroxyflunixin and 5-hydroxyproixcam) had 
not been procured until this point.  
Across all gradient elution programs there were similarities in the chromatographic 
profiles specifically, the general order of elution and retention times. The main 
differences between the methods was co-elution between compounds, the peak shape, 
resolution, and asymmetry factors. As such, it was recognized that chromatographic 
response was improved over the development stages, this is especially apparent on 
the comparison of Figure 3.3, when the first adaptions were made (Table 2.2), to 
Figure 3.6, the final method, ready for validation (Table 2.5). These improvements were 
brought about through initial changes in the gradient elution program (methods A and 
B), followed by an additional change in mobile phases (methods C and D).  
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Figure 3.3 Chromatographic profiles (TIC) of mixed NSAID standards (100µg/ml) 
obtained with method A (Table 2.2)  
 
minutes 
Figure 3.4 Chromatographic profiles (TIC) of mixed NSAID standards (100µg/ml) 
obtained with method B (Table 2.3) 
Method optimisation first started with the implementation of method A (Table 2.1), 
which resulted in nineteen peaks eluting from the column. Chromatographic separation 
was poor with peak exhibiting shouldering, tailing, fronting and splitting. There was also 
poor separation between compounds (Figure 3.3); this analysis was carried out on a 
mixed standard of twelve NSAIDs and two internal standards. Therefore, using 
previous knowledge of RT obtained from the analysis of single NSAID standards (Table 
3.1) it was possible to predict there were interference peaks with the possibility of co-
elution between compounds. On interpretation of the results, it was indicated there was 
co-elution between meloxicam and ketoprofen around 7.5 minutes and nimesulide and 
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phenylbutazone around 9.5 minutes (as highlighted in Figure 3.3). With these results, 
changes in the gradient elution program were made. In method A (Table 2.2), the 
mobile phases increased by 20% within 2 minutes resulting in meloxicam, ketoprofen, 
nimesulide and phenylbutazone eluting within the same time. By concentrating on the 
retention area where the co-elution had occurred (7.5 to 9.5 minutes), the gradient was 
changed to slow the change in polarity and the increase in percentage change of 
methanol (0.1% formic acid). This would slow the elution of compounds resulting in 
further separation (Table 2.3).  
Thereafter, similar results were achieved upon the application of method B (Figure 3.4), 
namely, flunixin, ketoprofen, meloxicam and nimesulide still co-eluted at 6.5 minutes. 
Undesirable chromatographic profiles were worsened in nimesulide and 
phenylbutazone with both compounds co-eluting with carprofen, diclofenac and 
aceclofenac at 9 minutes. Asymmetry factors were higher when comparisons were 
made between the two methods, for example carprofen asymmetry factor was 1.13 in 
method A compared to 2.97 in method B. Furthermore, where separation was present 
in the chromatogram, peaks did not exhibit base line separation, hence resolution and 
selectivity was low (<1).  
The results showed significant improvement from method B to method C (Figure 3.4 
and 3.5) with the removal of methanol from the mobile systems employed in method B 
(Table 2.3). All compounds eluted between 5 and 10 minutes whereby the percentage 
change of acetonitrile was from 5 to 90 % when this method (B) was employed. 
Acetonitrile has a higher elution strength than methanol which the compounds under 
investigation favoured. Therefore, in method C (Table 2.4), on the removal of methanol, 
the percentage change in acetonitrile was spread over a longer duration of time at a 
much slower rate, which resulted in the slower elution and better separation in 
compounds (Figure 3.5). Acetonitrile also has a lower viscosity than methanol and in 
turn reduces backpressure often resulting in better peak shape, as was the case 
across these two methods (Figure 3.4 and 3.5).  
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Figure 3.5 Chromatographic profiles (TIC) of mixed NSAID standards (100µg/ml) 
obtained with method C (Table 2.4)  
 
minutes 
Figure 3.6 Chromatographic profiles (TIC) of mixed NSAID standards (100µg/ml) 
obtained with method D (Table 2.5)  
The results showed further significant improvement between method C and D (Figures 
3.5 and 3.6, Table 2.4 and 2.5), the peaks were Gaussian in shape and were tall and 
narrow. In addition resolution (section 1.6.2.6) and selectivity (>1) (section 1.6.2.5) 
were improved and overall asymmetry (<2) was good (Table 3.3). Resolution was 
considerably improved for compounds flunixin, ketoprofen, meloxicam, nimesulide, 
carprofen, aceclofenac and phenylbutazone, which was unachievable with previous 
methods (A and B). Compounds diclofenac, suxibuzone and ibuprofen still continued to 
co-elute in TIC (highlighted in Figure 3.6), however, peaks corresponding to each 
compound were distinguishable in SIM chromatograms, whereby, these compounds 
had an ideal capacity factor (=2) (section 1.6.2.4), selectivity indicated that the 
compounds could be separated (≥1) (Table 3.3). Therefore, all were deemed to yield a 
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good chromatographic profile.  
This ideal chromatographic separation was brought by changes in the mobile phases 
employed. The method changes involved the removal of methanol and the increase in 
water and acetonitrile. Chromatographic separation is governed by the interaction 
between compounds and the mobile phase, the method employed was reverse phase 
chromatography (section 1.6.2). The compounds under investigation are weak acids in 
nature (section 1.4.1), hence an increase in the % organic in the mobile phase 
(acetonitrile in this case) increases the elution strength of the mobile phase. This 
worked to separate compounds that favoured this percentage change (Table 2.5) over 
a longer period. Hence, compounds would elute in order of decreasing polarity, with 
those of lower polarity having a higher affinity for the stationary phase and resulting in a 
higher capacity factor (Neue, 1997), as was the case for diclofenac, suxibuzone, 
ibuprofen, aceclofenac, phenylbutazone and mefenamic acid (k ≥2). The main 
differences between methods C and D was the addition of a longer equilibrium stage at 
the end, this provided a longer time to re-equilibrate the column, whereby, there is a 
shift from 0% mobile phase A to 99% as required at the start of the next run. This stage 
also served to elute any strongly retained impurities from column prior to the next 
injection (Synder and Dolan, 2007).  
The gradient elution program was optimised ensuring capacity factor, sensitivity, 
resolution, tailing factor and asymmetry were all within acceptable boundaries (section 
1.6.2) (CDER, 1994). Initial development until this point had only investigated NSAIDs, 
hence, after the procurement of metabolites under investigation the method was then 
trialled. A mixed standard including both NSAIDs and metabolites was analysed under 
method D. Results were interpreted in the same manner as the mixed NSAID standard 
prior and are given in Figure 3.7 and Table 3.3. 
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Figure 3.7 Chromatographic profiles (TIC) of mixed NSAID and metabolite standard (100µg/ml) obtained with method D (Table 2.5) 
(5HP= 5-hydroxypiroxicam, 4HN= 4-hydroxynimesulide, 5HF= 5-hydroxyflunixin, 3HMA= 3-hydroxymethyl mefenamic acid, OXY= 
oxyphenylbutazone) 
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Peak shapes were symmetrical, peaks were tall, sharp (narrow) and of Gaussian 
distribution. Resolution was high (>1) across all metabolites, with the exception of 5-
hydroxypiroxicam and oxyphenbutazone. Selectivity was ideal (=1) and tailing factors 
were low ≤1.6. Metabolites were all eluted within the first half of the run, this was 
expected as metabolites are polar compounds (hydrophilic) and as such have a higher 
affinity for the mobile phase hence, eluting first (section 1.3.6) (Neue, 1997). Despite 
some co-elution between 5-carboxymeloxicam and 5-hydroxypiroxicam (8.5 minutes), 
ketoprofen and 4-hydroxydiclofenac (10.1 minutes) and meloxicam and 
oxyphenylbutazone not fully resolved at 10.2 minutes, on analysis of extracted ion 
chromatograms, with differing molecular ions, peaks were well separated.  
Table 3.3 Qualitative data for the chromatographic profile of NSAIDs and 
metabolites, calculated during optimisation studies when employing method (D) 
NSAIDa RTb RRFc 𝒌d 𝜶e 𝑹𝒔f 𝑨𝒔g 
acetylsalicylic acid 5.08 ± 0.03 0.62 0.27 0.79 4.70 1.61 
piroxicam 8.27 ± 0.02 1.00 1.50 0.99 29.79 2.10 
5-carboxymeloxicam 8.40 ± 0.02 0.93 1.10 0.98 1.27 1.63 
5-hydroxypiroxicam 8.48 ± 0.02 1.02 1.12 0.99 0.60 2.10 
4-hydroxynimesulide 8.68 ± 0.02 1.05 1.17 0.98 2.00 1.71 
5-hydroxyflunixin 9.42 ± 0.03 1.14 1.27 0.95 4.37 1.60 
3-hydroxymethyl mefenamic 
acid 
9.35 ± 0.06 1.13 1.34 0.97 2.60 1.67 
flunixin 9.50 ± 0.02 1.15 1.37 0.99 1.25 2.08 
4-hydroxydiclofenac 9.94 ± 0.02 1.20 1.48 0.95 4.26 2.20 
ketoprofen 10.01 ± 0.02 1.21 1.50 0.99 0.68 1.86 
meloxicam 10.19 ± 0.02 1.21 1.54 0.98 1.75 2.95 
oxyphenylbutazone 10.27 ± 0.02 1.24 1.56 0.99 0.80 1.97 
nimesulide 10.73 ± 0.02 1.30 1.68 0.96 4.19 1.80 
carprofen 11.55 ± 0.02 1.40 1.88 0.93 7.70 1.94 
diclofenac 11.96 ± 0.02 1.45 1.98 0.97 4.22 2.22 
suxibuzone 11.96 ± 0.02 1.45 1.99 1.00 0.02 1.87 
Ibuprofen 11.97 ± 0.04 1.45 1.98 1.00 0.02 1.06 
aceclofenac 12.11 ± 0.03 1.47 2.02 0.99 1.71 1.93 
phenylbutazone 12.58 ± 0.02 0.96 2.14 0.96 0.25 1.49 
mefenamic acid 12.97 ± 0.02 0.99 2.24 0.97 0.26 1.73 
a100µg/ml, bretention time (mean RT ± SD) (n=30), c relative retention factor, dcapacity factor, 
esensitivity, fresolution, gasymmetry 
From these studies method D proved to be the optimal gradient elution program and as 
such, upon the implementation of these conditions, the recorded RT and RRF for all 
NSAIDs and metabolites (Table 3.3 and 3.4) were used throughout preliminary 
81 
 
investigations, method validation (Chapter Four) and ultimately the identification 
process in the analysis of matrices (Chapter Five).   
3.2.2 Optimal solvent selection for standards  
The selection of solvents in liquid chromatography is an important and effective step in 
achieving optimal chromatographic resolution (section 1.6.2.6 and 1.6.2.8). In method 
development, the solvent the analytes of interest were dissolved in, were investigated 
to find which was optimal (as per section 2.3.2). To investigate the optimal solvent, 
three mixed NSAID standards at 20µg/ml were each made up in acetonitrile, methanol 
and the mobile phase mix at the start of the analysis (98% water 0.1% formic acid / 2% 
acetonitrile 0.1% formic acid, Table 2.5), for the purposes of the reader the latter will be 
called MP at T0 (initial mobile phase (Table 2.5) at T0) from here on. After analysing 
samples made up in acetonitrile, methanol and MP at T0, Mean PAR were recorded 
(Table 3.4) and plot on comparison graphs alongside corresponding error bars of 
standard deviations (Figure 3.8).  
Table 3.4 Mean peak area data obtained (n=3) during solvent selection 
investigations 
NSAIDa 
Mean PAR recorded against corresponding mobile phase  
acetonitrile RSD% methanol RSD% MP at T0b RSD% 
acetylsalicylic acid 0.026 15.29 0.018 4.03 0.002 38.32 
piroxicam 0.523 13.09 0.601 3.41 0.547 24.59 
nimesulide 0.931 28.18 0.913 3.30 0.717 27.19 
meloxicam 0.869 9.23 0.928 3.69 0.890 24.77 
ketoprofen 0.157 7.23 0.185 0.46 0.121 36.18 
flunixin 0.610 17.51 0.749 3.54 0.644 29.08 
carprofen 0.238 4.36 0.273 0.83 0.115 39.71 
suxibuzone 0.267 7.58 0.169 5.04 0.133 27.27 
phenylbutazone 1.150 7.78 1.157 3.85 0.803 37.30 
diclofenac 0.627 4.55 0.699 1.36 0.598 29.46 
ibuprofen 0.007 7.34 0.013 8.37 0.003 70.29 
mefenamic Acid 0.426 3.40 0.466 1.61 0.143 49.49 
a20µg/ml, b MP at T0 (98% water 0.1% formic acid / 2% acetonitrile 0.1% formic acid) 
Results showed (Table 3.4, Figure 3.8) larger PAR when the analytes were prepared in 
acetonitrile and methanol whilst, analytical response using MP at T0 were typically 
lower. Similarly, the RSD of the PARs were larger in MP at T0 when compared to 
acetonitrile and methanol. Furthermore, standards prepared in MP at T0 resulted in 
larger deviation between the triplicate data sets across all NSAIDs, when compared to 
82 
 
acetonitrile and methanol. In acetonitrile, RSD ranged from 3.40 to 28.18% compared 
to methanol ranging from 0.46 to 5.04%. However, despite higher RSDs of the PARs in 
acetonitrile, PAR were comparable with methanol and on occasion higher (i.e 
suxibuzone) (Table 3.4, Figure 3.8).  
 
Figure 3.8 analytical response (mean PAR) for corresponding NSAIDs (1mg/ml) 
prepared in varying solvents  
On the assessment of chromatographic profiles of each compound, some peak 
distortion and splitting was noted between the different solvents employed. It is well 
reported that solvent strength, in relation to the sample solvent, can result in peak 
distortion and splitting (Hawkins and Dolan, 2003; Wrezel, and Pakulathat, 2005), this 
was especially the case in acetylsalicylic acid. Figure 3.9 is an example of peak 
splitting in acetylsalicylic acid when it was prepared in acetonitrile.  
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Figure 3.9 Peak splitting of acetylsalicylic acid made up in acetonitrile at 
100µg/ml 
This peak splitting was detected across all solvents in the case of acetylsalicylic acid. 
However, there was correlation between peak distortion and the use of MP at T0, and 
this was especially the case in phenylbutazone and mefenamic acid where peak shape 
was most improved in acetonitrile. Acetylsalicylic acid was calculated to have a low 
capacity factor <1 (section 3.2.1) implying this compound was not highly retained by 
the column and thus elution was very fast. Perhaps, the peak splitting seen here is 
related to the disproportion in solvent strength between the sample solvent (100% 
acetonitrile) and the mobile phase increasing at the elution time (water 0.1% Formic 
acid at 65%) (section 1.6.2.2).  
There were differences in peak shape across all solvents in majority of the NSAIDs 
investigated. A typical example is the NSAID suxibuzone (Figure 3.10), the overall 
peak appears symmetrical the main differences across the three solvents were at the 
base of the peak (shown using arrows).  While acetonitrile was used as a solvent, slight 
tailing was present however, in methanol and MP at T0 shouldering occurred alongside 
peak tailing, this was seen in all NSAIDs. Overall peak symmetry was improved in 
acetonitrile when compared with the other two solvents (Figure 3.10). As an exemplar, 
asymmetry factors (As) calculated in suxibuzone (as per section 1.6.2.7, Equation 1.7) 
resulted in the desired gaussian shaped peak (As = 1) (CDER, 1994) which was a tall, 
sharp and narrow. Meanwhile, in methanol exhibited tailing (As = 2). These affects were 
more prominent in MP at T0 with a loss in symmetry and tailing present (As = 3.2).  
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Figure 3.10 Peak shape in suxibuzone at 100µg/ml made up in acetonitrile (a), 
methanol (b) and MP at T0 (c), alongside corresponding images of the peak base 
to show effects of different solvents and tailing factors 
Based on the results obtained, most improved peak shape was obtained when 
acetonitrile was employed. Therefore, this was chosen as the solvent of choice. 
Thereafter, unless stated, all standards are prepared in 100% acetonitrile.  
3.2.3 Injection volumes 
Injection volumes were initially assessed in terms of the chromatographic profile i.e. 
peak asymmetry, using three volumes (0.2, 2 and 10 µl) (section 2.3.3). As previously 
highlighted (section 1.6.2.9), a good chromatographic peak should be Gaussian 
shaped. To determine optimal injection volumes, and consequently chromatographic 
response, tests were carried out on two NSAIDs, ibuprofen and mefenamic acid. These 
compounds were selected as ibuprofen had the lowest analytical response as an 
example (Table 3.6) of all NSAIDs (Table 3.2), and mefenamic acid was representative 
of all other NSAIDs (Table 3.6). Upon inspection of both samples injected at 10µl 
(20µg/ml), peak shapes were distorted, exhibiting poor peak symmetry as both 
compounds displayed band broadening, tailing and fronting (section 1.6.2.2, Figure 
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3.11 and 3.14). Tailing and fronting can occur when the peak shape becomes distorted, 
as was the case in Figure 3.11 and 3.14.  
With this poor peak symmetry, injection volumes of 2 and 0.2 µl (20µg/ml), were 
investigated further. Throughout method development, an injection volume of 0.2µl had 
initially been used and until this method optimisation stage, 0.2µl had yielded 
satisfactory selectivity and sensitivity. On testing 0.2 and 2 µl injection volumes, peak 
shape was improved when compared to 10µl (Figures 3.11 to 3.14). Peaks were tall, 
sharp and narrow with only slight fronting at 0.2µl. Overall, only minor improvements 
could be seen between 0.2 and 2 µl, however, there was a significant difference 
noticed when comparison is made to the larger volume, on visual inspection and 
calculating peak asymmetry (Figure 3.12, 3.13, 3.15 and 3.16). As comparisons had 
only been made on ibuprofen and mefenamic acid, it was necessary to investigate all 
NSAIDs at 0.2 and 2 µl injection volumes to determine if one volume yielded a better 
analytical response than another.  
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Figure 3.11 Chromatogram of ibuprofen with 
injection volume (10µl), resulting in volume 
overload (20µg/ml) 
Figure 3.12 Chromatogram of ibuprofen 
with injection volume (2µl) (20µg/ml) 
Figure 3.13 Chromatogram of ibuprofen with 
injection volume (0.02µl) (20µg/ml) 
 
   
Figure 3.14  Chromatogram of mefenamic 
acid with injection volume (10µl), resulting in 
peak distortion (20µg/ml) 
Figure 3.15  Chromatogram of 
mefenamic acid with injection volume 
(2µl) (20µg/ml) 
Figure 3.16  Chromatogram of mefenamic 
acid with injection volume (0.2µl) (20µg/ml) 
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After investigating all NSAIDs at 0.2µl and 2µl (20µg/ml), RSD of the PAR was 
calculated to assess the optimal injection volume. The RSD of PAR were higher for all 
NSAIDs at 0.2µl, (Table 3.5), compared to those recorded with the increased injection 
volume (2µl). RSD in PAR ranged between 3.4 to 28.18% in injection volumes of 0.2µl 
and 0.86 to 4.08% in 2µl injection volumes (Table 3.5). The only compound that did not 
conform to this was acetylsalicylic acid at 15.29% in 0.2µl injection and 39.39% in 2µl 
injection. The analytical response showed greater variation between triplicate analysis 
in the latter, leading to the increased RSD. As per the solvent investigations, 
acetylsalicylic acid, had lower analytical response compared to the other NSAIDs, 
therefore, this larger RSD is most likely to be associated with expected errors with low 
volumes. Upon injecting 0.2µl, the largest variations were seen in the analytical 
response for nimesulide with, 28.18% RSD in 0.2µl injection were compared to 1.09% 
RSD when injecting 2µl and with similar results recorded for flunixin (RSD ranging from 
17.51% to 2.22% respectively). This data is presented in Table 3.5 and has been 
presented graphically in Figure 3.17.   
Table 3.5 mixed NSAID analytical response (mean PAR, standard deviation and 
RSD%) recorded from injection volume studies at 0.2µl and 2µl in acetonitrile  
NSAID 
0.2µl Injection (0.02mg/ml) 2µl Injection (0.02mg/ml) 
Mean 
PAR (n=3) 
SD 
RSD 
% 
Mean PAR 
(n=3) 
SD 
RSD 
% 
acetylsalicylic acid 0.026 0.004 15.29 0.082 0.032 39.39 
piroxicam 0.523 0.068 13.09 0.517 0.010 1.92 
nimesulide 0.931 0.262 28.18 1.016 0.011 1.09 
meloxicam 0.869 0.080 9.23 0.811 0.021 2.57 
ketoprofen 0.157 0.011 7.23 0.197 0.006 3.06 
flunixin 0.610 0.107 17.51 0.580 0.013 2.22 
carprofen 0.238 0.010 4.36 0.235 0.003 1.27 
suxibuzone 0.267 0.020 7.58 0.248 0.010 3.90 
phenylbutazone 1.150 0.089 7.78 1.080 0.024 2.25 
diclofenac 0.627 0.028 4.55 0.655 0.006 0.86 
ibuprofen 0.007 0.000 7.34 0.006 0.000 4.08 
mefenamic Acid 0.426 0.014 3.40 0.452 0.012 2.63 
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Figure 3.17 Comparison graph of 0.2 and 2µl injection volumes: mixed NSAIDs 
standard in acetonitrile against PAR   
During the investigation of injection volumes, poor chromatographic profiles, including 
tailing and broadening, were noted at the highest volume of 10µl. This was likely to 
arise from the effects of mass transfer (section 1.6.2.2, in the Van Deemter Equation, 
Equation 1.3), where analytes may not have been able to equilibrate between the 
stationary phases and mobile phase leading to the band broadening. At the two lower 
injection volumes, peak distortion was likely linked with the effects of longitudinal 
diffusion, where slight distortion and higher RSD was reported when too lower volume 
(0.2µl) was injected. At this lowest volume higher RSD can be expected as results are 
less repeatable, with a tenfold increase to 2µl, the precision in analytical response was 
improved. Thus, as per the reported RSD, and chromatographic response discussed, 
when using an injection volume of 2µl instrumental response was higher with better 
precision across all NSAIDs. 
3.2.4 Identification of NSAIDs and Diagnostic ions 
To identify and confirm the presence of compounds in unknown samples, three 
identification reference points should be used in trace analysis, which this analytical 
method was ultimately applied (Commission Decision, 2002). Retention time (RT), 
relative retention factor (RRF), a quantification ion (Q), two confirmation ions (C1 and 
C2) and peak area ratios were used in this research (Migowska, 2012). 
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Retention times were previously recorded during the optimisation of the LC program, 
refer to Table 3.2 (section 3.2.1). Meanwhile, throughout method development, 
specifically during the identification of NSAIDs, using individual mass spectra for each 
compound (Table 3.2), possible fragmentation was predicted and ions were collated 
(Table 3.6). The collation of these ions allowed for the development of a SIM method. 
Following guidelines set out by World Anti-Doping Agency (WADA) (WADA, 2003), 
three diagnostic ions (one Q ion, two C ions) were used in the identification of NSAIDs 
and metabolites (section 1.6.3). In the case of metabolites oxyphenylbutazone, 4-
hydroxynimesulide, 5-hydroxyflunixin and 5-hydroxyprioxicam only 2 diagnostic ions 
were present with relative abundancies above the accepted 10% (Commission 
Decision, 2002). This would still ensure at least one ion ratio could be reliably made. 
Primarily, ions were selected based on the three most abundant ions, as per the 
predicted fragmentation of the chemical structure. 
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Table 3.6 Compound table and their corresponding ions (scan negative ionisation mode). For each ion corresponding proposed 
fragmentation is stated. 
NSAID 
Retention time 
(minutes) 
RMM 
mass to charge ratio (m/z) 
Quantification ion Confirmation ion 1 Confirmation ion 2 
acetylsalicylic acid 5.08 180.2 225 [M-H+HCO2H]- 179 [M-H]- 151 [M-CO-H]- 
piroxicam d3 8.26 331.4 333 [M-H]- 341 [M-H+HCO2H]- 250 [M-H-CHO2]- 
piroxicam 8.27 331.4 330 [M-2H]- 323 [M-8H]- 333 [M+2H]- 
5-carboxymeloxicam 8.40 381.4 380 [M-H]- 379 [M-2H]- 426 [M-H+HCO2H]- 
5-hydroxyprioxicam 8.48 347.4 346 [M-H]- 347[M]-  
4-hydroxynimesulide 8.68 324.3 322 [M-2H]- 323 [M-H]-   
3-hydroxymethyl mefenamic acid 9.35 257.3 256 [M-H]- 302 [M-H+HCO2H]- 257 [M]- 
5-hydroxyflunixin 9.42 312.2 311 [M-H]- 379 [M-H+HCO2H]-   
flunixin 9.50 491.5 295 [M-H]- 296 [M+H]- 341 [M-H+HCO2H]- 
4-hydroxydiclofenac 9.94 312.0 310 [M-2H]- 311 [M]- 356 [M-H+HCO2H]- 
ketoprofen 10.01 254.3 299 [M-H+HCO2H]- 253 [M-H]- 321 [M+Na-H]- 
meloxicam 10.19 351.4 350 [M-H]- 352 [M+H]- 396 [M-H+HCO2H]- 
oxyphenylbutazone 10.27 324.4 323 [M-H]- 391 [M-H+HCO2H]-   
nimesulide 10.73 308.1 307 [M-H]- 308 [M+H]- 375 [M-H+HCO2H]-  
carprofen 11.55 273.7 272 [M-H]- 318 [M-H+HCO2H]- 228 [M-H-CHO2]- 
diclofenac 11.96 295.0 294 [M-H]- 296 [M+H]- 250 [M-H-CHO2]- 
suxibuzone 11.96 438.0 307 [M-C5H7O4]- 483 [M-H+HCO2H]- 437 [M-H]- 
ibuprofen 11.97 206.3 251 [M-H+HCO2H]- 149 [M-C4H9]- 131 [M-C3H5O2]- 
aceclofenac 12.11 354.2 351 [M-H]- 354 398 [M-H+HCO2H]- 
phenylbutazone 12.58 308.4 307 [M-H]- 308 [M+H]- 375 
mefenamic acid 12.97 241.3 240 [M-H]- 307 265 [M-H+HCO2H]- 
flufenamic acid 13.08 281.2 280 [M-H]- 236 [M-H-CHO2]- 326 [M-H+HCO2H]- 
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Across all NSAIDs and metabolites, the most abundant ion was used as the 
quantification ion. In negative ionisation mode the deprotonated molecular ion [M-H]-, 
where M depicts the whole molecule, was used as the quantification ion for all the 
major metabolites, parent compounds and the two internal standards, flufenamic acid 
and piroxicam-d3, with the exception of 4-hydroxynimesulide, 4-hydroxydiclofenac, 
acetylsalicylic acid, ibuprofen, ketoprofen, piroxicam and suxibuzone respectively, as 
shown in Table 3.6 Similar approaches have been previously reported (Miksa, 
Cummings and Poppenga, 2005; Aberg, et al., 2009). As an example, Figure 3.18 
shows the negative ionisation mass spectra of diclofenac. The most abundant ion is 
m/z 293, which is the deprotonated molecular ion [M-H]- (Table 3.6).  
 
Figure 3.18 Negative ionisation mass spectra of diclofenac and corresponding 
proposed fragmentation (Moffat, Osselton and Widdop, 2004)  
In NSAIDs acetylsalicylic acid, ibuprofen and ketoprofen the intensity of [M-H]-  was not 
the most abundant ion, as shown in Figure 3.19, an example of ketoprofen. Instead the 
presence of ions representing a gain of 46Da indicated adduct formation with formic 
acid m/z 299 [M-H+HCO2H]- from the mobile phase (Table 3.7), therefore this base ion 
was used for quantification of these compounds.  
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Figure 3.19 Negative ionisation mass spectra of ketoprofen.  
Additionally, the base ion m/z 330 [M-2H]-  was used for piroxicam and m/z 307 [M-
C5H7O4]- for suxibuzone (Miao, Koenig and Metcalfe, 2002). Meanwhile the 
deprotonated [M-2H]- ion was identified as the base ion for 4-hydroxydiclofenac and 4-
hydroxynimesulide, these findings are in line with those reported by Kang and Kim 
(2008).  
Alongside the selection of quantification ions, the next abundant ions were selected for 
confirmation (Table 3.6), in majority of the compounds these were either deprotonated 
molecular ions or formic acid adducts where they had not previously been selected, 
often the loss of a CO2 group was used as the third confirmatory ion (Petrovic, et al., 
2005). In doing this, possible fragmentation can be predicted based on the chemical 
structure. For example, in the fragmentation of diclofenac (Figure 3.18), as an example, 
the molecular ion is identified at m/z 293 [M-H]-, the confirmatory ion, the next 
abundant, is selected at m/z 295 indicates a gain of 1 Da [M+H]-, thereafter m/z 250 
[M-H-CO2]– indicates a loss of 45 Da represents the loss of the CO2 group. The 
presence of ion m/z 339 [M-H+HCO2H]- represents a gain of 46Da, the adduct 
formation of formic acid. 
In the example of metabolites, the proposed fragmentation of the major metabolite of 
diclofenac; 4-hydroxydiclofenac (Figure 3.20), shows the molecular ion [M-] identified at 
m/z 312, whilst the base ion is recorded at m/z 310, indicating a loss of i.e. 2 Da [M-
2H]. A further confirmatory ion, the next abundant after the molecular ion, is selected at 
m/z 355 representing a gain of 46Da, the adduct formation of formic acid [M+HCO2H]-.  
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Figure 3.20 Negative ionisation mass spectra of 4-hydroxy diclofenac and 
corresponding proposed fragmentation 
All other fragment ions have been listed in Table 3.6, with chemical structures originally 
presented in section 1.3.4.  
3.2.5 Implementation of SIM for selectivity  
Due to the co-elution of piroxicam, piroxicam-d3 and 5-carboxymeloxicam at 8.26 
minutes, diclofenac, ibuprofen and suxibuzone co-eluting at 11.92 minutes and 4-
hydroxydiclofenac and ketoprofen (Figure 3.21) and the metabolite oxyphenylbutazone 
with meloxicam at 9.88 and 10.15 minutes respectively, SIM was used.  
With different molecular and confirmation ions, as depicted in Table 3.6, selective ion 
monitoring mode (SIM), was employed. By only scanning ions of interest, SIM allows 
for the discrimination between co-eluting compounds thus confirming SIM is the far 
more selective (Figure 3.21 and 3.22). Figure 3.21 shows the SIM chromatogram of 
diclofenac at 11.92 minutes and suxibuzone at 11.95 minutes, ibuprofen elutes at 
11.90 minutes, however, due to low intensity can only be seen in extracted ion mode. 
Whilst Figure 3.22 shows the SIM chromatogram of 4-hydroxydiclofenac at 9.85 
minutes and ketoprofen 9.92 minutes. Both are examples of how SIM has separated 
one peak eluted in TIC into two separate peaks.  
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Figure 3.21 The selected ion chromatogram of diclofenac (m/z 295), suxibuzone 
(m/z 307) (0.125µg/ml) 
 
Figure 3.22 The selected ion chromatogram of 4-hydroxydiclofenac (m/z 310) and 
ketoprofen (m/z 299) (10µg/ml) 
Similarly, problems with co-elution between oxyphenylbutazone and meloxicam were 
negated by the use of SIM as shown in Figure 3.23. By implementing the selected ions 
m/z 323, 391 for the metabolite oxyphenylbutazone and m/z 350, 352 and 396 for 
meloxicam, these compounds were identified at 10.19 and 10.11 respectively.  
 
Figure 3.23 The selected ion chromatogram of the NSAID meloxicam (m/z 350) 
and the metabolite oxyphenylbutazone (m/z 323) (10µg/ml) 
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Co-elution among three compounds; 5-carboxymeloxicam, piroxicam and piroxicam-d3, 
was negated through the use of SIM mode and selected ions m/z 380, 379 and 426 for 
5-carboxymeloxicam, m/z 330, 323 and 333 for piroxicam and m/z 333 for piroxicam-d3 
(as discussed in section 3.2.4) the compounds were separately identified at 8.23 and 
8.21 minutes respectively. The co-elution present in scan mode of piroxicam and its 
deuterated analog (piroxicam-d3) is to be expected (section 3.1), as the latter is the 
isotopically labelled version of piroxicam resulting in chemically similar structures just 
differed by 3 atomic mass units and thus same chromatographic retention times 
(Synder, Kirkland and Dolan, 2010).  
By employing SIM, compounds exhibiting co-elution can be identified and quantified 
(section 5.2.1). Based on the selectivity of the analytical method in SIM mode, results 
for the method validation presented in Chapter Four are obtained from analysis in SIM 
mode.  
3.3 INITIAL AUTOSAMPLER STABILITY IN AN INTRA-DAY STUDY OVER 54 
HOURS   
During initial method development, autosampler stability was investigated. This short 
term stability study was carried out to determine that the compounds investigated were 
stable in a mixed standard, made up in acetonitrile, for the duration of 54 hours. The 
time was selected based on the average analysis length during preliminary 
investigations to ascertain the optimal length on which mixed standards could be stored 
directly on the autosampler. During method validation, stability was reassessed 
(section 4.2) to allow for longer term analysis and investigated the stability of a mixed 
standard spread over a number of days with storage between analysis in -20ºC 
conditions. Stability was investigated as per method described in Chapter Two section 
2.3.4.  
3.3.1 Initial autosampler stability of internal standards 
It is necessary to consider the stability of both internal standards, piroxicam-d3 and 
flufenamic acid and, as quantification involves the ratio of analytical response between 
the analyte of interest and the internal standard.  
Analytical response were obtained through SIM analysis and mean relative response 
factor (Rc) is calculated using m/z 333 for piroxicam-d3 and m/z 280 for flufenamic acid 
(section 3.2.5, Table 3.6). Figure 3.24 and 3.25, shows the mean peak area values 
presented alongside 15% RSD (depicted by the horizontal lines). Results show the 
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deviation is random throughout the runs, without a pattern and within the 
recommended RSD of ±15% (Peters, Drummer, Musshoff, 2007). Therefore, over the 
54 hour stability studies both internal standards (0.01µg/ml) are stable with small 
fluctuations (RSD) within hours, denoted by the error bars at each corresponding hour, 
(Figure 3.24 and 3.25). Both internal standards are within the acceptable limits 
throughout the 54 hour duration.  
 
Figure 3.24 54 hour stability results (mean peak area against time) for internal 
standard piroxicam-d3 (m/z 332)  
  
Figure 3.25 54 hour stability results (mean peak area against time) for internal 
standard flufenamic acid (m/z 279)  
This short term study investigated the stability of both internal standards, present in a 
mixed standard at a concentration of 0.01µg/ml, when stored directly on the 
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autosampler during a 54 hour study. Following the interpretation of the data collected 
for the internal standards, both were proven stable for storage on the autosampler for 
the duration of the average analysis time (Figure 3.24 and 3.25).  
These results show the stability of flufenamic acid and piroxicam-d3 thus, supporting 
the selection and suitability as internal standards for this method of simultaneous 
detection of NSAIDs using LC-MS.  
3.3.2 Initial autosampler stability of mixed NSAIDs  
This method has determined stability for NSAIDs in a mixed standard prepared in 
acetonitrile. In short term stability studies, mixed NSAIDs standards were investigated 
at three different concentration levels (0.05, 0.5, 5µg/ml) (section 2.3.4). The results of 
the stability studies indicate compounds were stable (within acceptance criteria of 
±15% RSD, section 1.6.4) during analysis on the temperature controlled autosampler 
(15ºC) for the duration on 54 hours, albeit acetylsalicylic acid and ibuprofen (Figure 
3.27 and Appendix I).  
Figure 3.26 shows an example of the NSAID aceclofenac during the 54 hour study at 
all concentrations. For all NSAIDs (Appendix I to III), analytical response (mean PAR) 
were plot against time, with horizontal lines depicting the ±15% RSD and the mean 
PAR over 54 hours. Aceclofenac, like all NSAIDs investigated, apart from 
acetylsalicylic acid and ibuprofen, was within ±15% RSD throughout the 54 hours 
across all concentrations, with low RSD overall.  
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Figure 3.26 Graph of mean PAR (n=3) over 54 hours for aceclofenac stability at, 
(a) 0.05µg/ml, (b) 0.5µg/ml, (c) 5µg/ml.  
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In the case of acetylsalicylic acid and ibuprofen the analyte response fluctuated and 
resulted in larger standard deviations, especially at the lowest concentration (0.05 
µg/ml) with low PARs (Figure 3.27, Appendix I to III). This was also the case, for these 
compounds, throughout the method development and particularly the repeatability 
study in section 3.4.1. It is inherent that as the concentration lowers so did analytical 
response and the resulting ratio, thus errors and larger variance will increase (Saar, et 
al., 2012), but they should still be within the acceptance criteria Ibuprofen is stable at 
higher concentrations (0.5 and 50µg/ml) and Figure 3.27 shows the instability of this 
compound with larger standard deviations at the lower concentration.   
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Figure 3.27 Graph of mean peak area ratio (n=3) over 54 hours for ibuprofen 
stability at (a) 0.05µg/ml, (b) 0.5µg/ml, (c) 5µg/ml.  
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The stability over 54 hours of each NSAID in acetonitrile has been determined and are 
stable across 0.05, 0.5 and 5µg/ml concentrations for the full duration of 54 hours with 
the exception of acetylsalicylic acid that showed instability across all concentrations 
and ibuprofen at the mid and higher concentration. With regards to the metabolites, at 
the highest concentration (5 µg/ml) 5-carboxymeloxicam and 5-hydroxyflunixin were 
beyond ±15% RSD. With 5-carboxymeloxicam and 5-hydroxyflunixin, there were 
notable decreases in analytical response between 43 and 54 hours and this could 
suggest that these metabolites are only stable up to 43 hours when stored in a mixed 
standard directly on the autosampler (Appendix I to III). In the case of ibuprofen, 
instability was apparent at the lowest concentration, this could be linked with expected 
fluctuation near its limits of detection. The instability of ibuprofen is contrary to the 
published findings; analysing ibuprofen and its deuterated counterpart, ibuprofen-d3, 
with LC-MS/MS, Grenier, et al. (2011) reported ibuprofen to be stable for a period of up 
to 24 hours at concentrations of 0.03 and 0.7µg/ml in ambient temperature. The mix of 
compounds and the choice of technique is different between this research and the 
study by Grenier, et al. (2011), thus the stability of ibuprofen in mixed standards should 
be studied further.  
3.4 PRELIMINARY INVESTIGATION OF PRECISION  
This study assessed the repeatability of samples, prior to method validation. Intra-day 
precision was investigated over 54 hours as per methods section 2.3.5. 
3.4.1 Intra-day repeatability study 
This study was investigated using low, mid and high concentrations within the linear 
range (section 4.4) at 0.05, 0.5 and 5µg/ml. Each concentration was investigated with 
nine replications over a 54 hour period, each analysed in triplicate. The PAR (analyte: 
IS) and corresponding standard deviation (n=3) were recorded for the duration of 54 
hours. Corresponding relative standard deviation were calculated. In Table 3.7 the data 
is presented for mixed standards (containing NSAIDs and metabolites) at the 
concentrations, and includes their corresponding PAR.  
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Table 3.7 Intra-day repeatability results of peak area ratio (analyte:IS) and their 
respective SD and RSD of three concentrations of mixed NSAID standards. 
NSAID 
Intra-assay PARa repeatability 
0.05µg/ml 
RSDb 
% 
0.5µg/ml 
RSDb 
% 
5µg/ml 
RSDb 
% 
aceclofenac 0.41 ± 0.03 6.86 2.82 ± 0.17 5.98 40.56 ± 1.56 3.85 
acetylsalicylic acid 0.14 ± 0.04 26.99 0.77 ± 0.19 24.47 2.51 ± 0.31 12.41 
carprofen 2.02 ± 0.11 5.56 16.33 ± 1.49 9.12 46.72 ± 4.28 9.17 
diclofenac 2.93 ± 0.20 6.76 30.06 ± 2.32 7.72 91.75 ± 5.87 6.40 
flunixin 9.35 ± 0.67 7.17 80.06 ± 7.99 9.98 202.68 ± 9.81 4.84 
Ibuprofen 0.14 ± 0.04 28.43 1.68 ± 0.19 11.16 3.35 ± 0.17 5.10 
ketoprofen 2.05 ± 0.15 7.13 13.55 ± 1.01 7.48 39.38 ± 2.70 6.87 
mefenamic acid 1.20 ± 0.10 8.32 5.83 ± 0.31 5.32 75.05 ± 3.29 4.39 
meloxicam 4.79 ± 0.24 5.42 37.12 ± 3.49 9.41 138.57 ± 10.78 7.78 
nimesulide 17.44 ± 1.05 6.00 114.10 ± 9.23 8.09 220.30 ± 14.17 6.43 
oxyphenylbutazone 9.05 ± 0.66 7.33 89.39 ± 7.24 8.09 196.32 ± 10.03 5.11 
phenylbutazone 0.45 ± 0.04 9.58 3.71 ± 0.47 12.53 49.82 ± 3.39 6.80 
piroxicam 4.23 ± 0.30 7.16 30.15 ± 1.98 6.58 84.77 ± 6.64 7.84 
suxibuzone 4.40 ± 0.35 8.04 39.48 ± 3.71 9.41 120.83 ± 8.61 7.13 
3-hydroxymethylmefenamic 
acid 
2.29 ± 0.24 10.28 25.74 ± 2.11 8.21 82.25 ± 8.55 10.39 
4-hydroxydiclofenac 3.88 ± 0.28 7.18 38.10 ± 2.75 7.21 112.92 ± 6.90 6.11 
4-hydroxynimesulide 4.21 ± 0.28 6.71 45.44 ± 4.43 9.76 141.88 ± 9.38 6.61 
5-carboxymeloxicam 1.05 ± 0.09 8.14 8.29 ± 0.68 8.21 37.70 ± 13.68 36.27 
5-hydroxyflunixin 0.73 ± 0.10 13.51 3.59 ± 0.37  10.38 66.01 ± 10.78 16.33 
5-hydroxypiroxicam 5.78 ± 0.32 5.62 43.61 ± 3.92 7.90 162.62 ± 8.79 5.41 
apeak area ratio of analyte peak area/ internal standard peak area (n=3) ± SD bRelative 
Standard Deviation (RSD) 
At 0.05µg/ml, all NSAIDs, with the exception of acetylsalicylic acid and ibuprofen are 
within the accepted ±15% RSD, with precision actually closer to 10% RSD for all 
NSAIDs. In acetylsalicylic acid and ibuprofen, shown graphically in Appendix I, these 
compounds showed high variability (˃20% RSD) in results at this lowest concentration 
across the duration of the study (26.99% and 28.43% respectively, Table 3.7).  
At the two lower concentrations (0.05 and 0.5µg/ml) the analytical responses are low in 
comparison to those recorded across the other compounds analysed. This in turn 
resulted in low PARs, as an example, acetylsalicylic acid, at 0.05 µg/ml, PARs ranged 
between 0.02 and 0.38 thus producing a RSD of 63.5% overall. At this concentration 
both compounds exhibited poor peak symmetry (tailing factor >1), with similar results 
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achieved at 0.5µg/ml, in line with findings during the stability investigations in section 
3.3.2.  
At 0.5µg/ml all NSAIDs were within 15% RSD with most compounds actually nearer 
10% RSD. The exception to this was acetylsalicylic acid with a recorded RSD at 
24.47%. At this mid-range concentration, precision was improved in acetylsalicylic acid, 
recorded at 24.47%, and ibuprofen within 15% RSD (Table 3.7). In acetylsalicylic acid 
analytical response was also much closer to that of the internal standards when 
compared to 0.05µg/ml. However, at these concentration the internal standard, 
piroxicam-d3, is almost tenfold less than the concentration of acetylsalicylic acid being 
detected, this indicates that the sensitivity of this compound was much less than other 
compounds. This would mean a concentration that would otherwise yield a repeatable 
analytical response, in the case of acetylsalicylic acid sensitivity is much lower.  
At the high (5µg/ml) concentration investigated the majority of compounds are within 
15% RSD. However, larger variations were recorded in metabolites 5-
carboxymeloxicam and 5-hydroxyflunixin. In the case of 5-carboxymeloxicam and 5-
hydroxyflunixin, RSD was recorded at 36.27% and 16.33% respectively (Table 3.7). In 
both metabolites there was a notable decrease in analytical response between 43 and 
54 hours with large deviations between the triplicate data set, for example in PARs 
recorded for 5-hydroxyflunixin at 48 hours 53% RSD was recorded. This could be due 
a loss in stability of these compounds, whereby there are a number of factors are 
involved (section 3.3.2). After 43 hours, the compound may have started to degrade 
leading to a drop in concentration and ultimately a fall in analytical response, 
additionally 5-carboxymeloxicam was identified as a compound that co-eluted with 
piroxicam and piroxicam-d3 (section 3.2.5) whereby the latter compounds are more 
responsive at higher concentrations. On inspection of the chromatography of these 
metabolites both showed peak distortion, possibly exhibiting overloading, this was 
investigated further through the assessment of linear range (section 4.4).  
Overall, the results show that all the compounds were repeatable, all are within 10-15% 
RSD at the three concentrations studied, with the exception of the discussed 
acetylsalicylic acid and ibuprofen and metabolites 5-carboxymeloxicam and 5-
hydroxyflunixin beyond 43 hours. Furthermore, as the concentration increases so does 
the method’s precision. This was especially the case for ibuprofen and acetylsalicylic 
acid; at the lowest concentration it is apparent that the RSD is beyond the accepted 
15% for both compounds and more precisely 0.5µg/ml is beyond the calculated LOQ 
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for acetylsalicylic acid. At the highest concentration acetylsalicylic acid is within 15% 
RSD.  
3.5 SUMMARY 
The analytical method developed in this project was optimised through several 
preliminary investigations. These involved modifications in initial parameters to achieve 
an optimal analytical method, as has been presented in this chapter.  
Initial investigations were carried out to first access the chromatographic profile of both 
internal standards employed in this research. Peaks were tall and sharp and within 
recommended criteria. With differing mass spectral data, both compounds were 
separated from neighbouring peaks and therefore, proven to be selective enough.  
Meanwhile, in the case of flufenamic acid (the second internal standard) mutual overlap 
with neighbouring mefenamic acid was recorded, however resolution was within 
acceptable resolution limits (=1). Both internal standards were repeatable and 
reproducible throughout qualitative and quantitative studies, therefore, supported the 
selection of these compounds.  
Substantial changes were made to during the optimisation of the gradient elution 
program including, the mobile phases and column employed. Changes in polarity of the 
mobile phases resulted in shifts in elution order and the resolution of analytes. Peak 
shapes across NSAIDs and metabolites were Gaussian in shape and tailing factor was 
low (≤1.5). The final optimised method ensured resolution and selectivity (>1) was 
improved and overall asymmetry (<2) was ideal.  
Optimal solvent selection was also considered in the development stages; formic acid 
was used as an additive to improve chromatographic separations and resulted in better 
retention and peak shape. The optimal solvent was found to be acetonitrile, based on 
reproducible results, larger peak areas, better shaped peaks and improved base line 
resolution.  
Optimal injection volumes were investigated whereby notable peak distortion occurred 
at 10 µl, whilst 0.2 and 2µl resulted in symmetrical peak shape. Despite this, at the two 
lowest volumes only slight differences were noted. However, on analysis of RSD, at 
injection volumes of 2µl RSD were improved, examples were provided in the NSAID 
nimesulide at 0.2 µl RSD was recorded at 21.72% compared to 1.63% at 2µl. These 
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reductions in deviations were noted across majority of NSAIDs. Hence, based on this 
data, injection volumes at 2µl were found to be optimal. 
Selectivity was assessed and base line resolution was achieved in scan mode for all 
NSAIDs studied except for aceclofenac, diclofenac, ibuprofen, piroxicam, piroxicam-d3, 
oxyphenylbutazone, suxibuzone, 4-hydroxydiclofenac and 5-carboxymeloxicam. 
However, all compounds were resolved using SIM. From these results, it is concluded, 
that SIM mode is the far more selective method. Using SIM is advantageous when 
analysing feather samples as there may be ions present in the matrix of the sample 
that could possibly interfere. Blanks were analysed between samples to ensure no 
interferences were present that would inhibit the detection of analytes of interest. No 
cross contamination or interferences were observed, this further ensures that method 
developed here is selective.  
During method development initial investigations into the stability of mixed standards 
(in acetonitrile) were carried out to determine the stability of compounds when stored 
directly on the autosampler. The analysis time (54 hours) ensured the investigation of 
the average time a mixed standard spent on the temperature controlled autosampler 
(15ºC) during method development. The results from the study determined the short 
term stability of 5-carboxymeloxicam and 5-hydroxyflunixin is up to 43 hours when 
stored in a mixed standard directly on the autosampler. Whilst for all other compounds, 
with the exception of acetylsalicylic acid and ibuprofen, were stable for the duration of 
the 54 hour investigation. Stability studies also included 54 hour investigations of both 
internal standards in a mixed standard. Both were proven stable and within the 
required RSD of ±15% for 54 hours storage on the autosampler. 
Alongside initial autosampler stability, supporting precision studies were carried out to 
provide an initial indication of the methods precision, piror to validation (Chapter Four). 
From these precision studies, as expected, when the concentration increased so did 
the methods precision. Where the method was not deemed precise, this fell in line with 
the linear ranges as statistically analysed throughout section 4.3 and the LOD and 
LOQs (section 4.4.5) calculated thereafter. This was especially evident in the 
metabolites; 5-carboxymeloxicam and 5-hydroxyflunixin.  
Whilst method development resulted in improvements in chromatographic separations 
of most NSAIDs, compounds acetylsalicylic acid and ibuprofen consistently showed 
low analytical responses and variation throughout. The compounds showed 
inconsistencies in precision and stability studies and therefore could not reliably be 
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detected by this analytical method (falling outside the criteria set out by the 
Commission Decision). It was therefore not plausible to include these two compounds 
in the validated method (Chapter Four) nor apply them to the application in real 
samples (Chapter Five). This is an area for further investigation in future research 
(section 6.3).   
Upon optimisation and meeting the required guidelines (Huber, 2007; CDER, 1994), 
the method was ready for validation. Following this, Chapter Four presents the 
investigations and supporting data that were carried out and collated to validate the 
analytical method. 
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CHAPTER 4: METHOD VALIDATION RESULTS AND DISCUSSION  
The results from method validation (section 2.4) are included in this chapter 
subsequent to its development as outlined in Chapter Three. The LC-MS method has 
been developed in Chapter Three for the simultaneous detection of eleven NSAIDs and 
seven major metabolites (section 1.3.3). There are four aspects of this research that 
make this analytical method novel; (i) the range of NSAIDs selected, (ii) the inclusion of 
metabolites, (iii) the simultaneous detection of twenty compounds and two internal 
standards  and (iv) the sample preparation involved, the latter is detailed in Chapter 
Five.  
The analytical method presented was validated through a series of parameters and 
laboratory tests set out by Commission Decision (2002) and in Huber (2007) in 
accordance with the Centre for Drugs Evaluation and Research, and International 
Conference on Harmonisation. These studies establish whether the results met 
requirements for the intended analytical application. The studies carried out during the 
validation were selectivity (section 4.1), longer term, six day stability (section 2.4.2 and 
4.2), inter-assay precision (section 2.4.3 and 4.3), linear range (section 2.4.4 and 4.4) 
and limits of detection and quantification (section 2.4.4 and 4.4.5). The assessment of 
linear range included linear regression of which there was visual examinations of plots, 
analysis of residuals and statistical tests Shapiro-Wilk test for normality and Wald-
Wolfowitz runs test for randomness. These tests would ensure the data is free from 
bias and any variations from linearity are insignificant and random.  
4.1 RESULTS OF SELECTIVITY 
Selectivity was investigated during method development stages (section 3.2.1) and 
through the implementation of the SIM method. Diagnostic ions were collated for all 
analytes of interest and were used to resolve any co-elution between NSAIDs and their 
metabolites (section 3.2.4 and 3.2.5). As discussed in the preceding chapter, 
compounds found to overlap had different quantification and confirmation m/z ions 
(Table 3.7), this allowed for discrimination between compounds and thereafter enables 
reliable quantification. Based on the selectivity of the analytical method in SIM mode, 
this method was validated and results are presented in this chapter.   
4.2 LONGER TERM STABILITY IN AN INTER-DAY STUDY  
Autosampler stability time was investigated during initial method development (section 
3.3). In the method validation to allow for longer term analysis, i.e. if analysis was 
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spread over a number of days, stability of compounds over 6 days, with a freezing and 
thawing stage between analysis, was studied. 
4.2.1 Longer term stability of internal standards  
Like initial autosampler stability studies (section 3.3), the stability of both internal 
standards was also investigated over a longer term stability study as discussed in 
Chapter Two, section 2.4.3.   
Over the period of 6 days both flufenamic acid and piroxicam-d3 peak areas recorded 
are within acceptance criteria of ±15% RSD with no specific pattern. From the data 
presented (Figure 4.1 and 4.2) both internal standards are stable across the duration of 
6 days. This includes the time from sample preparation and the time spent in storage in 
freezer conditions.  
 
Figure 4.1 Six day stability results for internal standard piroxicam-d3 (m/z 332); 
mean peak area (0.1µg/ml).  
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Figure 4.2 Six day stability results for internal standard flufenamic acid (m/z 279); 
mean peak area (0.1µg/ml).  
On the second day there was slight increase in analytical response in piroxicam-d3 this 
has resulted in the mean peak area being close to the upper 15%. The analytical 
responses recorded on this day had an RSD of 5.6%, showing a small variation in peak 
areas, denoted by the error bars. This increase in response could be down to 
instrumental fluctuations i.e. indeterminate error, this is especially relevant as only peak 
area was used thus the results are not relative to any such fluctuations.  
During six day stability studies, the concentration of both internal standards was the 
same (0.1µg/ml), selected based on the linear range this research investigated (section 
4.4). It was however apparent, that whilst the concentration is the same not all analytes 
yield the same analytical response, as was the case in these two compounds.  
Together with the initial investigations (section 3.3), these results show the stability of 
flufenamic acid and piroxicam-d3 are also stable over the duration of six days. This, 
supports their selection and suitability as internal standards for this method of 
simultaneous detection of NSAIDs using LC-MS.  
4.2.2 Longer term stability of mixed NSAID standards in an inter-day study over 
six consecutive days 
Investigations were carried out over three concentrations (0.05, 0.5 and 5µg/ml) and at 
the lowest concentration of 0.05µg/ml the majority of NSAIDs and metabolites fell 
within ±15% RSD over the six day study, with some falling within ±10% RSD, showing 
high precision and stability in compounds (Figure 4.3 and Appendix IV, V and VI). As 
with initial autosampler investigations (section 3.3), similar results were noted in the 
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metabolites 5-carboxymeloxicam and 5-hydroxyflunixin, both having RSD larger than 
±15%. It was apparent that at this concentration (0.05µg/ml), 5-carboxymeloxicam was 
close to its calculated LOD (0.03µg/ml, Table 4.5) and beyond the LOQ at 0.12µg/ml 
(section 4.4.5, Table 4.5), where larger fluctuations in analytical response are 
expected, as discussed in section 3.3.2 (Peters, Drummer and Musshoff, 2007). 
However, RSD was within the lower acceptance range of ±20% RSD throughout the 
duration of the study (section 3.4). In the case of 5-hydroxyflunixin, the analytical 
response on day 3 and 4 was outside of these lower accepted ranges indicating a drop 
in analytical response. On inspection of the chromatogram, poor peak symmetry was 
noted and peaks were less intense. This is most likely to relate to fluctuations in 
instrumental response and indeterminate errors that cannot be explained.  
At the 0.5µg/ml all NSAIDs were within the accepted ±15% RSD with NSAIDs 
aceclofenac (Figure 4.3), meloxicam and piroxicam even lower (Appendix IV). At 
5µg/ml all compounds were within acceptance values (refer to Appendix VI and VII). 
These results indicate that the compounds under investigation are most stable at 
concentrations above LOD. 
Figure 4.3 shows an example of the NSAID aceclofenac during the 6 day stability study 
at all concentrations. Horizontal lines depict ±15% RSD for each concentration (0.05, 
0.5 and 5µg/ml), and the mean PAR over the duration of six days. Figure 4.3 shows 
that aceclofenac is stable over 6 days in a mixed NSAID standard in acetonitrile when 
stored as per storage conditions in section 2.4.2. 
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Figure 4.3 Graph of Mean Peak Area Ratio (n=3) over 6 days for aceclofenac 
stability trial, (a) 0.05µg/ml, (b) 0.5µg/ml, (c) 5µg/ml.  
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From the 6 days stability study, all NSAIDs, except 5-carboxymeloxicam and 5-
hydroxyflunixin, were within acceptance criteria of ±15% RSD (Appendix IV, V and VI), 
thus, are stable for the duration of the study. In the case of the mentioned metabolites, 
5-carboxymeloxicam (IV-e) and 5-hydroxyflunixin (IV-f) appear stable at higher 
concentrations (0.5 and 5 µg/ml) with an RSD for each within ±15% for the duration of 
six days. However, at the lowest concentration (0.05µg/ml), i.e. near LOD, stable up to 
3 days.  
4.3 PRECISION OF THE ANALYTICAL METHOD  
Precision of the analytical method was initially investigated during the development of 
the analytical method. This section presents an inter-assay reproducibility precision 
study based over six days in triplicate analysis as per protocols in section 2.4.3.   
4.3.1 Inter-day reproducibility precision study 
At the lowest concentration, 0.05µg/ml, all NSAIDs results were precise and within 15% 
RSD. However, the metabolites 5-carboxymeloxicam and 5-hydroxyflunixin had RSD 
over 15% (16.46% and 22.59% respectively); the results are shown in Table 4.1. Like 
intra-day repeatability studies (section 3.4), data collected for these compounds had 
larger RSD at the lowest concentrations only. Hence, as the concentration increased 
so did corresponding precision. This indicates, in the case of these compounds, the 
analytical method is the most precise at higher concentrations.   
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Table 4.1 Inter-day repeatability results of three concentrations of mixed NSAID 
standards 
NSAID 
Inter-assay PARa repeatability 
0.05µg/ml 
RSDb 
% 
0.5µg/ml 
RSD
b % 
5µg/ml 
RSDb 
% 
aceclofenac 0.16 ± 0.01 8.93 1.18 ± 0.03 2.43 15.41 ± 0.83 5.36 
carprofen 0.20 ± 0.02 7.69 1.29 ± 0.12 9.93 7.46 ± 0.38 5.13 
diclofenac 0.52 ± 0.05 9.62 2.90 ± 0.28 9.51 17.51 ± 0.86 4.90 
flunixin 2.60 ± 0.27 10.25 17.55 ± 1.70 9.67 16.47 ± 0.96 2.06 
ketoprofen 0.18 ± 0.03 14.77 0.81 ± 0.05 6.79 3.84 ± 0.14 3.61 
mefenamic acid 0.37 ± 0.05 13.95 2.28 ± 0.20 8.63 27.00 ± 2.38 8.82 
meloxicam 12.04 ± 0.78 6.44 60.44 ± 2.60 4.30 73.77 ± 1.72 2.34 
nimesulide 21.82 ± 1.68 7.69 73.33 ± 5.65 7.71 77.17 ± 2.03 2.64 
oxyphenylbutazone 5.94 ± 0.44 7.47 43.98 ± 3.27 7.43 56.48 ± 1.11 1.97 
phenylbutazone 0.60 ± 0.06 10.02 3.42 ±0.19 5.50 38.76 ± 2.18 5.62 
piroxicam 5.21 ± 0.40 7.75 30.35 ± 0.98 3.24 62.42 ± 0.92 1.47 
suxibuzone 0.80 ± 0.03 3.76 4.02 ± 0.39 9.62 23.38 ± 0.96 4.10 
3-hydroxymethyl 
mefenamic acid 
0.48 ± 0.04 8.90 3.55 ± 0.32 8.89 19.61 ± 0.81 4.11 
4-hydroxydiclofenac 0.36 ± 0.02 6.49 2.69 ± 0.26 9.65 16.18 ± 0.88 5.46 
4-hydroxynimesulide 9.33 ± 0.83 8.88 50.86 ± 3.48 6.84 61.97 ± 1.27 2.05 
5-carboxymeloxicam 0.05 ± 0.01 16.46 0.53 ± 0.03 6.50 4.13 ± 0.20 4.81 
5-hydroxyflunixin 0.12 ± 0.03 22.59 0.21 ± 0.02 11.24 1.26 ± 0.06 4.87 
5-hydroxypiroxicam 0.75 ± 0.05 6.75 7.18 ± 0.56 7.86 33.47 ± 0.72 2.14 
apeak area ratio of analyte peak area/ internal standard peak area (n=3) ± SD brelative standard 
deviation (RSD) 
On inter-day repeatability study results, it was apparent that 5-carboxymeloxicam and 
5-hydroxyflunixin had larger RSD (>15%) (Table 4.1) at the lowest concentration, 
however it was still within 15% in mid-range and high concentrations. In 5-
carboxymeloxicam and  5-hydroxyflunixin, at the lowest concentration, when 
investigating the RSD of triplicate analysis on day 3 and 4 there were large deviations 
and lower analytical responses than those recorded across the other four days. 
However, as these were in mixed NSAID standards, and no other compounds exhibited 
the same drop in analytical response, these fluctuations were compound dependent 
and thus, in section 4.2.2, linked to indeterminate errors. Meanwhile, in section 3.3.2 
(autosampler stability) and section 3.4.1 (intra-day precision) high RSD and similar 
drops in analytical response were recorded around 43 hours suggesting that on the 
autosampler that 5-carboxymeloxicam and 5-hydroxyflunixin were unstable beyond this 
time in a mixed standard. The data presented in Table 4.1 is supported by these earlier 
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findings and suggests that the analytical method cannot yield precise data, for these 
compounds, beyond this point at low concentrations. RSD within day three was 26.13% 
and on day 4, analytical response was lower (peak area ratio 0.09) than those recorded 
across the six days (mean peak area ratio 0.14), similar variations were observed in 5-
carboxymeloxicam, (refer to Appendix IV). This could be the result the previously 
discussed fluctuations at the lower concentration of the working concentration range, 
where more fluctuation is expected when closer to LOQ (Peters, Drummer and 
Musshoff, 2007). LOQ for 5-carboxymeloxicam (0.123µg/ml) and 5-hydroxyflunixin 
(0.070µg/ml) is reported in section 4.4.5, Table 4.5) 
At 0.5µg/ml all NSAIDs were within ±15% RSD, therefore analysis at this concentration 
appears precise (≤7.54%) across intra-day studies. At 5µg/ml all NSAIDs, are within a 
RSD of ±15%, ranging from 1.47% for piroxicam to 4.90% for diclofenac.  
Overall, the inter-assay reproducibility study has shown the analytical method to be 
precise and within acceptance criteria (Huber, 2007; Peters, Drummer and Musshoff, 
2007) and often lower, within 5-10% RSD. The precision of the method also increased 
as the concentration increased.  
4.4 THE ASSESSED LINEAR RANGE 
The linear range (section 1.6.6) of the analytical method presented in this thesis was 
accessed experimentally as per the method described in section 2.4.4. Results from 
this study are presented and discussed in sections 4.4.1 to 4.4.5. The linear range of 
each NSAID and selected metabolites was investigated through (I) linear regression 
(section 4.4.1), (II) relative response (section 4.4.2), (III) analysis of residuals (section 
4.4.3) and (IV) statistical tests (section 4.4.4). Statistical tests such as Shapiro-Wilk and 
Wald-Wolfowitz were employed to test the normality of results and randomness of 
errors in each data set (first described in section 1.6.6). Thereafter, the limits of 
detection (LOD) and limits of quantification (LOQ), together with signal to noise ratio, of 
each compound was determined from linear regression and compared to literature 
where possible (section 4.4.5). 
4.4.1 Linear regression    
In the first assessment of the linear range, regression analysis was carried out. Linear 
graphs were plotted of PAR versus concentration (µg/ml) for each NSAID and 
metabolite. Through this analysis, it is expected that at very low and very high 
concentrations there are points that tail off and plateau where instrumental response is 
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non-linear, these concentrations are thus beyond the linear range of the compound and 
furthermore, beyond the working range of the detector (Huber, 2007). The latter is 
especially obvious at higher concentrations where it is possible to see peaks that 
exhibit overloading, refer to section 1.6.2.2 and 1.6.2.9. Over the whole concentration 
range investigated (0.01 to 25 µg/ml), results were non-linear at the highest 
concentrations of 5, 10 and 25 µg/ml. All NSAIDs and metabolites showed MS detector 
saturation at these concentrations (5, 10 and 25 µg/ml) and in some cases at 1 and 2.5 
µg/ml (i.e. nimesulide, oxyphenylbutazone and 3-hydroxymethyl mefenamic acid). 
Figure 4.4 is the linear graph of nimesulide plotted over the whole concentration range, 
it shows the highest concentrations that have plateaued and resulted in a non-linear 
response.   
 
Figure 4.4 Linearity plot of nimesulide (0.01 to 25µg/ml) 
The ICH defines the linear range as the interval between the upper and lower 
concentration whereby the analytical response exhibits linearity. To investigate further, 
these non-linear concentrations were removed from each of the linear regression 
graphs and a further calibration graph of PAR versus concentration was plot. As an 
exemplar shown in Figure 4.5 of nimesulide, each NSAID resulted in a linear 
relationship (Appendix VII).  
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Figure 4.5 linear range plot of nimesulide (0.01 to 0.5µg/ml) 
Correlation coefficients (R2) value were calculated and recorded at 0.993 ± 0.002 
(n=22) across all compounds. R2 is a measure of the degree of linear association 
between x and y residuals. Ranging from 0.0 to 1.0, the larger the R2 value, the closer 
the correlation between all the data points and the line of best fit, an R2 value of 1 
represents a perfect fit. It is said, a 10% relative uncertainty in this linear range would 
require R2 values of 0.99 (Ellison, Barwick and Farrant, 2009). On comparison to the R2 
values obtained in the linearity study, all NSAIDs conformed to 10% relative 
uncertainties (Apendix VII, Table 4.2). It is important to remember that R2 cannot 
generally be taken as a sole measure of linearity. Whilst it is an indication of good 
linearity when data is spread evenly, around the line of best fit, and without anomalies, 
high R2 values can be obtained from a large spread of data that would otherwise 
produce a non-linear graph (Miller and Miller, 2010). Therefore, the linear range of 
each compound was investigated statistically through a series of tests including, the 
analysis of residuals, goodness of fit and runs test.    
4.4.2 Relative response  
Linearity data was further analysed by plotting a graph of relative response (mean PAR 
divided by concentration) against the concentration, on a log scale (Figure 4.6 and 4.7 
and Appendix VIII). Deviations from linearity can be difficult to detect so by analysing 
plots of relative response, if linearity is achieved then the resulting plot should be within 
±5% (95 to 105%) of the mean relative response factor (Rc) (Huber, 2007). It is 
possible to predict the linear range as the method is deemed linear until the point 
where the relative response falls outside the accepted RSD. Deviations should 
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therefore, be equally distributed between positive and negative values, however, areas 
of high and low concentration will typically yield a negative deviation a result of their 
non-linear response. Rc designates the line of constant response (Figure 4.6, 4.7 and 
Appendix VIII).   
As an example, Figure 4.6 shows the plot for nimesulide where data points beyond the 
linear range were identified at the highest concentrations (5, 10 and 25 µg/ml 
respectively), as originally highlighted in Figure 4.4 and in Figure 4.6. Including these 
data points cause bias in the intercept by shifting the regression line hence the 
resulting correlation coefficient falls outside the accepted 0.99 (Figure 4.4, R2 = 0.28). 
On the removal of these data points a further concentration point (2.5 µg/ml, 
highlighted in Figure 4.6) was identified outside ±5% and hence was removed. The 
data points were plot again (Figure 4.7) and became spread around the mean, within 
±5%, indicating, until this point and through this interpretation, the linear range of the 
compound was 0.01 to 1µg/ml.  
 
Figure 4.6 Relative response (mean PAR/C) of nimesulide versus log 
concentration  
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Figure 4.7 Relative response (mean PAR/C) of nimesulide versus log 
concentration (0.01 to 1µg/ml) 
Upon examination of the relative response graphs for each compound (Appendix  VIII) 
and correlating linear graphs a predicted linear range was obtained (Table 4.2). 
Thereafter, another method was used on the concentration range investigated to 
confirm the linear range of the compounds, namely the analysis of residuals, the 
calculated difference between the observed value and the predicted value obtained 
from the linear regression (section 4.4.3).  
4.4.3 Analysis of residuals  
The analysis of residuals can aid further in the identification of problems with poor or 
incorrect curve fitting (Figure 4.8) (Ellison, Barwick and Farrant, 2009). If the data is of 
good fit, the residuals are expected to be randomly distributed around zero (the ideal 
result indicating there is no deviation from the observed value) (Figure 4.9). Deviations 
from this random distribution can indicate problems within the data set, for example, a 
curve indicates the line of best fit has been fitted through the data set that follows a 
non-linear trend, this was initially seen in Figure 4.4 (section 4.4.1) at the highest 
concentrations for nimesulide (5, 10 and 25 µg/ml) where MS detector saturation was 
recorded.  
On analysis of the residuals, residual plots were produced (residuals against 
concentration). Uneven distribution of values was apparent at lower and upper 
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concentrations (Figure 4.8), as previously discussed in the interpretation of Figure 4.5. 
This resulted in residual plots not randomly distributed around zero and therefore 
represented a loss of linearity, this can be seen in nimesulide, Figure 4.8, which 
resulted in a curve. Subsequently, the analytical responses that were non-linear, at the 
high and low end of the concentration range investigated (section 4.4.1, Table 1.2), 
were removed for all compounds and residual plots were obtained (Appendix IX). 
Figure 4.9 shows an ideal response in nimesulide; the residuals are randomly 
distributed around zero in linear range 0.01 to 0.5µg/ml. 
 
Figure 4.8 Biased residual plot of nimesulide (0.01 to 25 µg/ml) 
 
Figure 4.9 Unbiased residual plot of nimesulide (0.01 to 0.5 µg/ml) 
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Using regression and residual analysis (Microsoft Excel) (Appendix IX), concentration 
ranges were assessed and the resulting linear range are given in Table 4.2. 
Table 4.2 linear range and R2 values after regression and residual analysis  
NSAID linear range µg/ml R2a 
aceclofenac 0.010-2.5 0.996 
carprofen 0.025-1.0 0.991 
diclofenac 0.010-5.0 0.995 
flunixin 0.010-1.0 0.996 
ketoprofen 0.025-5.0 0.993 
mefenamic acid 0.010-10 0.991 
meloxicam 0.010-2.5 0.996 
nimesulide 0.010-0.5 0.993 
oxyphenylbutazone 0.010-0.5 0.994 
phenylbutazone 0.050-2.5 0.996 
piroxicam 0.010-2.5 0.990 
suxibuzone 0.025-2.5 0.990 
3-hydroxymethyl mefenamic acid 0.010-0.5 0.993 
4-hydroxydiclofenac 0.010-1.0 0.998 
4-hydroxynimesulide 0.010-5.0 0.995 
5-carboxymeloxicam 0.025-1.0 0.995 
5-hydroxyflunixin 0.025-5.0 0.998 
5-hydroxyprioxicam 0.010-2.5 0.998 
amean correlation coefficient (R2) (n=3) data from linear regression 
4.4.4 Statistical analysis 
For further analysis of the residual plots and to confirm the normality of the results for 
the linear range (Table 4.2), the statistical package IBM SPSS Statistics (SPSS) was 
employed to perform the Shapiro-Wilk test (Shapiro and Wilk, 1965). Normality of 
results can be assessed by two main methods: graphically or numerically. Suitable for 
small samples sizes of less than 50 samples, this statistical test involves the numerical 
assessment of normality through the comparison of analytical response, PAR, with the 
predicted analytical response obtained from the residual analysis (linear range as per 
Table 4.2). The difference between the two is calculated and residuals obtained and 
analysed (Miller and Miller, 2010).  Thereafter, the output of normal quantile-quantile 
(Q-Q) plots are assessed graphically for normality (Figure 4.10).  
The Shapiro-Wilk test will return a mean, its standard deviation and a p-value. P-values 
represent the probability of observing a value greater than or equal to the critical value 
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(0.05), representing 95% confidence interval, if the null hypothesis is retained. If the 
distribution of errors is normal, the statistical test retains a null hypothesis (≥0.05) 
indicating the data is of normal distribution. If the p-value is lower than the significance 
level of 0.05, the null hypothesis must be rejected as it indicates a result significantly 
different from non-normal distribution. In the statistics used throughout the linearity 
study the confidence limit used has been 95% thus, the significance level used was p = 
0.05. 
For graphical assessment, in the case of the Q-Q plots (Figure 4.10), if the data is 
normally distributed then the data points will be close to the regression line. If the data 
appears in a non-linear manner then the data is not normally distributed. Normality is 
depicted graphically by Q-Q plots and an exemplar is shown in Figure 4.10 of 
nimesulide.  
  
Figure 4.10 One-Sample Shapiro Wilk Test; Q-Q plot for nimesulide 
On visual analysis, the linearity of the data points (Figure 4.10 and Appendix  X) for all 
NSAIDs and metabolites are close to the regression line thus showing normal 
distribution. Employing the Shapiro Wilk test on all compounds to numerically test for 
normality resulted in the null hypothesis being retained (≥ 0.05) (Table 4.3). Significant 
122 
 
values ranged from 0.052 to 0.818, above the required 95% significance limit (≥ 0.05), 
and in agreement with the Q-Q plots, indicating the data points were normally 
distributed and thus linear. 
Table 4.3 Shapiro Wilk test results; null hypothesis of normal distribution and 
corresponding significance value (tested on predicted linear range in Table 4.2) 
NSAID P valuea 
Retain null 
hypothesis 
aceclofenac 0.240  
carprofen 0.306  
diclofenac 0.093  
flunixin 0.052  
ketoprofen 0.236  
mefenamic acid 0.550  
meloxicam 0.322  
nimesulide 0.088  
oxyphenylbutazone 0.067  
phenylbutazone 0.124  
piroxicam 0.298  
suxibuzone 0.096  
3-hydroxymethyl mefenamic acid 0.126  
4-hydroxydiclofenac 0.064  
4-hydroxynimesulide 0.143  
5-carboxymeloxicam 0.298  
5-hydroxyflunixin 0.818  
5-hydroxyprioxicam 0.130  
a≥ 0.05= retain, <0.05= reject  = retained 
After the Shapiro Wilk test, it was necessary to consider the randomness in the data 
set; therefore, the Wald-Wolfowitz runs test was employed (Wapole, 2002). In linearity 
it is expected that there will be a slight negative or positive residual from the line of best 
fit and these will occur at random. However, by including points that tail off and plateau 
at the very low and high concentrations, attempting to fit the line of best fit through a 
set of data points actually on a curve may yield a sequence of non-random negative 
and positive residuals. These residuals are a sequence of increasing and decreasing 
events called runs. By testing these residuals, the test makes no assumptions on the 
normality or distribution of the data. However, by utilising the runs test on the same 
principle of the Shapiro Wilk test, this can be used to evaluate the linearity by verifying 
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the distribution of the residuals. This test considers whether the number of runs is small 
enough for the null hypothesis, to be retained or rejected. (Epshtein, 2004). As such, if 
the distribution of residuals is of random distribution, the statistical test retains a null 
hypothesis (p ≥ 0.05). If the sample has too many or too few runs then the test 
suggests that the residuals are not randomly distributed confidence limits are still the 
same and work on 95% probability level (Epshtein, 2004).  
Figure 4.11 is an example of the graphical presentation of Runs test for the NSAID 
nimesulide. If the Runs are of normal distribution and mutually independent errors then 
the p-value will increase and in doing so the number of Runs gets closer to the centre 
of Gaussian distribution curve. If the p-value falls below the significance interval of 95% 
(˂0.05) then the number of runs falls within one of the ends of the curve, indicating too 
few or too many runs. According to Miller and Miller (2010) too few or too many runs 
indicates a departure from randomness, hence, falling below the significance level. In 
Figure 4.11, as depicted by the red line and overlapping description, the number of 
observed runs is 4, with a p-value of 1 this indicates that the null hypothesis is retained 
and the distribution of residuals is randomly distributed.  
 
Figure 4.11 One-Sample Runs Test, Gaussian distribution curve for nimesulide 
(data based residuals) 
As expected the null hypothesis is retained for all NSAIDs with p-values above the 
significance level of ≥ 0.05 ranging from 0.160 to 1.000 (Table 4.4). This shows that the 
distribution of data is normal and results are of random distribution. 
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Table 4.4 Wald-Wolfowitz hypothesised runs test results; null hypothesis (normal 
distribution of error) and p-values 
NSAID p-valuea 
Retain null 
hypothesis 
aceclofenac 0.648  
carprofen 0.648  
diclofenac 0.160  
flunixin 0.648  
ketoprofen 0.648  
mefenamic acid 1.000  
meloxicam 1.000  
nimesulide 1.000  
oxyphenylbutazone 0.648  
phenylbutazone 0.648  
piroxicam 0.252  
suxibuzone 0.431  
3-hydroxymethyl mefenamic acid 1.000  
4-hydroxydiclofenac 0.913  
4-hydroxynimesulide 0.648  
5-carboxymeloxicam 0.648  
5-hydroxyflunixin 1.000  
5-hydroxyprioxicam 0.952  
a≥ 0.05= retain, <0.05= reject  = retain 
The Shapiro-Wilk and Wald-Wolfowitz statistical tests have been successfully applied 
to residual analysis and have verified results determined from regression analysis. Both 
tests have confirmed the analytical data, from the linear range (Table 4.2), is of normal 
distribution and residuals are randomly distributed.  
On comparison to the literature, the linear ranges reported here are comparable and in 
some cases span a wider concentration range including linearity at lower 
concentrations. For example, Abdel-Hamil, Novotny and Hamza (2001) used a LC-MS 
method and determined the linear range of diclofenac between 0.05-0.3µg/ml and 0.1-
0.5µg/ml for ketoprofen compared to the wide range of 0.01-5.0 µg/ml and 0.025-
5.0µg/ml (Table 4.2) obtained in this research respectively. Furthermore, research by 
Hu, et al. (2012), reported linear ranges for compounds flunixin and meloxicam (0.008 - 
0.786 µg/ml, for both compounds), whilst the lowest concentration in this range was 
lower than reported in this research (0.010-5.0µg/ml for flunixin and 0.010-2.5µg/ml for 
meloxicam), research by Hu, et al. (2012), implemented LC-MS/MS. Therefore, it could 
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be deemed that these lower concentrations are a result of the increased sensitivity 
obtained using tandem MS, but the lower limits found by this research only using LC-
MS are very close. This current research offered the same degree of linearity over a 
wider working range suitable for application in real samples.  
In the context of the research area these linear ranges fall in line with the 
concentrations that have been detected in wildlife samples, such as diclofenac 
residues detected at 0.05-0.643 µg/g (Oaks, et al., 2004). Thus, the linear range 
reported in this method spans concentrations that could be detected in a real sample 
setting.  
4.4.5 Limits of detection and quantification  
The IUPAC method (Equation 1.8 and 1.9) was used to calculate the LOD and LOQs 
for each NSAID and comparisons are made to the literature and presented in Table 
4.5. LOD values range from 0.010 to 0.196µg/g and LOQ range from 0.033 to 
0.576µg/g for nimesulide and ketoprofen respectively. Expressed as units of mass on 
column, these values were checked alongside the signal to noise ratio (S/N) as another 
means of estimating the LOD and LOQ. The lowest concentration at which the signal to 
noise ratio is 3:1 is considered as LOD and 10:1 is considered as LOQ (Table 4.5).  
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Table 4.5 Comparison of calculated and reported Limits of detection and quantification 
NSAID 
LODa (from 
this research) 
S/Nb 
 
LOD (from 
literature) 
LOQc (from 
this research) 
S/Nd 
 
LOQ (from 
literature) Analytical technique and 
matrix 
µg/ml µg/g µg/ml µg/g µg/ml µg/g µg/ml µg/g µg/ml µg/g µg/ml µg/g 
aceclofenac 0.044 0.056 0.050 0.064 0.002 0.003 0.139 0.177 0.250 0.318 NR NRe LC-MS/MS, rat  plasmaf 
carprofen 0.042 0.053 0.050 0.064 0.002 0.003 0.131 0.167 0.100 0.127 0.004 0.005 LC-MS/MS, bovine milkg 
diclofenac 0.057 0.073 0.050 0.064 1.000 1.094 0.189 0.240 0.100 0.109 1.000 1.094 LC-MS, bovine serumh 
flunixin 0.02 0.025 0.025 0.032 0.100 0.109 0.061 0.078 0.050 0.055 0.100 0.109 LC-MS, bovine serumh 
ketoprofen 0.154 0.196 0.050 0.064 0.002 0.002 0.453 0.576 0.250 0.255 0.003 0.003 LC-MS/MS, bovine milkg 
mefenamic acid 0.088 0.112 0.025 0.032 0.500 0.547 0.309 0.393 0.050 0.055 0.500 0.547 LC-MS, bovine serumh 
meloxicam 0.043 0.055 0.025 0.032 0.018 0.018 0.146 0.186 0.100 0.102 0.020 0.020 LC-MS/MS, bovine milkg 
nimesulide 0.008 0.010 0.025 0.032 0.002 0.003 0.026 0.033 0.250 0.318 0.005 0.006 LC-MS/MS, Swine musclei 
oxyphenylbutazone 0.022 0.028 0.025 0.032 1.000 1.094 0.048 0.061 0.100 0.109 1.000 1.094 LC-MS, bovine serumh 
phenylbutazone 0.095 0.121 0.050 0.064 0.050 0.055 0.293 0.373 0.100 0.109 0.050 0.055 LC-MS, bovine serumh 
piroxicam 0.038 0.048 0.050 0.064 0.100 0.109 0.127 0.162 0.100 0.109 0.500 0.547 LC-MS, bovine serumh 
suxibuzone 0.036 0.046 0.025 0.032 0.003 0.003 0.123 0.156 0.100 0.109 0.005 0.005 LC-MS/MS, bovine milkg 
3-hydroxymethyl mefenamic acid 0.023 0.029 0.025 0.032 NR NR 0.071 0.090 0.100 0.102 NR NR NR 
4-hydroxydiclofenac 0.031 0.039 0.025 0.032 0.0002 0.0002 0.094 0.120 0.100 0.127 NR NR LC-MS/MS, rat  plasmaf 
4-hydroxynimesulide 0.063 0.080 0.100 0.127 NR NR 0.218 0.277 0.100 0.102 NR NR NR 
5-carboxymeloxicam 0.034 0.043 0.050 0.064 NR NR 0.123 0.156 0.500 0.511 NR NR NR 
5-hydroxyflunixin 0.022 0.028 0.025 0.032 0.056 0.057 0.07 0.089 0.100 0.102 0.072 0.074 LC-MS/MS, bovine milkg 
5-hydroxyprioxicam 0.028 0.036 0.025 0.032 NR NR 0.084 0.107 0.100 0.102 NR NR NR 
aLOD= 𝑦𝐵 + 3𝑠𝐵 bsignal to noise ratio 3:1 cLOQ= 𝑦𝐵 + 10𝑠𝐵 dsignal to noise ration 10:1 eNot Reported, fKim, et al., 2012, gDowling, et al., 2009, hMiksa, 
Cummings and Poppenga, 2005, iHu, et al., 2012, 
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The LODs from this research are lower than compared to the literature (Table 4.5) in 
the case of diclofenac, flunixin, mefenamic acid, oxyphenylbutazone, piroxicam and 5-
hydroxyflunixin. Out of these compounds, of particular interest are the limits calculated 
for diclofenac. Not only do these falls below reported LOD and LOQ data previously 
published, at an LOD of 0.073µg/g this is in line with the previously detected residues 
of diclofenac at concentrations between 0.05 – 0.643µg/g (Oaks, et al., 2004). 
Additionally, Taggart, et al. (2009) detected residues in liver samples ranging from 0.16 
to 5.60µg/g for ketoprofen and 0.01 to 1.65µg/g for meloxicam. As seen in linearity 
studies, not only do these fall within the working linear range (0.01 – 3.18 µg/g, Table 
4.2) of this method, for ketoprofen the highest concentration detected is below the 
calculated LOD (0.196µg/g) and for meloxicam, at an LOD of 0.055µg/g, the lowest 
concentration is well within the detection limits of this method. Thus, the LODs and 
LOQs as presented here, fall in line with concentrations that could be present in a real 
sample which is paramount to this research area (Oaks, et al., 2004; Taggart, et al., 
2009). If similar levels are detected in feather samples, which have not be studied until 
now, this method is fit for purpose with regards to the linear range, LODs and LOQs 
found.  
As shown in Table 4.5, the LOD for flunixin, calculated by this research, is 0.025µg/g 
compared to the reported 0.1µg/g (Miksa, Cummings and Poppenga, 2005). This was 
the same for mefenamic acid reported at 0.547 µg/g compared to the calculated LOD 
from this research at 0.112µg/g (Miksa, Cummings and Poppenga, 2005; Dowling, et 
al., 2009). The authors have employed LC-MS/MS, which is considered a more 
sensitive analytical technique. However, this LC-MS method has proven more sensitive 
than previously published (Table 4.5). Furthermore, in nimesulide the calculated LOD is 
below its calculated linear range (Table 4.2) at 0.01µg/g and for metabolites 3-
hydroxymethyl mefenamic acid, 4-hydroxynimesulide, 5-hydroxyflunixin calculated 
LODs (0.029, 0.080, 0.028µg/g respectively) are very close to the lower end of the 
linear range. This is important when quantifying as the linear range is effectively 
measuring the sensitivity, whilst the LOD is the lowest concentration detected within a 
degree of statistical certainty (Bernal, 2014). The principal benefit of determining these 
limits is the methods capability of detecting and determining trace concentrations, thus, 
it is important to develop methods that offer lower LODs capable of detecting trace 
levels in a real sample setting (Miller and Miller, 2010).  
Where LODs and LOQs were higher than those reported in the literature (e.g. 
meloxicam at 0.055µg/g and nimesulide at 0.010µg/g (Dowling, et al., 2009; Hu, et al., 
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2012), LC-MS/MS was used (Table 4.5). LC-MS/MS is considered more sensitive than 
LC–MS used in this research and as such, lower limits would be expected. However, it 
is important to remember the limits of detection between techniques only differs very 
little when LC-MS/MS is supposed to offer greater sensitivity.   
To the author’s knowledge, oxyphenylbutazone, 4-hydroxydiclofenac and 5-
hydroxyflunixin are the only metabolities, in this research, that LOD and LOQ has been 
previously reported (Miksa, Cummings and Poppenga, 2005; Kim, et al., 2012; 
Dowling, et al., 2009). No data is currently available for 3-hydroxymethyl mefenamic 
acid, 4-hydroxynimesulide, 5-carboxymeloxicam and 5-hydroxyprioxicam. This is the 
first time in which these metabolites have been included in method validation and in a 
simultaneous detection method. Therefore, these LODs and LOQs for metabolites 3-
hyrdoxymethyl mefenamic acid, 4-hydroxynimesulide, 5-carboxymeloxicam and 5-
hydroxypiroxicam are revealed for the first time.  
4.5 OVERALL DISCUSSION AND OUTCOMES OF METHOD VALIDATION  
Method validation parameters were selected as per the guidelines set out in Huber and 
CDER, incorporating parameters set out by Commission Decision, ICH, USP and 
WADA. The LC-MS method was validated in selected ion monitoring (SIM) mode. 
In the intra-day precision studies, similar results were obtained to initial intra-day 
studies (section 3.3). At the lowest concentration (0.05µg/ml) large RSD were recorded 
for 5-carboxymeloxicam and 5-hydroxyflunixin. On closer inspection of the individual 
data sets, variation was particularly high on day 3 and 4 of analysis. Lower analytical 
responses of the analytes than those of the internal standards resulted in low analytical 
ratios thus introduced larger variation. High RSD at the lowest concentrations were in 
line with the working linear range and expected variabilities at the lower end. Overall 
analytical responses recorded for all other NSAIDs were precise and within the 
accepted RSD. 
For the linearity study, each NSAID was tested at a wide concentration range (0.01 to 
25µg/ml). Linearity was assessed using the following methods; i) visual examination, ii) 
linear regression, iii) relative response graphs (R/C vs log C) iv) analysis of residuals, 
vi) Shapiro Wilk test for normality and Wald-Wolfowitz runs-test of randomness to 
determine the working range, linear range and most importantly the LOD and LOQ for 
each NSAID.  
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Results showed that not all NSAIDs followed a linear trend especially at the lower and 
higher concentrations thus indicating these concentrations were beyond the linear 
range. Through visual analysis of the correlation coefficient predictions on the linear 
range were made but through statistical tests, for example plotting graphs of relative 
response, looking at the residuals and the test of normality and randomness, outliers 
were identified and eliminated to predict the linear range. The resulting correlation 
coefficients resulted in near true linear fit for all NSAIDs. The Shapiro Wilk test and 
Runs test were applied and showed normal distribution and randomness in data for all 
NSAIDs. Therefore, from the interpretation of these statistical tests, the results are valid 
to use. 
Using the data from linear range LODs and LOQs were calculated. The LODs for 
diclofenac, flunixin, mefenamic acid, oxyphenylbutazone, piroxicam and 5-
hydroxyflunixin are lower than compared to the literature and very close to reported 
LODs for meloxicam, nimesulide and phenylbutazone, suggesting that this method is 
comparable, if not more sensitive, than some currently published methods. The LOD 
for diclofenac is below the reported 0.098 and 0.225 µg/g lethal dose to vultures and in 
line with previously detected residues at concentrations between 0.05 – 0.643µg/g. 
Meanwhile, for metabolites 3-hydroxymethyl mefenamic acid, 4-hydroxynimesulide, 5-
carboxymeloxicam and 5-hydroxyprioxicam this is the first reporting of LODs and 
LOQs. The LODs and LOQs should be published hereafter. The limits across the 
compounds were found to be in line with the linear range as documented in Table 4.2.  
Therefore the validation of a novel analytical method employing LC-MS for the 
simultaneous detection of eleven NSAIDs and seven metabolites has been reported. 
From the interpretation and critique of the results the data presented is within 
acceptance criteria. The method has been validated to allow for identification in 
negative ionisation SIM with high precision and accuracy, whilst also being sensitive 
and selective to detect at concentrations that are known to be toxic in this research 
area.  
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CHAPTER 5: SAMPLE EXTRACTION METHOD DEVELOPMENT AND 
ANALYSIS, THE APPLICATION OF THE VALIDATED METHOD 
This chapter presents the results and discussion obtained from the analysis of donated 
animal hairs and feathers. It includes the development of an optimal sample 
preparation/extraction method and the application of the validated method (Chapter 
Four). The focus of this chapter is the requirement for a time efficient and cost effective 
method for potential application in laboratories with low budgets for analytical testing 
and sample testing. Selectivity and recovery (section 5.2) of NSAIDs in spiked feather 
samples were studied in order to take into account any matrix affect that may prove 
problematic to the trace analysis of NSAIDs, are described. Feather samples (red kite 
and parrot feather) (n=15) and cat hair (n=2) were analysed (section 5.3) and two 
NSAIDs detected, quantified.  
5.1 OPTIMAL SAMPLE PREPARATION METHOD DEVELOPMENT 
5.1.1  Sample pre-treatment development 
During the development of the sample preparation/extraction three sample preparation 
methods were trialled. They consisted of i) manual cutting with nail scissors, ii) a 
mechanical homogenizer (MP Bio FastPrep), using a lysing matrix to grind the sample 
in individual tubes and iii) a PM100 Planetary Ball Mill, using a specialist grinding jar 
and liquid nitrogen as a dry freezing additional preparation step. During sample 
preparation development, time optimisation (from whole sample to desired powdered 
sample ready for analysis), alongside the homogenisation were important. Very early in 
the sample preparation method development, manual cutting was disregarded due to 
inconsistency in overall homogenisation (the tough nature of the barb and rachis were 
problematic and resisted fine cutting with nail scissors), the time involved (2-3 hours 
per sample, Table 5.1) and loss of sample (small particles of the sample were lost on 
the surface of the nail scissors, the wall of the container and to the external 
environment). Whilst this method has the lowest set up costs (approximately £2 to £15, 
Table 5.1) of all three methods, the time to process the sample (Table 5.1) was longer 
than other methods.  
The second method investigated was the use of a mechanical homogenizer. This 
method made grinding the vane of the feather possible, thus, was advantageous over 
manual cutting, particularly in terms of the consistency in homogenisation of the 
sample (1 - 2mm sized particles, powder like consistency), that was previously 
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unachievable. Despite this advantage, like manual cutting, mechanical means failed to 
grind the rachis, which were only broken down into smaller fragments. Therefore, this 
method was disregarded as overall homogenisation of the sample could not be 
achieved, with some parts of the feather still intact. Additionally, this technique is 
particularly costly compared to the other methods investigated (Table 5.1). When using 
the homogeniser, each sample is ground in small tubes containing a specialist lysing 
matrix (small grinding particles used to break down the sample) so these tubes can 
only be used once. The costs of each tube is £20 (MP Biomedicals, 2016), thus is 
obviously a disadvantage with regards to a low cost method. Therefore, it would prove 
costly when used in the field with large numbers of samples.   
The last method employed in this research was the PM100 Planetary Ball Mill. This 
method was particularly advantageous over the previous two methods investigated. All 
parts of the feather were broken down; the vanes pulverised into a powder and grinding 
of the barbs and rachis partially achieved, which had not been possible until this point 
using the other two methods. Furthermore, the grinding jar and balls are re-useable 
meaning there is only one set up cost involved. Whilst this method had achieved 
improved homogenisation of the all parts of the sample, the brittle yet tough nature of 
the rachis resisted complete pulverisation. After carrying out a review of the literature 
into feather grinding methods, there was a variety of methods used for sample pre-
treatment, however, there was no single method suitable for all samples. Often authors 
employed an additional preparation stage to the samples, to make them more 
malleable, for example acid digestions, dry ashing and freezing, with the latter of 
particular interest (Barone and Schmidt, 2006; Chen, 2015; Dauwe, et al., 2004; 
Gochfield, 1991).  
The use of dry-freezing in the preparation of chicken feathers used in feather meal was 
recently reported by Chen (2015). Samples were dry-frozen with liquid nitrogen prior to 
any grinding, which resulted in making the sample, particularly the troublesome rachis, 
more brittle-like, thus easier to grind. Whilst improvements had been made in the 
homogenisation of the rachis, until this point no method achieved a powder like 
consistency of this part of the sample. Therefore, liquid nitrogen as an additional 
prepared stage was employed (Figure 5.1 and 5.2). Samples were pre-cut (Figure 5.1) 
and placed into sample bags and frozen (Figure 5.2). After freezing the sample for 2 
minutes, 2-3 cm pieces were placed into the grinding jar (Figure 5.3) and pulverised for 
30 minutes in two 15 minute intervals using the ball mill (Figure 5.4). This additional 
preparation step made a notable difference to the rachis, by splitting into smaller (0.5 – 
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1 cm) pieces, making them much easier, but still included, an additional hand cutting 
step thereafter (Figure 5.5). However, considering the disadvantages of the hand 
cutting method, particularly the time involved, development to improve this method 
further continued.  
 
 
Figure 5.1 Feathers roughly cut Figure 5.2 Feathers frozen in liquid 
nitrogen for 2 minutes 
Improvements started with greatly reducing the initial size of feather samples from 2 - 3 
cm to 2 - 3 mm pieces, of which were ground for 15 minutes initially to see if there were 
any improved visible results. By cutting into smaller pieces the rachis were ground to 
powder in half the time of the larger size pieces whilst eliminating and improving the 
need for manual cutting (Figure 5.3 to 5.5).  
 
 
 
Figure 5.3 Samples are 
cut into 2-3mm pieces 
into a grinding jar 
Figure 5.4 Samples are 
ground for 15 minutes in 
PM100 Planetary Ball Mill 
Figure 5.5 large 
remaining pieces are cut 
until a powder like 
consistency is achieved 
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Variation in sample structure type and quantity, created differences in the end product 
after the grinding process. Some feathers were soft down type, others were stronger 
contour and veined feathers with hard rachis (see section 1.4.3.1 for feather types with 
respect to optimal feather selection). Hence, on occasions, large pieces were left after 
grinding. However, these were brittle at this stage therefore an additional manual 
cutting step was manageable with nail scissors. As all parts of the sample were ground 
into a powder, with the satisfactory results, this sample pre-treatment method was 
employed, using the PM100 Planetary Ball Mill to prepare all samples. A comparative 
view of all three sample preparation methods trialled is presented in Table 5.1.
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Table 5.1 Sample preparation methods against time optimisation, associated cost, quality of sample, advantages and disadvantages 
of the method used 
Method 
Approximate time to 
process one sample 
Set-up 
costs (£) 
Cost per 
sample (£) 
Homogenisation of 
sample 
Advantages Disadvantages 
Hand cutting with 
nail scissors 
2-3 hours 2 -15 none 
Different sized pieces, 
some larger pieces of 
barbs present 
Low set up costs 
Risk of minor injuries to 
user, loss of sample and 
very time consuming 
MP Bio FastPreo 
Mechanical 
homogeniser 
30 minutes – 1 hour 4100a 20.0b 
Vane is ground, Barb 
in intact 
Shorter time 
Consistency in 
homogenisation of vane 
Sample is left very static 
And barbs are left whole 
PM100 Planetary 
Ball Mill 
30 minutes 990c 0.27d 
All parts of the sample 
are ground 
Shortest time of sample 
grinding 
Consistency in 
homogenisation of vane 
and barb 
Some large pieces of barbs 
require hand cutting 
aMP Biomedicals, 2016,  bcost of  lysing matrix tube per sample, MP Biomedicals (2016),  cRetsch, dcost of liquid nitrogen per litre, Retsch (2016)
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5.1.2 The selection of Liquid-Liquid Extraction 
Biological matrices, such as hair and feathers, contain proteins, salts and other organic 
compounds that could be chemically similar to the analyte of interest (i.e. 
pharmaceutical compounds). As such, some of these can be extracted and hence can 
cause interference. Therefore, it is often necessary to employ an extraction step that 
will remove unwanted interferences (Majors, 2013), in turn improving chromatographic 
interpretation (section 1.6.2.6 and 1.6.2.7), and enhance the detection of analytes of 
interest whilst minimising background noise (Kataoka 2003).  
During a study by Richards (2010), the use of SPE in keratinous matrices was 
investigated and resulted in unsatisfactory results, particularly in the detection of 
NSAIDs, as no detectable peaks were produced. This included those expected for the 
internal standards. In this research, alternative sample clean-up process was 
investigated. Liquid-Liquid extraction (LLE) involved initial extraction with hexane to 
remove the majority of the interferences, i.e. non-polar compounds, fats and proteins, 
and methanol to extract NSAIDs (section 2.5.2). This hypothesis was assumed as that 
the NSAIDs are freely soluble in methanol but this is not the case in hexane. 
Furthermore, methanol is commonly used in the extraction of organic compounds from 
keratinous matrices, such as hair (Gratacos-Cubarsi, et al., 2006). After the 
employment of LLE the chromatography was cleaner and interference peaks were 
reduced (Figure 5.6). 
There are both advantages and disadvantages to the LLE process; the advantages 
include it is lower in costs in comparison to SPE, has shorter method development time 
and is easy to perform. The disadvantages are the use of large volumes of solvents, 
difficulty in automation, and expensive. The advantages outweigh the disadvantages 
and this is why LLE was selected as the sample clean-up method in this research.  
The LLE method employed in this research is described in section 2.5.2, where 
samples were extracted with hexane and methanol in triplicate. The methanol layer 
was dried and reconstituted in acetonitrile (100µl), the optimal solvent investigated 
during method development (section 3.2.2). 
5.2 ANALYSIS OF SPIKED SAMPLES 
Blank feathers and feather samples spiked with mixed NSAID and metabolite standard 
(0.1µg/ml) in the presence of internal standards at 1µg/ml (section 2.5.3) were 
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analysed using the validated method (Chapter Four, section 2.4.1). This section 
examines any possible matrix effects post extraction and therefore doesn’t compromise 
the selectivity of the validated method (Huber, 2007) and calculates the recovery of 
extraction method. While working with complex matrices and LC-MS, it is important to 
consider matrix effects. These effects alter the ionization efficiency when molecules in 
the matrix co-elutes with the analytes of interest (Taylor, 2005). To remove such effects 
sample extraction method LLE (section 5.1.2) was used. 
5.2.1 Selectivity 
Upon the application of the validated SIM method (section 3.2.5), it was paramount to 
first analyse a blank feather sample (without spiking, Figure 5.6) to document any 
possible interferences from the matrix, which may have remained after the sample 
clean-up process. Furthermore, a solvent blank was analysed in between each sample 
(Figure 5.7). The results showed that, there were no interference peaks which 
overlapped the retention times of interest, and furthermore, no ions of interest in SIM 
were detected relating to the blanks.  
Selectivity was also investigated by analysing spiked feather samples. As such, these 
samples were initially spiked with 0.1µg/ml mixed NSAID and metabolites standard. 
The selection of this concentration was based on the findings from the literature, as 
described in section 4.4, whereby Taggart, et al. (2009). The samples were spiked at 
concentrations within the working linear range of the NSAIDs under investigation 
(Table 4.2) and above the corresponding LOD and LOQ (Table 4.5). Peaks other than 
those of compounds of interest were eluted within the sample run (Figure 5.6) however, 
they did not interfere and could have been typical of proteins and other organic 
compounds associated, and to be expected, with keratinous matrices (as first 
introduced in section 5.1.2).  
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Figure 5.6 Chromatogram of a blank feather sample used as a negative control 
 
minutes 
Figure 5.7 Typical chromatogram of a mid-run blank 
On the analysis of the spiked feather samples (0.1µg/ml), all compounds, with the 
exception of 5-carboxymeloxicam and 5-hydroxyflunixin, were detected (fully resolved, 
Figure 5.8 and 5.9) and retention times recorded (Table 5.2). Throughout analysis, 
deviation in retention times was low ranging from ± 0.02 to 0.11. RRF were calculated 
and varied ±0.02 from those recorded in Table 3.2 and 3.3. Low variation in retention 
times were recorded between compounds detected in spiked samples compared to 
retention times of standards (Table 3.2 and 3.3). Variation in retention time between 
standards and spiked samples ranged from 0.00 to 0.22 minutes. 
In compounds 5-carboxymeloxicam and 5-hydroxyflunixin, the analytical response was 
affected by a more intense peak eluting at the end of the analysis time (12.5 minutes, 
Figure 4.6). This larger peak in turn reduced the sensitivity and detection limit. Despite 
this, in method validation results (Chapter Four) these compounds were not only 
detectable at the spiked concentration (0.1µg/ml) (section 4.4), the PAR was greater 
(Table 4.1) and above the calculated LODs and LOQs (Table 4.5). This suggests, 
these compounds experienced ion suppression most likely related to other organic 
compounds in the feather under analysis.   
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Figure 5.8 SIM chromatogram of mixed NSAIDs in a spiked (0.1µg/ml) feather 
sample (8.00 to 10.30 minutes) 
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Figure 5.9 SIM chromatogram of mixed NSAIDs in a spiked (0.1µg/ml) feather 
sample (10.50 to 13.25 minutes) 
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Table 5.2 Retention times and RRF of NSAIDs and metabolites in spiked feather 
samples at 0.1µg/ml  
NSAID RTa (minutes) RRF 
piroxicam 8.31 ± 0.23 0.99 
piroxicam-d3 (internal standard) 8.28 ± 0.04 1.00 
5-carboxymeloxicam Not detected 
5-hydroxypiroxicam 8.55 ± 0.03 1.02 
4-hydroxynimesulide 8.75 ± 0.03 1.05 
3-hydroxymethyl mefenamic acid 9.42 ± 0.03 1.13 
5-hydroxyflunixin Not detected 
flunixin 9.60 ± 0.03 1.15 
4-hydroxydiclofenac 10.00 ± 0.03 1.19 
ketoprofen 10.08 ± 0.03 1.20 
meloxicam 10.27 ± 0.03 1.23 
oxyphenylbutazone 10.05 ± 0.02 1.20 
nimesulide 10.82 ± 0.03 1.29 
carprofen 11.60 ± 0.02 1.39 
diclofenac 12.02 ± 0.02 1.44 
suxibuzone 12.03 ± 0.02 1.44 
aceclofenac 12.09 ± 0.07 1.44 
phenylbutazone 12.60 ± 0.13 0.96 
mefenamic acid 13.04 ± 0.02 0.99 
flufenamic acid (internal standard) 13.08 ± 0.02 1.00 
aRT ± SD (n=3)  
Throughout the method development, three diagnostic ions (one quantifying ion, two 
confirmation ions) were selected for each of the analytes of interest, with exception of 
the metabolites, 5-hydroxypiroxicam, 4-hydroxynimesulide, 5-hydroxyflunixin and 
oxyphenylbutazone, as discussed in section 3.2.4 (Table 3.6). The use of three 
diagnostic ions is paramount in the identification and confirmation of target analytes in 
samples (section 5.3). In this analysis, alongside identification, the use of SIM negated 
any issues with co-elution between compounds as discussed in section 3.2.5, in 
particular, parent compounds aceclofenac, diclofenac, piroxicam, piroxicam-d3, 
suxibuzone and metabolites; 4-hydroxydiclofenac and oxyphenylbutazone 
As previously discussed, interferences from complex matrices can have effects on the 
detection of compounds that are present at trace levels. As such, these interferences 
can affect the detection of the analytes. Whilst SIM, together with LLE can help such 
issues, it is important to remember that complete removal of background peaks is not 
possible (LGGC, 2010). This was particularly the case, as highlighted previously, in 
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compounds 5-carboxymeloxicam and 5-hydroxyflunixin, whereby the analytical 
response was affected by a more intense peak related to the matrix (Figure 4.6). As a 
result, it is expected that complex matrices may share particular m/z with analytes of 
interest and hence cause problems when identifying compounds. Through the 
implementation of three diagnostic ions, this research meets the requirements set out 
by various agencies, such as the American Society for Mass Spectrometry (ASMS), 
Commission Decision (2002), United Nations Office on Drugs and Crime (UNODC) 
(2009) and WADA (2003), whilst allowing for the confirmation of compounds of interest 
in spiked and unspiked samples. For all compounds investigated, diagnostic and 
quantification ions were always distinguishable from interferences as were the ion 
ratios of the internal standards.  
From the results obtained during the analysis of spiked samples, the validated method 
was proven capable of detecting all NSAIDs of interest in the complex feather and 
furthermore, their identification thereafter is made with both reliability and confidence.  
5.2.2 Recovery 
After the preparation of the sample, including the extraction of the analytes of interest 
from the matrix, the percentage recovery was determined as a measure of the 
effectiveness of sample preparation (accuracy). In doing so the percentage recovery 
can be used to correct the final results accordingly for the compounds of interest that 
may or may not be detected in the unspiked samples (section 5.3). To calculate the 
percentage recovery, a comparison is made of mean PAR of the extracted samples 
with those recorded from standards prepared in the same way (Equation 5.1) (UNODC, 
2009).  
% Recovery = (
𝑚𝑒𝑎𝑛 𝑃𝐴𝑅 𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑚𝑒𝑎𝑛 𝑃𝐴𝑅 𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠
) x 100            (Equation 5.1) 
The RSD was calculated alongside % recovery in both the extracted spiked samples 
and standards as a means of testing the precision of the extraction method.  
The percentage recoveries were recorded for each compound and are presented in 
Table 5.3. Similar to selectivity studies (section 5.2.1) 5-carboxymeloxicam and 5-
hydroxyflunixin were not detected as the analytical signal was low and could not be 
distinguished from a larger peak eluting at the end of the analytical run (section 5.2.1, 
Figure 5.6). Over the compounds investigated % recoveries were high ranging between 
62.3% for 3-hydroxymethyl mefenamic acid to 99.6% for flunixin. Low recoveries were 
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recorded in 4-hydroxynimesulide, oxyphenylbutazone and 5-hydroxypiroxicam at 7.2%, 
11.4% and 14.2% respectively. These low recoveries can be attributed to signal 
suppression due to matrix effects or the extraction process itself, as highlighted in 
section 5.2.1. When comparisons are made between PAR during method validation 
(section 4.3) and those in Table 5.3, the loss in signal is apparent as analytical 
response is reduced, supporting this hypothesis. Furthermore, whilst this research has 
resulted in a low percentage recovery for oxyphenylbutazone at 11.4%, Grippa, et al. 
(2000), proposed that degradation of the compound can cause low % recovery. The 
authors hypothesised that oxyphenylbutazone, and its parent compound 
phenylbutazone, start to degrade at acidic pH. However, both compounds had not 
shown degradation during stability studies previously (sections 3.3.2 and 4.2.2). Thus, 
the low % recoveries are most likely related to matrix effects, particularly signal 
suppression and areas of large noise affecting detection limits. 
Additionally, in this study % recoveries were higher than previously reported for 
ketoprofen, diclofenac and piroxicam. In recovery studies in wastewater analysis 
ketoprofen had a reported recovery of 61%, compared to 70.6% reported in this 
method, and 78% compared to 88.9% for diclofenac in the same study (Gros, Petrovic 
and Barcelo, 2006). These compounds were extracted from wastewaters using SPE 
and LC-MS/MS. Furthermore, in aceclofenac studies, a % recovery of 85% was 
reported by Kim, et al. (2012) in rat plasma using LC-MS/MS. This is only 5% 
difference to the 80.5% reported by this research. This method has therefore shown 
that improved and comparable accuracies can be achieved with the cheaper alternative 
LLE in combination with LC-MS, supporting the aims of this experiment (section 1.7).  
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Table 5.3 A table of % recoveries, including corresponding peak area and %RSD 
for extracted spiked samples and extracted standards. 
NSAID 
Extracted 
Spiked Sample 
Extracted 
Standard 
Recovery 
% Mean 
PAR 
(n=3) 
RSD 
% 
mean 
PAR 
(n=3) 
RSD 
% 
aceclofenac 0.007 17.3 0.008 17.6 80.5 
carprofen 0.062 10.2 0.065 9.3 95.1 
diclofenac 0.106 13.0 0.119 13.2 88.9 
flunixin 0.282 7.7 0.284 7.0 99.6 
ketoprofen 0.101 6.4 0.143 18.3 70.6 
mefenamic acid 0.031 12.2 0.034 15.1 88.2 
meloxicam 0.500 14.9 0.712 11.9 70.3 
nimesulide 0.689 11.0 0.798 13.3 86.4 
oxyphenylbutazone 0.058 3.7 0.516 20.0 11.4 
phenylbutazone 0.037 7.7 0.043 18.5 87.1 
piroxicam 0.268 13.2 0.290 7.7 92.5 
suxibuzone 0.135 10.9 0.154 13.8 87.8 
3-hydroxymethyl mefenamic acid 0.045 11.7 0.071 17.8 62.3 
4-hydroxydiclofenac 0.076 11.2 0.105 16.2 72.0 
4-hydroxynimesulide 0.132 12.4 1.844 14.6 7.2 
5-carboxymeloxicam Not detected 0.007 13.9  
5-hydroxyflunixin Not detected 0.046 15.4  
5-hydroxypiroxicam 0.101 17.0 0.717 19.0 14.2 
As a measure of precision, RSD were recorded for extracted spiked samples. All 
compounds RSD were recorded within ≤20% acceptance criteria (FDA, 2001) ranging 
from 7.0% for flunixin to 20% for oxyphenylbutazone (Table 5.3). Overall, this would 
indicate that the extraction method precision varies between compounds and offers low 
to high precision. 
In the extracted standards, there was a combination of low to high precision, with RSD 
ranging from 3.7% for oxyphenylbutazone to 17% for 5-hydroxypiroxicam. These 
higher RSD values can be attributed to errors in sample preparation and during the 
extraction process, such as filtration. Where 5-carboxymeloxicam and 5-hydroxyflunixin 
were detected in extracted standards, this suggests these compounds are more than 
likely to have experienced ion suppression from matrix effects, hence not being 
detected in the spiked feather samples. Comparison between RSD of extracted 
samples and extracted spiked samples were on average comparable, differing by 
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±2.6%, with the exception of ketoprofen, oxyphenylbutazone and phenylbutazone with 
larger deviations of 13%. 
The FDA (2001) states that the recovery of an analyte need not be 100%, but should 
be consistent, reproducible and precise (the latter of which, RSD were recorded within 
≤20% for all compounds). This method ensured the best representation of percentage 
recoveries by using comparisons between extracted spiked samples and standards 
prepared under the same conditions, essentially, ensuring both samples would be 
exposed to the same solvent and sample preparation and thus, allow for more realistic 
results and percentage recoveries. This avoided unrealistic comparisons to reference 
standards which effectively represent 100% recovery and thus result in unusually high 
recoveries. The recovery values and supporting RSDs achieved in this study show the 
suitability of the method in hand and its reproducibility.  
5.3 ANALYSIS OF UNSPIKED SAMPLES 
A number (n=17) of unspiked feather and animal fur samples were analysed (in 
triplicate) using the validated method, these included wild bird feathers (from Red Kite 
(Milvus milvus), Buzzard (Buteo buteo) and Raven (Corvus)) (n=13), donated parrot 
feathers (n=2) and cat hair (n=2). These samples were prepared as per the methods 
detailed in section 2.4.4, and were analysed in the presence of both internal standards, 
piroxicam-d3 and flufenamic acid, at a concentration of 1µg/ml. This section considers 
the systematic approach undertaken to identify target analytes in unspiked samples. 
For each suspected target analyte in an unspiked sample, the mass spectrum was 
compared to that of the spiked sample to allow for an authentic comparison. In 
particular it presents the analysis of two real samples, in which piroxicam and 
phenylbutazone have been detected in feather samples. 
Guidelines, as set out by the Commission Decision (2002) and UNODC (2009), were 
followed in the identification process in the analysis of unspiked samples. Data 
collected in the form of mass spectra were analysed in conjunction with retention time 
(RT) and relative retention factor (RRF) for identification purposes (Table 5.4). 
5.3.1 Feather analysis and detection of NSAIDs 
On the analysis of unspiked feather and animal fur samples (n=17) (Table 5.4), two 
peaks, corresponding to both internal standards, were positively identified. At retention 
times of 8.28 ± 0.04 minutes for piroxicam-d3 and 13.08 ± 0.02 minutes for flufenamic 
acid (Figure 5.10), all three diagnostic ions characteristic to each internal standard 
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(piroxicam-d3 m/z 333, 341, 250 and flufenamic acid m/z 280, 236, 326) were present 
and in the same ratio. Figure 5.10 shows the analysis carried out in SIM, implementing 
diagnostic ions to establish correct identification of piroxicam-d3 and flufenamic acid 
alongside corresponding mass spectra. 
Peaks other than those of interest, were detected at the end of the analytical run 
(Figure 5.6). These were disregarded, through the interpretation of mass spectra, 
namely diagnostic ions, as no identification matches were made to compounds of 
interest. Due to the complex nature of keratinous matrices (section 1.4), these peaks 
are most likely to relate to components within the matrix (as discussed in section 5.2) 
(Figure 5.6).  
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Figure 5.10 Detected peaks of internal standards piroxicam-d3 (8.28 ± 0.04 
minutes) and flufenamic acid (13.08 ± 0.02 minutes) in an unspiked feather 
sample at concentrations of 1µg/ml 
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Upon the analysis of the various samples (Table 5.4), retention times and mass spectra 
were compared to the positive controls and spiked samples. From two samples, Red 
Kite feather (S1, Table 5.4) and parrot feathers (S14, Table 5.4) analysed, two 
additional peaks at retention times consistent with the NSAIDs piroxicam (7.59 
minutes) and phenylbutazone (12.87 minutes) were detected using the validated SIM 
method (section 3.2.4, 3.2.5 and Chapter Four), in two individual samples (Figures 5.11 
and 5.12). Thereafter, corresponding retention times were compared to standards and 
verified not to be present in the blank. No interference peaks were consistent with the 
retention times for the identified target analytes consequently, supporting their 
identification. Figures 5.11 and 5.12 show SIM and extracted Ion chromatogram (EIC) 
chromatograms of piroxicam and phenylbutazone as detected in a spiked feather 
sample (0.1µg/ml). Alongside standards (positive controls) at 0.1µg/ml compared to 
that of the in unspiked feather samples for qualitative identification. EIC 
chromatograms show only one peak relating to the quantification ion, this allows for the 
accurate quantification of each compound.  
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Table 5.4 Keratinous matrices analysed (n=3) during the analysis of unspiked 
samples 
Sample 
number 
Animal Sample Type 
Traceability 
code 
Compound(s) detected 
S1 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.029) 
Piroxicam, internal standards- 
piroxicam-d3 and flufenamic acid 
S2 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.083) 
internal standards- piroxicam-d3 
and flufenamic acid 
S3 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
01.026) 
S4 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
07.004) 
S5 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
05.076) 
S6 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.064) 
S7 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.062) 
S8 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.041) 
S9 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.037) 
S10 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
02.003) 
S11 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
05.22) 
S12 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
03.92) 
S13 Red Kite 
Moulted primaries and 
downy feathers 
(nest code 
05.032) 
S14 
Crimson 
Rosella Parrot 
moulted primaries, 
downy and filoplume 
feathers 
026 
Phenylbutazone and internal 
standards- piroxicam-d3 and 
flufenamic acid 
S15 
Crimson 
Rosella Parrot 
moulted primaries, 
downy and filoplume 
feathers 
028 
internal standards- piroxicam-d3 
and flufenamic acid 
internal standards- piroxicam-d3 
and flufenamic acid 
internal standards- piroxicam-d3 
and flufenamic acid 
S16 Cat 
Domesticated cat hair, 
collected during 
brushing 
024 
S17 Cat 
Domesticated cat hair, 
collected during 
brushing 
025 
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Figure 5.11 SIM and EIC chromatograms of piroxicam in a Red Kite feather, spiked feather sample and 0.1µg/ml standard 
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Table 5.5 details the detection of piroxicam and phenylbutazone in terms of comparing 
retention times and ions present and ion intensities correlating to that of their presence 
in spiked samples and standards. Figure 5.13 is a comparison of mass spectra to 
spiked samples and standards. The differences in retention times (Table 5.5) ranged 
from 0.04 minutes in detected piroxicam and 0.44 minutes in phenylbutazone. This 
meant the retention times, when compared with those recorded from spiked samples 
and standards, were proven to fall within the 0.5 and 7.6% for piroxicam and 3.3 and 
3.6% in phenylbutazone respectively. Difference in retention time for piroxicam was 
within ±2% acceptance criteria set by the UNODC (2009) when comparisons were 
made between the unspiked and spiked feather samples and thus support its positive 
identification. Despite the retention time of detected phenylbutazone being over the 
±2% acceptance criteria, calculated RRF were within the tolerance value of 2.5% for 
LC (Commission Decision, 2002). Differences in RRF (Table 5.5) were recorded at 
1.03% for phenylbutazone. It was therefore possible to make a positive identification 
based on retention time for piroxicam and RRF for phenylbutazone. 
The UNODC (2009) state that the mass spectrum should have a good visual match 
hence, thereafter, comparisons were made to the mass spectra of the detected 
NSAIDs in the spiked samples and the presence of diagnostic ions (Figure 5.13). Three 
diagnostic ions were used in the identification of each compound as per section 3.2.4 
(m/z 330, 323 and 332 in piroxicam and m/z 307, 308 and 375 for phenylbutazone) 
(Table 3.6). All diagnostic ions were present and within the same ratio and 
abundancies further confirming the positive match (Table 5.6). 
Table 5.5 and Figure 5.13 show the ratio of diagnostic ions for each detected NSAID. 
The abundancies of these ions were recorded and are listed in Table 5.5. Ion 
abundancies differed by ±3.4 to 3.6% in piroxicam ±0.8 to 2.3% in phenylbutazone 
(between ions in unspiked and spiked feather samples and unspiked feather samples 
and standards respectively). For the purpose of identification, these relative 
abundancies are within the ±20% allowable error as set out by the Commission 
Decision (2002) and UNODC (2009).    
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Table 5.5 Comparison table of NSAIDs detected in standards, unspiked and spiked feather samples including relative ion abundancy 
Sample NSAID detected 
Detection in Unspiked samples 
RRF 
Detection in Spiked samples 
RRF 
Detection in Standards 
RRF 
RT 
(min)a 
Ions 
present 
(m/z)b 
Ion 
abundancy 
% 
RT 
(min)a 
Ions 
present 
(m/z)b 
Ion 
abundancy 
% 
RT 
(min)a 
Ions 
present 
(m/z)b 
Ion 
abundancy 
% 
S1- Red 
Kite feather 
piroxicam 7.63 
Q 330 100 
0.92 7.59 
Q 330 100 
0.99 8.26 
Q 330 100 
0.99 C1 323 10 C1 323 14 C1 323 7 
C2 332 4 C2 332 4 C2 332 3 
S14- parrot 
Feather 
phenylbutazone 12.43 
Q 307  100 
0.97 12.87 
Q 307 100 
0.96 12.90 
Q 307 100 
0.96 C1 308 29 C1 308  28 C1 308  25 
C2 375 2 C2 375 2 C2 375 3 
aminute (n=3), bmass to charge, Q quantification ion, C confirmatory ion 
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Figure 5.13 Mass spectra comparison of piroxicam in a Red Kite feather and phenylbutazone in a parrot feather, spiked feather 
sample and 0.1µg/ml standard
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Ion ratios were calculated between the quantification ion and each confirmatory ion 
thereafter. Table 5.6 presents this data which includes the peak areas and ion ratios 
(Q/C1 and Q/C2) as calculated for piroxicam and phenylbutazone alongside their 
corresponding diagnostic ions.  
The Commission Decision (2002) state that one ion ratio, within ±20%, can be used as 
an identification point. Typically calculated between Q/C1, as this research 
implemented three diagnostic ions, two ion ratios were calculated in the identification of 
piroxicam and phenylbutazone (Q/C1 and Q/C2). From the data shown (Table 5.6) at 
least one ion ratio of both compounds is within the accepted threshold thus, meeting 
the minimum requirements for a further identification point. Cooper (2010) states that 
for assays in LC-MS, ratios may be more dependent on concentration and time than 
GC-MS. Therefore, proposes a more appropriate range to use with LC-MS would be 
acceptable up to ±30%. In spite of this upper threshold this method has shown to be 
comparable to GC-MS lower acceptance criteria.  
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Table 5.6 Ion ratios and % differences of piroxicam and phenylbutazone from feather sample. Data shown includes diagnostic ions 
and corresponding peak areas 
Ion 
Peak Area Ion ratios % difference 
between ion ratios 
(unspiked and 
spiked sample) 
% difference 
between ion ratios 
(unspiked and 
standard) 
Unspiked 
feather 
sample 
Spiked 
Feather 
sample 
Standard 
(positive 
control) 
Unspiked 
feather 
sample 
Spiked 
Feather 
sample 
Standard 
(positive 
control) 
Q/C1 Q/C2 Q/C1 Q/C2 Q/C1 Q/C2 Q/C1 Q/C2 Q/C1 Q/C2 
piroxicam 
Q-330 63078 74595 130245 
7.15 25.15 9.33 29.07 13.20 35.22 30.6 15.6 23.3 17.5 C1-323 8827 7992 9865 
C2-332 2508 2566 3698 
Phenybutazone 
Q-307 10278814 15495746 12908935 
3.61 51.04 3.88 52.93 3.91 29.25 7.51 3.70 1.9 82.8 C1-308 2651521 4297337 3301523.7 
C2-375 194196 303580 441270 
Q = quantification ion, C = confirmatory ion 
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This research implemented four identification points per analyte detected, as 
recognised by the Commission Decision (2002) (section 3.2.5). There has been little 
research published on the detection of NSAIDs in keratinous matrices, especially their 
detection using LC-MS. Therefore, following the criteria as set out by the Commission 
Decision (2002), has ensured any positive identification exceeds those in currently 
available guidelines. 
Therefore, at this stage all identification points have been fulfilled and within the 
accepted limits as set out by guidelines in Commission Decision (2002), Cooper (2010) 
and the UNODC (2009). Comparisons were made to piroxicam and phenylbutazone as 
detected in a spiked feather sample, to account for the matrix effect, and to positive 
control standards, where highlighted these also met acceptance limits; thus, confirming 
the presence of the two aforementioned NSAIDs. Additionally, as there were no 
interferences at the retention times for piroxicam and phenylbutazone this indicated the 
presence of such NSAIDs was not a result of contamination nor carryover, as not found 
in the blank, from the spiked samples. Following this confirmation, it was necessary to 
follow steps to quantify these compounds.  
5.3.2 Quantification of detected NSAIDs in feather samples 
Using linear regression, the resulting peak area ratios were used to calculate the 
concentrations of piroxicam and phenylbutazone, after their positive identification. The 
concentrations (µg/ml), once calculated, were converted into µg/g for comparisons. As 
a result both compounds were detected (n=3) at concentrations of 1.2 ± 0.002µg/g for 
piroxicam (S1, Red Kite feather) and 1.8 ± 0.011µg/g for phenylbutazone (S14, 
Crimson Rosella Parrot).  
Both piroxicam and phenylbutazone were detected at concentrations above their LOD 
(0.048 and 0.121µg/g, respectively) and LOQs (0.162 and 0.373µg/g, respectively) 
(Table 4.5). The national association of testing authorities (NATA) defines these limits 
as the smallest concentration at which analytical response is readily distinguishable 
from the noise (NATA, 2013) and, the lowest point at which compounds can be 
positively identified according to predetermined criteria, threshold limits and levels of 
confidence. This was the case in the detection of these compounds in the unspiked 
feather samples. Both compounds were easily distinguishable from the noise and, at 
concentrations of 1.2µg/g and 1.8µg/g (piroxicam and phenylbutazone respectively), 
were within the linear range validated for this method used in this research (Table 4.2), 
which were determined as 0.01-2.5µg/ml and 0.05-5 µg/ml, respectively.  
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Bernal (2014) stated that this lowest concentration should be determined within 
acceptable precision and accuracy (Bernal, 2014). Thus, throughout method 
development and validation (section 3.4 and 4.3) the precision of the method was 
proven to be within acceptable limits. Therefore, these factors support the 
quantification of these compounds. Additionally, these compounds (piroxicam and 
phenylbutazone) have been positively identified through four separate identification 
points all within the thresholds.  
5.3.3 Linking findings with the literature 
The Red Kite feathers analysed in this research were collected from the nests of birds 
of prey and monitored feeding sites in association with the Welsh Kite Trust. Whilst the 
health background of the wild birds is unknown, as these samples were collected at 
feeding sites, where the meat given to the birds is supplied through local abattoirs. 
There is a real possibility that such meat may have been contaminated with 
compounds from veterinary prescriptions, such as NSAIDs (first highlighted in section 
1.2.4). Furthermore, indications to the possible identity of the species sampled were 
provided. These included the Red Kite (Milvus milvus), Buzzard (Buteo buteo) and 
Raven (Corvus). In the case of the donated parrot feathers, these were collected from 
a crimson rosella parrot Platycercus elegans. With this background information and 
owing to the positive identification of piroxicam and phenylbutazone, it is possible to 
link with consumption, exposure route and threat they may pose.  
Originally confined to Wales, the Red Kite, has been through a reintroduction scheme 
run by the Royal Society for the Protection of Birds (RSPB) in 1989. This programme 
has seen their populations increase and now spread across England and Wales. 
Despite increased sightings and populations, the IUCN still have these birds of prey 
registered as near threatened status, stating this species are currently experiencing 
moderately rapid population decline. It is suggested, that their population declines are 
now typically from poisoning caused by pesticides and persecution, such as illegal 
poisoning to kill predators of livestock e.g. foxes and wolves. Additionally, the Red Kite 
suffered intense human persecution until the mid-1950s where, rabbit myxomatosis 
devastated food supply. Since then, poor breeding success in the 1960s, caused by 
effects of organochlorine pesticides have resulted in further population decline. 
A recent study by Orros and Fellowes (2014) suggested that the feeding habits of 
these red kite species are changing. Birds have been reported in the city of Reading 
feeding in residential gardens. The authors documented the red kites are not fussy 
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eaters, stating that they feed on leftovers, processed meat and small carcasses. This is 
not without concern as exposure to this meat may be contaminated with potentially 
toxic by-products, whether this be veterinary pharmaceuticals or pesticides that would 
effectively be uncontrolled. It is important to remember that veterinarians are, legally, 
allowed to make their own decisions when prescribing approved compounds not 
normally used in the species being treated (RCVS, 2015). However, it is more likely 
that the meat used as the feeding stations was contaminated with these 
pharmaceuticals. Naidoo, et al., (2010) stated that there are several NSAIDs whose 
safety to birds of prey, such as the protected vultures, has not been tested and 
therefore this highlights the ongoing concern of such practices. Often alternative 
cheaper NSAIDs are frequently used in the place of the more expensive prescribed 
compounds (Cuthbert, et al., 2011). This was and still is the case with the use of 
diclofenac after its ban in 2006 on the Indian subcontinent instead of the recommended 
meloxicam, the cost of diclofenac reported at £0.37 compared to £0.77 for a vial of 
meloxicam, as first discussed in section 1.2.3.  
Unlike the detection of piroxicam in the wild bird feathers, detection of phenylbutazone 
in the parrot feather is more than likely to relate to birds direct treatment with the 
veterinary compound. Commonly a pharmaceutical used in equine medicine, 
phenylbutazone is a widely used NSAID that has been reported in avian medicine 
including Psittaciformes (parrots) and raptors (Ritchie, et al., 1994). In veterinary 
medicine, piroxicam and phenylbutazone are typically used to treat arthritic pain and 
occasionally, piroxicam is prescribed in cases of cancers in treatment for cats, dogs 
and horses (Bullman-Fleming, Turner and Rosenberg, 2010; Iwabe, Ramírez-López 
and Juárez-Sánchez, 2009; Knapp, et al., 1994). Although, currently, there is no 
published research on the treatment of birds of prey with piroxicam, like 
phenylbutazone, its use has been reported in avian species, such as parrots. This is 
supported by necropsy findings and biomedical analysis carried out by Awan, et al. 
(2012) whereby the authors found piroxicam to be safe in avian species at 
concentrations of 2µg/g. It was suggested piroxicam’s good pharmaceutical effects in 
human medicine may lend itself useful in veterinary medicine. Research carried out by 
Dama (2014), proposed piroxicam is likely to be safe to endangered species, such as 
vultures, due to the similarity to the safer alternative meloxicam. Dama (2014) also 
reported the increased use of oxicam derivatives (Table 1.1) is more than likely to 
occur and urged that the proposed safety of piroxicam is first validated experimentally. 
Increased incidents of oxicam derivatives is supported by Cuthbert, et al, (2011), study 
which states piroxicam is available for sale in areas of protected species.  
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The toxicity of phenylbutazone in avian species has been tested in broiler chickens 
(Awan, et al, 2003). In line with a study by Embert (1986), Awan, et al. (2003) 
concluded that phenylbutazone is hepatotoxic in avian species at 50µg/g body weight 
after increased serum levels were recorded indicating cellular degeneration in the liver 
muscles. Despite this, no nephrotoxicity and no increase in uric acid levels were 
recorded to further suggest toxicity, as was previously found in line with mortality from 
diclofenac (Oaks, et al., 2004; Taggart, et al., 2009). Furthermore, the reported toxic 
dose is more than double the dose recommended in raptors (Ritchie, et al., 1994), and 
thus should be used with some degree of caution. However, there have been a number 
of authors reporting instances of mortality with renal disease and gout in protected 
species of vultures after treatment with phenylbutazone thus supporting such findings 
(Cuthbert, et al., 2007; Naidoo, et al., 2010; Pain, et al., 2008; Ragni, 2014). 
Particularly a study by Fourie (2014) into South African Cape vultures (Gyps 
coprotheres) found these birds were toxic to phenylbutazone at concentrations of 
1.7µg/g, stating those levels are double that found in ungulate tissue.  
As first introduced in Chapter One (section 1.3.7), if the use of piroxicam and, 
especially the toxic phenylbutazone, is to increase, it should be executed with some 
degree of caution as both NSAIDs are inhibitors of the COX-1 enzyme and are 
associated with adverse abdominal conditions like ulcers of the gut (Lees, et al. 2004). 
In response, the development and introduction of newer, more favourable COX-2 
inhibiting NSAIDs, such as the NSAID meloxicam, have seen an increase in use. 
Selectively inhibiting COX-2, meloxicam reduces the risk of adverse effect on renal 
function whilst offering the analgesic, anti-inflammatory and antipyretic properties.  
If piroxicam use is deemed to be safe, its use should be encouraged in areas of 
protected species or under continued reintroduction programs. Research into the 
indications suggesting phenylbutazone is toxic advocate that its continued use through 
conservation programmes should be discouraged. Animals treated with the latter 
should be controlled as to avoid ending up at approved feeding sites, this in turn would 
limit the possible exposure routes and would ultimately safeguard protected species 
from potentially devastating population declines.  
The detection of these compounds highlights the exposure routes that birds of prey and 
other species are at risk to. More studies need to be carried out on the safety of 
common veterinary pharmaceuticals that are readily available in areas of protected 
species, including cheap and safe alternatives that can be continually implemented. 
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Whilst only piroxicam and phenylbutazone were detected in the bird feathers, this is not 
to say that other NSAIDs were not present in the matrix. Other compounds could well 
have been in trace amounts lower than the limit of detection of the method 
developed/validated in this research. As this method allows detection of eleven parent 
compounds and five metabolites, it could be employed as an initial screening method 
as a means of testing, quickly, efficiently and most importantly pre-mortality, species 
that show signs of poisoning or ill health prior to more expensive confirmatory methods.  
5.4 OVERALL SUMMARY 
Method development of an optimal sample preparation method involved the trial of 
various means of grinding feathers, from manual cutting to using a mechanical ball mill. 
As expected, mechanical means reduced processing time and resulted in better 
homogenisation of the sample. The use of a mechanical PM100 Planetary Ball Mill, 
together with the use of liquid nitrogen as proposed in this research to help dry freeze, 
shortened preparation time drastically to achieve optimal results in 30 minutes 
compared to the hours spent manual cutting. LLE was employed for extraction of 
analytes and an additional clean-up stage was introduced to avoid interferences.  
Results, during selectivity studies (section 5.2.1) showed the diagnostic ions to be 
distinguishable from any interferences present. There were no changes in RT and RRF 
of parent NSAIDs and metabolites recorded. The results obtained in the selectivity 
investigation have proven the capability of the validated method, particularly the ability 
of detecting all NSAIDs, albeit 5-carboxymeloxicam and 5-hyrdoxyflunixin, of interest in 
the complex matrix.  
Recovery studies showed majority of NSAIDs with recoveries between 62.3 to 99.6%, 
with the exception of 4-hydroxynimesulide, oxyphenylbutazone and 5-
hydroxypiroxicam. Where low recoveries were recorded this was linked with errors 
during sample extraction method. Throughout the study, precision in the extraction 
method was always within ≤20% RSD acceptance criteria. Results were comparable 
and in some cases better than the literature showing the extraction methods suitability, 
repeatability and reliability.  
In feather analysis, two compounds of interest (piroxicam and phenylbutazone) were 
detected in unspiked wild bird and parrot feathers. These were identified using RT and 
RRF, of which were proven to fall within acceptance criteria and tolerance values. The 
diagnostic ions were also important in the identification process of these NSAIDs. Good 
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visual match and ions within the same ratio and abundancies resulted in both 
compounds within the ±20% allowable error. After confirming the presence of piroxicam 
and phenylbutazone, both compounds were quantified. Piroxicam was detected at a 
concentration of 1.2µg/g and 1.8µg/g for phenylbutazone. These were within the linear 
range and above the LOD.  
The LD50 (lethal for 50% of the population) data available for piroxicam and 
phenylbutazone in birds of prey species is limited with discrepancies (section 5.3.3). 
The concentration of phenylbutazone detected in this research, falls below the 
published toxic levels and in line with the recommended dosages as discussed in 
section 5.3.3. Meanwhile detected at 1.2µg/g, piroxicam is recommended to be safe in 
avian species due to its similarity to the safer alternative meloxicam and after toxicity 
studies revealed no hepatotoxicity or renal abnormalities at concentrations of 2.2µg/g.  
The safety of piroxicam should be investigated scientifically like meloxicam, before it is 
use is encouraged. Research into the toxicity of phenylbutazone advocate that its use 
should be discouraged, if implemented in toxicity and mass mortality like diclofenac, a 
ban on the use of phenylbutazone in veterinary treatment should follow. Hence, more 
studies need to be carried out on the safety of common veterinary pharmaceuticals that 
are readily available in areas of protected species.  
This, to the author’s knowledge, is the first instance that this type of pharmaceuticals 
have been detected in feathers. The method ensures a low-cost simple alternative to 
currently used expensive post-mortem tissue samples when analysing the exposure to 
NSAIDs that may pose a real threat to populations of endangered species.  
  
Page 162 
 
CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
This chapter concludes the findings from this research and provides recommendations 
for areas of further research. The chapter summarises the rationale behind the 
research, whilst providing an overall conclusion to the analytical findings, relating 
results to the research aims throughout, as discussed throughout Chapter Three 
(method development), Four (method validation) and Five (application of the method). 
At the close of the conclusion the opportunities for collaboration are discussed in terms 
of conservation and recommendations of the research. 
6.1 SUMMARY OF THE STUDY RATIONALE 
Endangered species and their exposure to compounds, such as NSAIDs, in the 
environment has become an increasing challenge in wildlife forensics. First 
documented as the cause of the 95% population decline of the Gyps vulture species, 
NSAIDs, namely diclofenac have a toxic effect on protected populations. Research, as 
introduced in section 1.1.1, showed diclofenac to be toxic to eagles and detection of 
ibuprofen on the external surface of otter hair. Thus, concerns regarding possible 
exposure to other protected species, such as the water vole and red kite, both of which 
have seen population declines in the UK over recent years, are of continued concern. 
Despite research increasingly looking into the effects and risks that such compounds 
pose in the environment, surprisingly, there are no analytical methods employing hair 
testing to allow for testing pre-mortality in wildlife forensic cases. Current methods rely 
on post-mortem tissue samples (section 1.4), despite the knowledge that these can be 
affected by environmental conditions. Hair samples are not only environmentally robust 
but allow for a much wider window of detection. Thus, this gap in knowledge highlights 
the importance for hair/feather sample analysis which enables pre-mortality detection 
of target compounds.  
Therefore, the primary focus of this research was to develop, and validate, a 
simultaneous detection method capable of detecting nineteen compounds and two 
internal standards metabolites with LC-MS as the chosen technique. Thereafter, 
feathers from red kite and parrots and cat hair samples were analysed and positive 
identifications were made (Chapter Four). Additionally, it was important to ensure the 
analytical method was not only current but the most relevant to the research field. 
Hence, an important aim of this study was to identify the NSAIDs of concern, and to 
include these in the detection method alongside NSAIDs that could pose a future 
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impact and their metabolites, for example aceclofenac, highlighted as future threat and 
metabolises into the toxic diclofenac.   
Since the vulture crisis, many conservationists and researchers have reported on the 
toxicity and availability of NSAIDs in areas of protected species, particularly vultures 
(section 1.3.2). For example in diclofenac and ketoprofen, whilst highlighting the lack of 
safety testing in other NSAIDs which are readily available, but have been proven to be 
toxic in other mammalian species, for example nimesulide and mefenamic acid. 
Metabolites were not included in previous studies. As such, thirteen NSAIDs and seven 
metabolites were included in this research for the development of simultaneous 
detection method as introduced in section 1.3.3 and 1.3.7.1.  
6.2 ANALYTICAL STUDIES 
6.2.1 Method development  
A series of preliminary investigations were carried out in the method development 
stages to ensure the analytical method developed is robust, sensitive, specific and fit 
for purpose. Investigations included LC-MS method optimisation, of which included 
solvent selection, injection volumes, stability and selectivity investigations.  
Early in the method development, necessary changes to the LC program were required 
to optimise the most suitable conditions to allow for the simultaneous detection of 
thirteen NSAIDs, seven metabolites and two internal standards. Alterations were made 
to the gradient elution settings and mobile phases used. The weakly acidic nature of 
NSAIDs favoured (98-0%) a decrease in water and an increase in acetonitrile (2-
100%). The elution strength of acetonitrile proved much better than that of methanol 
thus, the latter was removed from the mobile phases employed. Ultimately, separation 
of all NSAIDs, albeit diclofenac, ibuprofen and suxibuzone, was achieved using total 
ion chromatogram.  
Thereafter, solvents for standard preparation; 100% acetonitrile, 100% methanol and 
the starting mix of mobile phase, and injection volumes of 0.2, 2 and 10 µl were 
investigated. Injection volumes of 2µl in 100% acetonitrile yielded the best analytical 
response and high repeatability (10.5% RSD (n=12)) of results for all NSAIDs studied.   
Initial analysis were carried out individually and then as mixed standards in scan mode. 
For final method validation and sample analysis, SIM was used. With three diagnostic 
ions per analyte between 4-14 minutes, separation of eleven NSAIDs, seven 
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metabolites and two internal standards, in one analytical method was achieved. Due to 
low ion intensities (above the accepted 10% abundance) for oxyphenylbutazone, 4-
hydroxynimesulide, 5-hydroxyflunixin and 5-hydroxyprioxicam, only two ions were 
used.  
Initial autosampler stability studies (54 hours) were conducted to determine the suitable 
duration from preparation to storage of compounds of interest. Both internal standards 
were proven to be stable over the duration of the study. Meanwhile, the NSAIDs and 
metabolites were stable across 0.05, 0.5 and 5µg/ml concentrations for the duration of 
54 hours with the exception of acetylsalicylic acid, ibuprofen and metabolites 5-
carboxymeloxicam and 5-hydroxyflunixin. In the case of the latter two compounds (5-
carboxymeloxicam and 5-hydroxyflunixin), were proven to be stable for up to 43 hours 
with storage directly on the autosampler. In precision studies, at the three 
concentrations investigated, analytical responses were repeatable and within 10-15% 
RSD. Where the acceptance criteria was not met, namely in the compounds above, the 
concentrations at which this investigation was conducted fell, on occasions, beyond the 
working range of the compounds mentioned, therefore, this should be investigated 
further. 
6.2.2 Method validation conclusions 
Subsequent to the method development, longer term stability (six consecutive days) 
and corresponding precision for validation of the analytical method was conducted. 
Stability studies indicated that mixed standards were stable for the full six days 
however, for metabolites 5-carboxymeloxicam and 5-hydroxyflunixin for up to 3 days. 
This assay was based on a mixed standard that was stored in the freezer between 
analysis. Like initial studies, the method was deemed precise and within 10-15% RSD, 
with the exception of 5-carboxymeloxicam and 5-hydroxyflunixin. Good linearity (R2 
>0.99) was obtained. The data was tested for normality and randomness of errors, of 
which both statistical tests retained the null hypothesis, thus data was deemed to be of 
normal distribution.  
The employment of the cheaper LC-MS has proven to be an effective alternative to the 
often employed LC-MS/MS and GC-MS. This has been demonstrated through 
comparable and in some cases lower LODs and LOQs than those reported in the 
literature. In instances of higher LODs, comparisons were made to the more superior 
LC-MS/MS, as such, LODs fell within previously reported concentration ranges 
investigated (section 4.4.5) despite sensitivity expected to be lower in LC-MS. 
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Furthermore, on comparison to the reported detection of NSAIDs in tissues (Taggart, et 
al., 2008), diclofenac was detected at concentrations of 0.05 to 0.0643µg/g. As such, 
the method developed in this research is capable of detecting NSAIDs at these 
concentrations (Table 4.5) in a real sample setting and therefore fit for purpose. No 
comparisons could be made for the metabolites as no such data is available, to the 
author’s knowledge. This is an area for further research nonetheless. As it stands, 
would mean this research is the first instance whereby such analytes have been 
included in the simultaneous detection reported.  
With the successful validation of the analytical method (Chapter Four), to the author’s 
knowledge, this is the first LC-MS method that is not only capable of detecting 
simultaneously the selection of NSAIDs included in this study, but furthermore, 
facilitates the detection of seven major metabolites alongside parent compounds. This 
may be the first reporting of LODs of metabolites.  
6.2.3 Application of the analytical method; feather analysis 
The LC–MS method developed and validated in this research was applied to real 
sample analysis, particularly the testing of feathers. In its first stages, an optimal 
sample preparation method was developed and optimised. Throughout this 
development, time and cost implications were of upmost importance. The method was 
developed to the use of liquid nitrogen, whereby overall homogenisation was improved 
and shorter preparation time achieved. The optimal preparation method involved the 
use of a PM100 planetary ball mill. Unlike other cutting methods, mechanical means 
resulted in all parts of the feather ground to a powder like consistency suitable for 
analysis and in only 30 minutes. To ensure matrix effects were minimal, liquid liquid 
extraction was optimised. LLE was selected due to its user friendly procedure over the 
costly and complex nature of solid-phase extraction. 
Feather samples were spiked at concentrations in line with the literature and analysed 
in selectivity and recovery studies. This tested the capabilities of the method proving it 
was selective and sensitive enough for the application in complex matrices. Such 
studies considered the efficiency of the sample clean-up and how much of the analyte 
of interest was recovered. All compounds, with the exception of 5-carboxymeloxicam 
and 5-hydroxyflunixin, were detected in spiked samples and resolved with no 
interferences at the retention times of interest. The method was capable of 
simultaneously detecting eleven NSAIDs and five major metabolites in complex feather 
samples. In recovery studies RSD was within acceptance criteria for majority of 
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NSAIDs with overall recovery ranging from 62.3 to 99.6%. In precision studies, results 
were precise and within acceptance criteria throughout which showed the suitability 
and reliability of the extraction method.  
In unspiked feathers two NSAIDs were detected above their LOD, piroxicam in a red 
kite feather and phenylbutazone in a parrot feather. Both compounds were positively 
identified according to four separate identification points (retention time, relative 
retention factors, relative ion intensities and a minimum of one ion ratio). Piroxicam was 
detected at a concentration of 1.2µg/g and phenylbutazone at 1.8µg/g.  
The successful application of this method fulfils the research question; can NSAIDs be 
detected in alternative keratinous matrices, such as hair and feathers? This has been 
possible with the detection of piroxicam and phenylbutazone from two individual bird 
feathers. The analytical method, as presented in this thesis, thus provides a means of 
testing eleven NSAIDs and five metabolites in environmentally robust samples, which 
has not been published before. Whilst within high precision and acceptance criteria as 
set out by various recognised organisations (Commission Decision, 2002; FDA, 2014; 
EMA, 1995; Huber, 2007; UNODC, 2009).    
Therefore, the analytical method presented in this thesis has proven to be both 
sensitive and selective for detection and quantification of compounds of interest in 
complex matrices. It is hoped that findings from this research can be circulated to 
conservationists and organisations currently relying on conventional tissue analysis, as 
an alternative method. As well as being a means of detecting NSAIDs, the use of 
feathers and hairs provides a way of screening protected species pre-mortality. The 
testing of hair and feathers for this reason is essential, whether it is applied to testing 
the food source directly or in the initial signs of poisoning.  
6.3 SUGGESTIONS FOR FURTHER RESEARCH 
The lack of precision and instability, as reported throughout method development, in 
compounds acetylsalicylic acid and ibuprofen were problematic and ultimately led to 
their exclusion in the validated method. Whilst this method offers a means of detecting 
compounds identified as a threat and those that may pose a threat, further work should 
be carried out to include acetylsalicylic acid and ibuprofen in future methods.  
During stability studies this research considered the typical analysis time encountered 
by the analyst. It would be beneficial to consider the longer term stability of mixed 
NSAID standards so that not only can it provide researchers and conservationists alike 
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with an accurate time permitted for sample analysis, but would account for any 
instrument breakdowns which could span for several days or weeks.  
Recovery studies proved the extraction offered precision between samples however, 
overall recovery could be considered further. Where RSD was high and recoveries 
were low, this indicates potential areas of error. Loss in sample may be experienced 
during the extraction, filtration and evaporation stage and hence could be an area 
suggested for further research. This is especially important if research into detection of 
compounds in keratinous matrices continues, as recovery studies are absent in current 
publications.  
The testing of keratinous matrices should continue and be encouraged with longer term 
sample analysis. This research has provided a relatively short sample preparation time 
of eighteen hours from sample collection to analysis, including the timely grinding, 
filtration and digestion stages. It is important to remember that the time mentioned is 
not per sample but would be allocated for >5 samples prepared and analysed 
concurrently. The continuation of this research and development to include many other 
commonly prescribed compounds would strengthen this novel method further. It would 
provide conservationists and researchers with an alternative means of detecting 
potentially toxic by-products in wildlife forensic cases. 
Calls for further donations of keratinous matrices should continue especially in cases of 
suspected NSAID toxicity or suspicious mortality. Whether these samples come from 
the UK or other areas of protected species such as Europe and the Indian subcontinent 
would be dependent on collaborators but should be encouraged. One species that 
could be used to investigate the possible exposure and hence presence of NSAIDs 
could be the American mink (Neovison vision). Hair samples could be collected for 
analysis of NSAIDs during mink culling programmes or during bio-monitoring efforts. As 
a result the detection of NSAIDs, in these cases, would indicate their presence in the 
water ways of protected species. 
Though LC-MS has been selected based on cost and comparable sensitivity to more 
expensive techniques, other techniques could be employed to provide a relatively novel 
method implementing a variety of instrumentation. In-house method transfer would be 
possible and would implement GC-MS. This would be valuable research to see if 
results achieved using LC-MS were comparable to GC-MS. However, method transfer 
should be carried out with some degree of caution; as discussed in Chapter One, 
Page 168 
 
derivatisation steps are required in the analysis of NSAIDs in GC-MS so would require 
further method optimisation.  
Further research into the detection of metabolites in keratinous matrices should be 
considered in greater detail. The analytical method presented in this research was a 
first in terms of detecting parent compounds alongside seven major metabolites.  
However, there is support for further research into their presence in keratinous 
matrices. As discussed in Chapter One, metabolites are often more persistent in the 
body and given that NSAIDs are taken under repeat administration, these potentially 
toxic compounds are likely to accumulate in the body. Thus, making their detection in 
keratinous samples possible. However, as metabolites were not detected in a real 
sample setting this still remains to be confirmed or refuted.  
There is also a lack of research into the metabolic pathways of common veterinary 
pharmaceuticals in birds of prey and livestock. Pharmacokinetic and pharmacodynamic 
studies are far beyond the remit of this research and would involve ethical 
considerations throughout however, should be considered in future toxicity studies. 
Such results would aid in the identification of safer alternatives to toxic compounds.  
6.4 RECOMMENDATIONS OF THE RESEARCH 
Fundamentally, the testing of keratinous matrices should continue and most importantly 
be adopted in cases of wildlife forensics and conservationists working with protected 
and endangered species. Whether this is in the UK, EU or Indian subcontinent, this 
analytical method offers a means of monitoring protected species pre-mortality, which 
is currently not available. With reports of NSAID toxicity as recently as 2015, for 
example nimesulide, international collaboration is needed. In areas of protected 
species the adoption of the testing of keratinous matrices is most important, this 
includes conservation groups monitoring endangered and protected species in the UK, 
such as the red kite and water vole. If the adoption of this method has a slow uptake 
then it could be used as a supplementary method. This would be especially 
advantageous in biomonitoring efforts of protected species prior to potential instances 
of mass mortality. 
The need of safety testing, in birds of prey especially, is paramount. Currently only 
meloxicam has been scientifically tested and deemed safe to avian species, more 
NSAIDs need to be studied. Control of potentially toxic NSAIDs in veterinary medicines 
need to be considered too, and where possible, at the point of treatment. When clinical 
Page 169 
 
decisions made regarding treatment of an animal, the consequential exposure to other 
populations needs to be considered.  
It is the hope of the author that this intriguing and interesting area of research is 
continued, whether that be through the further research discussed in section 6.3 or the 
recommendations made above. It is anticipated that together with currently published 
research and knowledge gained, NSAIDs in the environment will not result in such a 
devastating population decline as was documented in the vultures in the 1990s.   
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APPENDICES 
Appendix  I-a Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml 
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Appendix I-b Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml 
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Appendix I-c Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml
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Appendix I-d Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml
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Appendix I-e Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml
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Appendix I-f Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.05µg/ml 
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Appendix  II-a Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml 
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Appendix II-b Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml
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Appendix II-c Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml
 
 
 
0
10
20
30
40
50
60
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
meloxicam
upper 15% RSD
mean PAR
lower 15% RSD
0
20
40
60
80
100
120
140
160
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
nimesulide
upper 15% RSD
mean PAR
lower 15% RSD
0
20
40
60
80
100
120
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
oxyphenylbutazone
upper 15% RSD
mean PAR
lower 15% RSD
Page 196 
 
Appendix II-d Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml
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Appendix II-e Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml
 
 
 
0
5
10
15
20
25
30
35
40
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
3-hydroxymethyl mefenamic acid
upper 15% RSD
mean PAR
lower 15% RSD
0
10
20
30
40
50
60
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
4-hydroxydiclofenac
upper 15% RSD
mean PAR
lower 15% RSD
0
10
20
30
40
50
60
70
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
4-hydroxynimesulide
upper 15% RSD
mean PAR
lower 15% RSD
Page 198 
 
Appendix II-f Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 0.5µg/ml
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Appendix  III-a Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml 
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Appendix III-b Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml
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Appendix III-c Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml
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Appendix III-d Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml
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Appendix III-e Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml
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Appendix III-f Graph of mean peak area ratio (n=3) over 54 hours stability trial 
studied at 5µg/ml
 
  
0
10
20
30
40
50
60
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
5-carboxymeloxicam
upper 15% RSD
mean PAR
lower 15% RSD
0
10
20
30
40
50
60
70
80
90
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
5-hydroxyflunixin
upper 15% RSD
mean PAR
lower 15% RSD
0
20
40
60
80
100
120
140
160
180
200
1 7 13 19 25 31 37 43 49
M
e
a
n
 p
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
Time (hours)
5-hydroxypiroxicam
upper 15% RSD
mean PAR
lower 15% RSD
Page 205 
 
Appendix  IV-a Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix IV-b Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix IV-c Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix IV-d Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix IV-e Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix IV-f Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.05µg/ml 
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Appendix  V-a Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml 
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Appendix V-b Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml
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Appendix V-c Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml
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Appendix V-d Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml
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Appendix V-e Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml
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Appendix V-f Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 0.5µg/ml
 
 
  
0
0.05
0.1
0.15
0.2
0.25
0.3
1 2 3 4 5 6
M
e
a
n
 p
e
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
)
Time (days)
5-hyroxyflunixin
upper 15% RSD
mean PAR
lower 15% RSD
0
1
2
3
4
5
6
7
8
9
1 2 3 4 5 6
M
e
a
n
 p
e
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
)
Time (days)
5-hydroxypiroxicam
upper 15% RSD
mean PAR
lower 15% RSD
Page 217 
 
Appendix  VI-a Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 5µg/ml 
Appendix VI-b Graph of mean peak area ratio (n=3) over 6 days stability trial 
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studied at 5µg/ml
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Appendix VI-c Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 5µg/ml
 
0
20
40
60
80
100
1 2 3 4 5 6
M
e
a
n
 p
e
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
)
Time (days)
nimesulide
upper 15% RSD
mean PAR
lower 15% RSD
0
20
40
60
80
1 2 3 4 5 6
M
e
a
n
 p
e
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
)
Time (days)
oxyphenylbutazone
upper 15% RSD
mean PAR
lower 15% RSD
0
5
10
15
20
25
30
35
40
45
50
1 2 3 4 5 6
M
e
a
n
 p
e
a
k
 a
re
a
 r
a
ti
o
 (
n
=
3
)
Time (days)
phenylbutazone
upper 15% RSD
mean PAR
lower 15% RSD
Page 220 
 
Appendix VI -d Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 5µg/ml
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Appendix VI -e Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 5µg/ml
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Appendix VI -f Graph of mean peak area ratio (n=3) over 6 days stability trial 
studied at 5µg/ml
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Appendix  VII-a linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3) 
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Appendix VII-b linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3) 
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Appendix VII-c linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3) 
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Appendix VII-d linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3) 
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Appendix VII-e linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3) 
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Appendix VII-f linearity plots of NSAIDs concentration against mean peak area 
ratio (n=3)  
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Appendix  VIII-a Mean peak area ratio/concentration vs log concentration plots 
for all NSAIDs 
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Appendix VIII-b Mean peak area ratio/concentration vs log concentration plots 
for all NSAIDs  
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Appendix VIII-c Mean peak area ratio/concentration vs log concentration plots for 
all NSAIDs  
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Appendix VIII-d Mean peak area ratio/concentration vs log concentration plots 
for all NSAIDs  
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Appendix VIII-e Mean peak area ratio/concentration vs log concentration plots for 
all NSAIDs  
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Appendix VIII-f Mean peak area ratio/concentration vs log concentration plots for 
all NSAIDs  
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Appendix  IX-a Residual plots of NSAIDs over working linear range (µg/ml) 
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Appendix IX-b Residual plots of NSAIDs over working linear range (µg/ml) 
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Appendix IX-c Residual plots of NSAIDs over working linear range (µg/ml) 
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Appendix IX-d Residual plots of NSAIDs over working linear range (µg/ml)  
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Appendix IX-e Residual plots of NSAIDs over working linear range (µg/ml) 
 
-15
-10
-5
0
5
10
15
0 1 2 3 4 5 6
R
e
s
id
u
a
ls
Concentration (µg/ml)
4-hydroxynimesulide
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
0 0.2 0.4 0.6 0.8 1 1.2
R
e
s
id
u
a
ls
Concentration (µg/ml)
5-carboxymeloxicam
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
0 0.5 1 1.5 2 2.5 3
R
e
s
id
u
a
ls
Concentration (µg/ml)
5-hydroxyflunixin
Page 240 
 
Appendix IX-f Residual plots of NSAIDs over working linear range (µg/ml) 
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Appendix  X-a  Q-Q plots for one-sample Shapiro Wilk test 
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Appendix X-b  Q-Q plots for one-sample Shapiro Wilk test 
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Appendix X-c  Q-Q plots for one-sample Shapiro Wilk test 
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Appendix X-d  Q-Q plots for one-sample Shapiro Wilk test 
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Appendix X-e  Q-Q plots for one-sample Shapiro Wilk test 
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Appendix X-b  Q-Q plots for one-sample Shapiro Wilk test 
 
 
 
 
 
 
 
 
